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ABSTRACT 
 
AIMS 
The purpose of this thesis was to fully quantify the dysregulation between body mass index 
(BMI) and body adiposity in 3 phenotypically different groups of adults for whom BMI may be 
particularly unreliable. The 3 groups were:  
 
1. The ‘Thin Fat’ ,  2. The ‘Fat Fit’   3. South Asians. 
 
A secondary purpose of the thesis was to evaluate the accuracy of 2-C body composition 
devices and proxy measurements to accurately assess regional and whole body adiposity.  
 
METHODS 
In order to establish a cohort baseline, whole body and regional adiposity were quantified 
using MRI and MRS. Cohort = 500 healthy adults. Participant’s adiposity data obtained were: 
TAT, SAT, ASAT, NASAT, IAAT, IHCL, S-IMCL, S-IMCL. Anthropometric data included: 
height, weight, waist circumference, hip circumference (and skinfolds in some sub-groups).  
 
Study 1: (A).  In 21 healthy non-obese, males; 4 different 2-C body composition techniques 
(UWW, BIA, SKF, ADP) were compared to MRI adiposity data.  
Study 1: (B).  In 74 adult Caucasian (40 females and 34 males) abdominal adiposity was 
measured using an abdominal BIA device (Viscan) and compared to MRI adiposity.  
Study 2: In 477 participants (343 male & 234 female) an in-depth comparison of BMI was 
conducted to identify TOFI individuals by developing a clinical index from the abdominal 
internal fat: subcutaneous abdominal fat (IAAT/ASAT) ratio for a normal range.  
Study 3: 50 males, fitness tested using VO2 max and then categorized by their fitness (fit vs 
unfit), and fatness (fat vs slim) according to MRI adiposity data. 
Study 4: 260 participants (68 Asian & 192 Caucasian) – age and BMI matched. Proxy 
measures WHR, WC etc compared. Apply study 3, TOFI cut-off to Asians adiposity data.   
 
RESULTS 
From the baseline adiposity data I confirmed that there is a wide range of regional body fat 
distributions  (internal abdominal adipose tissue, IAAT; and abdominal subcutaneous adipose 
tissue, ASAT) by BMI, and that individuals with similar BMI values can show great variation in 
IAAT and ASAT.  
Study 1. (A). When whole cohort data were compared to MRI adiposity data there was no 
significant difference between the measures derived. However when the cohort was divided 
by ethnicity (Asian vs Caucasian) differences were more apparent.  Caucasian adiposity was 
overestimated by up to 3% and Asian adiposity was underestimated by up to 11%. BodPod 
would be best suited to measuring Asian adiposity and BIA devices would be best suited to 
measuring Caucasian adiposity.  
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Study 1. (B). The abdominal adiposity device (Viscan) using BIA method was not able to 
accurately measure IAAT in obese males and females. It appeared better at measuring 
subcutaneous adiposity (ASAT). It also appeared to be influenced by organ volumes in some 
cases – particularly the liver. 
Study 2. The ‘Thin on the Outside – Fat on the Inside’ (TOFI) phenotype can be defined using 
the ratio of IAAT and ASAT (IAAT/ASAT). The resulting TOFI index provides a quantitative 
means of comparing intra-abdominal fat deposition and thereby identifying “at risk” 
individuals. In Caucasians, cut-off values of >1.0 in males and >0.45 in females are proposed 
for TOFI definition. Additionally, anthropometric measurements such as waist circumference 
(WC) and waist to height ratio (WHtR) are not appropriate for classifying the TOFI phenotype.  
This is because these surrogates generally correlated more with total and subcutaneous 
adipose tissue stores than internal or ectopic depots. 
Study 3. IAAT and liver fat are lower in men who are fat, fit and active than in men who are 
fat, unfit and inactive. These ‘metabolically healthy’ individuals have the capacity to store 
excess fat in insulin-sensitive abdominal subcutaneous adipose tissue (ASAT) and this may 
help explain why the risk of chronic disease is lower in the ‘fat-fit’ than the ‘fat-unfit’.  As a 
consequence, aerobic activity and the pursuit of physical fitness may be more appropriate 
goals in the battle against chronic disease than weight loss. 
 Study 4. Asian Indian males were found to be significantly ‘fatter’ with significantly higher 
subcutaneous fat depots compared to similar Caucasian males. Given the increased 
metabolic risks seen in the Asian population increased IAAT measures were not found to be 
significantly higher. Additionally, the TOFI classification was not useful in identifying ‘at risk’ 
individuals in the Asian group. Also, waist circumference measurements did not identify Asian 
males that had significantly elevated ASAT. However, elevated liver fat stores were seen in 
Asian males and females compared to Caucasians. Liver fat may therefore be a potential ‘at 
risk’ identifier in this ethnic group. 
 
CONCLUSION  
The results of this thesis confirm BMI may be an inexpensive, non-invasive measure of 
obesity for predicting the risk of related complications, but its accuracy is limited by its 
dysregulation with adiposity. While obesity means excess body fat, the current definition of 
obesity using BMI is based on body weight regardless of its composition. The studies in this 
thesis have highlighted that fact that there are several different sub-populations of individuals 
for whom BMI does not tell the whole story. The Fat-Fit, the TOFI and the Asian Indian are 
specific phenotypic examples of these sub-populations. This is evidence of the fact that BMI 
should not be considered as the only measure of obesity. 
The results of this thesis also confirm that some techniques to measure adiposity are 
suboptimal for measuring percent body fat.  For this reason MRI and other high quality (and 
high cost) imaging methods are still the best method for health risk based research.  
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Chapter(1.(Introduction&
 
1.1. General Introduction 
 
Obesity is classified as a disease of multifaceted aetiology, with its own disabling capacities, 
pathophysiologies and comorbidities2. It meets the medical definition of disease3,4 in that it is 
a physiological dysfunction with environmental, genetic and endocrine aetiologies. Obesity is 
a response to environmental stimuli, genetic predisposition and metabolic abnormalities, and 
has a characteristic set of signs and symptoms with consistent anatomical alterations5,6. It is a 
chronic condition characterized by excess fat deposition in adipose tissue and other organs, 
for example, liver, skeletal muscle, heart, and pancreatic islets and is associated with a large 
number of debilitating and life-threatening disorders7-9. The excess adipose tissue adversely 
effects health by increasing the work of the heart, altering pulmonary, endocrine and 
immunological functions.  This has enormous public health consequences as obesity is a 
strong risk factor (relative risk >3) for type-2 diabetes and dyslipidemia, a moderate risk factor 
(relative risk 2–3) for coronary heart disease (CHD) and hypertension1 and shares a linear 
relationship with all causes of mortality10. Obesity also increases the risk of atherosclerosis, 
obstructive sleep apnea11-14, certain cancers15-17, and osteoarthritis18. Abdominal obesity in 
particular is an important component of the metabolic syndrome, a condition associated with 
insulin resistance, type 2 diabetes, hyperlipidemia, and cardiovascular disease (CVD) 5.  
 
Incidence of Obesity 
Obesity incidence is increasing rapidly on a global scale. Based on body mass index (BMI), 
the World Health Organization (WHO) estimates that more than 1 billion adults worldwide are 
overweight (i.e. BMI ranging from 25 to 29.9); and of these, at least 300 million are obese (i.e. 
BMI of 30 and above)19. Over the past decade levels of overweight and obesity have 
increased on average between 10-40%20. WHO recently stated that "the growth in the 
number of severely overweight adults is expected to be double that of underweight during 
1995-2025" (WHO 1998). Crude projections, from extrapolating existing data, suggest that by 
the year 2025 levels of obesity could be as high as 45-50% in the USA, between 30-40% in 
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Australia, and Mauritius and over 20% in Brazil.” Today it is believed nearly 25% of all 
Americans are obese21. These figures are mirrored in the UK, where excess weight affects 
68% of adult men (44% overweight, 24% obese) and 60% of women (34% overweight, 26% 
obese)22,23. Furthermore, in England the prevalence of obesity has trebled in the last 25 
years24. Recent data also show the continuing steep rise in the prevalence of childhood 
overweight and obesity, between the ages of 2 and 15 years, with boys averaging 21.8% (5% 
obese) and girls averaging 27.5% (7% obese)25.  Other studies have put the number of 
children classified as obese closer to 12-16%26. The WHO (2007) estimated that 
approximately 22-million children under 5 years were overweight, with more than 75% of 
these children living in low and middle income countries, particularly in urban settings.27 
 
The financial burden of obesity in the UK, in terms of direct (health care) and indirect (work-
related economic losses) costs, is also growing as a consequence. Recent estimates of the 
total annual direct cost of obesity (i.e. those individuals with a BMI >25) for the UK as a whole 
were £6 billion; £4.4 billion for obese (i.e. those individuals with a BMI >30) adults, £1 billion 
for overweight (i.e. those individuals with a BMI ranging from 25 to 29.9) adults, and £0.5 
billion for childhood obesity (i.e. those individuals with a BMI >25)28. Of this estimated £6 
billion, approximately £1 billion is spent on health care provision such as general practitioner 
consultations, in-patient / out-patient admissions and drug costs. The majority of the 
estimated annual £6 billion is spent on treating the consequences of obesity such as type 2 
diabetes, cardiovascular disease, stroke and osteoporosis. The total annual indirect cost of 
obesity, estimated by the House of Commons Health Select Committee (HSC), is 
approximately £4 billion. This estimate is based on factors such as lost potential national 
output, loss of earnings from premature (obesity related) mortality and lost earnings owing to 
certified sickness.  Additional costs as a result of obesity that have yet to be estimated 
include: the social care costs of obesity, the impact of lower wages for obese individuals in 
employment29-31, welfare costs for incapacity and unemployment benefit, as well as the 
potential lost earnings owing to lower employment (believed to be in excess of £10 billion).  
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In addition to the financial burden of obesity there is also the human cost to consider.  It was 
estimated by the HSC that approximately 6.8% of all deaths were attributable to obesity and 
associated pathologies32, a more recent study put the figure for England at 0.14% (certified 
cause of death) and 24.8% (underlying cause of death) between 1995 and 200633.  
The financial costs of obesity are clearly very high, but the smaller, yet significant healthcare 
costs demonstrate the burden placed on an increasingly stretched National Health Service 
(NHS). Obesity is one of the most profound public health problems today, and simplistic 
explanations based on excessive nutritional consumption or lack of physical activity may be 
inadequate to account for this dramatic and literal growth in obesity in our world population. 
As with other complex disorders, obesity is heavily influenced by genetic and environmental 
factors. The genetic makeup of some individuals may make them more prone to obesity34-37. 
Twin studies38 showed that genes were responsible for 77% of the difference in BMI and 
waist circumference, and environmental influences accounted for the remaining 23%.  While 
obesity appears to be a heritable trait, the genes contributing to it have been difficult to 
identify. Obesity is also a feature of at least 24 genetic disorders39. However, the genetic 
influence of obesity has to be considered as related to two main processes: (1) the presence 
of a normal drive to eat despite low energy requirements, and (2) the susceptibility to 
overeating despite normal energy requirements. Appetite and the drive to eat may be affected 
by several genetically programmed metabolic pathways..  
 
 
Defining Obesity (BMI) 
The World Health Organization (2000) recommendations for the diagnosis of obesity are 
based on the body mass index (BMI). Originally named the Quetelet index in 1835 by a 
Belgian statistician (Adolphe Quetelet) as part of his theory of the average man (in Sur 
l'homme et le développement de ses facultés, essai d'une physique sociale), the body mass 
index (BMI) was a simple measure used to classify people’s weight relative to an ideal weight 
for their height. Its high correlation to adiposity (measured by skinfold and hydrodensitometry) 
was explored by Keys40 in the early 1970s before Garrow41 proposed high levels of BMI to 
define grades of obesity with different categories. In the late 1980s BMI was adopted by the 
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International Dietary Energy Consultancy Group (IDECG) as an operational definition for the 
degree of a loosely defined term for a nutritional health hazard: ‘chronic energy deficiency’ 
(CED) in adults resulting from inadequate household food supply.  This simple anthropometric 
index provided invaluable results for classifying both malnutrition and obesity, owing to its 
fundamental repeatable and valid components, which relate to the physical description of an 
individual or population. Supported by research, the usability of this index forms the basis of 
the World Health Organization (WHO) BMI cut-off points for classifying underweight, healthy 
weight, overweight and obese.  
 
Figure 1.0.  Classification and cut-off points for overweight and obesity versus thinness and malnutrition, according to 
WHO1. CED, chronic energy deficiency, PEM, protein-energy malnutrition. (adapted from Dulloo, 201042) permission 
granted 
 
 
The fundamental principle behind BMI classifications and health is that nutritional status is 
linked to longevity and mortality43-46.  Individuals with low BMI values (18.5-22.5 kg/m2) have 
an increased risk of death (mainly from respiratory diseases) compared to those with higher 
BMI (27.5 - 30 kg/m2) values owing to their diminished immune status and low protection from 
fat stores during acute illness47,48.  Additionally, low BMI individuals are also prone to 
developing problems such as nutritional deficiency and osteoporosis. The optimal survival is 
achieved at a BMI of 22.5 - 25 kg/m2. Conversely, individuals in the overweight (> 25 kg/m2) 
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and obese (> 30 kg/m2) categories are at the greatest risk of chronic diseases such as type 2 
diabetes and cardiovascular diseases44 as well as certain site specific cancers including 
colorectal and breast cancer 49,50.  A recent report from the Prospective Studies Collaboration 
with data from 57 prospective studies (based on 900,000 participants and > 66, 000 deaths) 
confirms that obesity shortens lifespan by 3 years in individuals with moderate obesity (BMI 
30-35 kg/m2) and by 10 years in individuals with extreme obesity (BMI 40-50 kg/m2). The 
increased mortality attributed to high BMI is mainly owing to ischaemic heart disease, stroke, 
diabetes and liver disease and is equivalent to years lost by lifetime smoking 44.  BMI is often 
used as a measure of adiposity in large epidemiological studies due to its ease of use, 
simplicity and low cost in both time and money. However, owing to it being correlated with 
more direct measures of adiposity51,52 BMI is assumed to represent the degree of overall 
adiposity.  It has never been a direct measure of adiposity – merely the index of assumed 
adiposity by right of it's the total fat mass contribution to an individual’s weight. While an 
individual with increased adipose tissue will have a concomitant increase in weight, BMI does 
not distinguish between fat mass (FM) and fat free mass (FFM). Therefore, BMI only provides 
information about body volume and mass, with no information about body composition and 
shape.  
 
1.2. Adiposity in Obesity  
 
Although obesity means excess body fat, the current definition of obesity, using BMI, is based 
on body weight regardless of its composition. Increasingly the risks associated with excess 
adiposity have consistently been shown to be a function of regional fat distribution, rather 
than overall fat volume53,54 owing to the stronger associations with physiological and 
pathological processes55-58. These processes are intrinsically linked to the multifunctional 
nature of adipose tissue itself. Adipose tissue (AT) is primarily made up of lipid-filled 
adipocytes held together by a collagen fiber framework, and has many roles including 
mechanical cushioning, heat insulation, as well as being a major energy storage reservoir (in 
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the form of triglycerides)59. Additionally, adipose tissue is an active endocrine organ secreting 
adipocyte products such as leptin, (involved in appetite regulation), adiponectin (glucose 
regulation), free fatty acids (energy expenditure), plasminogen activation inhibitor-1 (blood 
clotting), interleukin-6 (IL-6), complement factor 3, adipsin, tumour necrosis factor – alpha 
(TNF-α ) (immune response). These adipocyte secretory products are necessary for a 
favourable metabolic profile. Disruption of the complex hormonal pathways that control the 
regulation of these homeostatic processes can therefore lead to pathophysiological events 
believed to be involved in both the development and progression of several obesity-related 
comorbidities such as CVD, hypertension and dyslipidemia60.  
An understanding of the complex nature of human body fat distribution is therefore essential 
in order to reassess the definition of obesity at the individual level.  
 
Body fat storage / distribution. 
Generally, in humans most adipose tissue (approximately 85%) is located under the skin as 
subcutaneous adipose tissue (SAT) and a smaller (approximately 15%) is located in the 
abdomen and referred to as intra-abdominal adipose tissue (IAAT) or visceral fat. In certain 
circumstances fat can also be stored in other (non-adipose tissue) parts of the body and is 
known as ectopic (‘out of place’) fat. These undesirable (ectopic) fat depots include the liver 
(hepatic), skeletal muscle, heart and pancreas, which can cause serious problems with 
carbohydrate and lipid metabolism61-63. 
 
Intra-abdominal (Visceral) fat depot  
Intra-abdominal adipose tissue (IAAT), can be subdivided into intraperitoneal fat (mesenteric 
and omental fat) which drains into the portal circulation and retroperitoneal fat which drains 
into the systemic circulation64. It has been proposed that excess IAAT (intra-abdominal 
adipose tissue) may indicate that an individual’s subcutaneous AT is unable to serve as an 
“energy sink” for a calorie surplus resulting from excess energy intake or reduced energy 
expenditure. Factors associated with preferential accumulation of IAAT include smoking, 
genetic susceptibility65, and a maladaptive response to stress66. This inability may cause fat to 
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accumulate in other places as a consequence (i.e. ectopic fat accumulation) with subsequent 
metabolic disruption. Excess IAAT may therefore be seen as a warning sign of increased risk 
of diabetes and cardiovascular disease. This deposition of excess fat in the upper part of the 
body (ie. central or abdominal, android obesity) is more often associated with a constellation 
of comorbidities that include diabetes, insulin resistance, dyslipidaemia, hypertension and 
cardiovascular disease67-70. This form of obesity is often simplistically attributed to an 
accumulation of intra-abdominal (visceral) fat, resulting in an increase in basic anthropometric 
measures (waist circumference, skinfolds etc.).  
 
While there is much evidence supporting the notion that intra-abdominal fat accumulation is 
an important correlate of the features of the insulin-resistant syndrome71-73, it has also been 
proposed that excessive IAAT is a marker of dysfunctional adipose tissue rather, than a 
cause of insulin resistance74. In this scenario its possible that when subcutaneous adipose 
tissue fails to act as an ‘energy sink’, during excess energy intake or a sedentary lifestyle (or 
a combination of both), the IAAT compartment accumulates75. It is not yet certain whether 
visceral adiposity causes insulin resistance (IR) or insulin resistance causes adiposity 
dysfunction owing to excessive release of non-esterified fatty acids (NEFA) which may impair 
insulin sensitivity 76.  
 
With obesity, patterns of adipose tissue metabolism are altered, with impaired production of 
the ‘anti-insulin resistance’77 hormone - adiponectin and increased release of NEFAs and pro-
inflammatory cytokines tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). Such a 
pattern may contribute to systemic insulin resistance. Evidence of this fat depot’s adverse 
metabolic effects is seen when IAAT is removed (i.e. omenectomy) - it results in decreased 
insulin and glucose levels in humans78. Also, loss of IAAT following diet and exercise is 
associated with improvements in insulin sensitivity, blood pressure and circulating lipid 
levels79-81. These metabolic relationships are particularly prominent in intra-abdominal 
adipose tissue, thus contributing to the heightened risk associated with abdominal pattern 
obesity82.  
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Subcutaneous fat depot 
 
Subcutaneous adipose tissue (SAT) is believed to play an equally important role  – albeit one 
in which the metabolic consequences are less clear 83-86. Under normal circumstances SAT 
depot is believed to act as an energy sink. The body’s ability to deal with surplus energy 
intake (in excess of requirements) is believed to be owing to SAT function. When SAT 
function is impaired or altered, the excess fat is stored ectopically. While SAT has been linked 
to obesity-related insulin resistance87-90 and metabolic syndrome91, human and animal studies 
have also indicated a possible protective role for this compartment. In humans, increased 
SAT in the leg is associated with decreased risk of altered glucose and lipid metabolism92. 
Furthermore, in patients with high levels of IAAT, an increase in SAT correlated with reduced 
triglyceride content and a diminished susceptibility of metabolic syndrome84. However, 
removal of SAT by liposuction does not result in improvement in any aspect of the metabolic 
syndrome93. In mice, surgical transplantation of SAT into visceral compartments results in 
improved glucose metabolism (through improved insulin sensitivity of their liver and muscles94) 
and a reduction in body mass and total fat mass95.  
Additional evidence of SAT’s protective role96,97 is that it is the strongest predictor of plasma 
leptin levels, the fat-derived hormone that reduces appetite98,99. Also, in patients treated with 
a drug (thiazolidinedione) to improve insulin sensitivity in type 2 diabetics, their total body fat 
mass increases – but primarily the SAT depot100. Finally, in cases where there is no protective 
SAT mass (eg. lipodystrophy), severe insulin resistance and diabetes develops101-103. In 
congenital lipodystrophy there is a failure to develop adequate adipose tissue storage and fat 
is redistributed and stored ectopically.  
 
 Abdominal subcutaneous adipose tissue (ASAT) in particular has a potential ‘diagnostic’ 
capacity. Since greater amounts of IAAT than ASAT have been associated with increased 
insulin resistance and the metabolic syndrome104,105, it is possible to use a ratio of the two fat 
depots as an index of abdominal adiposity.  From detailed measures of the respective 
abdominal fat depots a ratio of IAAT to abdominal subcutaneous adipose tissue (ASAT) can 
be used as a relative index of intra-abdominal fat accumulation. This ratio was shown to be 
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strongly related to disorders of glucose and lipid metabolism in obese participants. The 
metabolic parameters concerned being significantly higher in a more visceral group than a 
more subcutaneous group106.  
 
Ectopic fat depots 
Whilst most cells have a small intracellular reserve of fat for either an immediate energy 
source or essential functions such as membrane structure and signalling, ectopic fat refers to 
the accumulation of fat in non-adipose cells (i.e. outside the classical adipose depots) in 
organs such as the liver, skeletal muscle, heart, kidneys and pancreas. The presence of fat in 
these non-adipose tissues overwhelms their normal clearance capacity and leads to tissue 
dysfunction (through “lipotoxicity”)107 and subsequent specific metabolic risk. Ectopic fat the 
lipids accumulating within the muscle cells (intramyocellular lipids, IMCL) and the liver 
(intrahepatocellular lipids, IHCL)108-111 in particular, has been linked to obesity, insulin 
resistance, type 2 diabetes mellitus. However, recent data have suggested that IHCL is more 
closely related to the development of insulin resistance than IMCL112.  
 
Hepatic fat depot 
Fat storage in the liver in particular is associated with a range of metabolic complications 113-
118 and is mostly accompanied by the metabolic syndrome119-122. Excessive accumulation of 
fat in the liver has been proposed as a new potential component of the metabolic syndrome 
when it manifests as non-alcoholic fatty liver disease (NAFLD) owing to its ability to predict 
T2D risk and its association with various metabolic disturbances. NAFLD 123 is a broad 
condition with symptoms similar to that of alcohol-induced fatty liver damage but found in non-
alcohol abusers. Symptoms of NAFLD are wide ranging and include benign fatty infiltration of 
the liver (hepatic steatosis), fatty infiltration and liver inflammation (non-alcoholic 
steatohepatitis - NASH), and fibrosis and cirrhosis, which can lead to liver failure. In a small 
minority, NAFLD can progress to hepatocellular carcinoma (HCC). NAFLD has been reported 
in approximately 30% of the adult population, but it also varies with race; being most common 
among Hispanics (45%), Caucasians (33%) and Afro-Caribbean (24%) populations124. 
Although liver fat is commonly associated with obesity125, it can also be present in normal 
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weight, non-obese (non-diabetic) individuals with risk factors including dyslipidemia, insulin 
resistance and abdominal obesity 117,123,126,127 128. Liver fat has also been linked to health risk 
factors, including hypertension129, elevated insulin 115,117,118,130, elevated triglycerides 113,115, 
and low levels of HDL cholesterol 114,115,130.  
 
While the relationship of liver fat to metabolic risk, insulin resistance in particular, is clear, the 
mechanisms are not completely understood as the pathophysiology that leads to NAFLD has 
yet to be defined. Generally, it has been suggested that the adipocyte resistance to the anti-
lipolytic effects of insulin131 and/or the exhaustion of adipose tissue storage capacity 
increases lipolysis rates and free fatty acid (FFA) delivery to the liver. This “overflow” of lipids 
from adipose tissue to the liver eventually exceeds the liver’s ability to secrete fatty acids in 
the form of VLDL132, causing liver fat. Excess lipid storage in lean tissues, such as the liver 
can lead to lipid-induced dysfunction (lipotoxicity) and lipid-induced programmed cell death 
(lipoapoptosis)133. Increased delivery of FFA to the liver, primarily from the intra-abdominal 
depot  (IAAT), via the portal vein134 is believed to be responsible for hepatic insulin resistance 
135,136 triglyceride accumulation in the hepatocytes118,137-139, and increased synthesis and 
secretion of atherogenic lipoproteins140. These findings are consistent with the strong 
relationship seen between IAAT and IHCL117 where there is an increased hepatic delivery of 
FFA as the visceral fat compartment expands116,118. Additionally, liver fat content correlates 
with total and intra-abdominal adiposity, and liver enzyme abnormalities110.  
 
The release of lipids into the circulation in proportion to the individuals’ fat mass (adipose 
organ) may also increase the FFA flux to other non-adipose tissue even in the presence of 
“functional” adipose tissue131. Obese individuals, with their increased fat mass, may become 
insulin resistant generating large quantities of atherogenic and diabetogenic FFA. However, 
the elevated outflow (“overflow”) of FFA does not entirely explain the development of NAFLD. 
It is also proposed141,142 that oxidative stress / cytokine action is a second step in the model. 
This second “phase” suggests that a reactive oxygen species can degenerate the excess 
lipids now stored in the liver, causing both hepatitis (liver inflammation) and hepatocyte 
damage or necrosis143. It is also possible that excess liver fat storage can increase hepatic 
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production of bioactive materials such as tumour necrosis factor (TNF-alpha), which are also 
capable of damaging the liver144. The blunting of a protective mechanism provided by plasma 
adiponectin (adipocyte-secreted protein) is believed to be an additional contributor to NAFLD 
progression. Adiponectin is produced exclusively by adipocytes (white and brown) and 
circulating levels fall in obesity. Adiponectin is involved in the modulation of insulin 
sensitivity145 and has an anti-inflammatory action in vascular function146-148. Abdominal obesity 
in particular has been linked to low levels of plasma adiponectin149, insulin resistance150 and 
fatty liver151,152. Adiponectin acts as an anti-diabetic and anti-atherogenic adipokine in 
suppressing the production and function of TNF-alpha, as well as decreasing hepatic 
lipogenesis and increasing hepatic insulin sensitivity153. Adiponectin may regulate fatty acid 
metabolism by activating AMP-activated protein kinase in hepatocytes154, which stimulates B-
oxidation and simultaneously inhibits lipogenesis. Depressed plasma adiponectin levels (as 
seen in obesity) may therefore lead to liver inflammation and liver fat accumulation by 
reducing insulin sensitivity, and damage through TNF-alpha action. The metabolic effect of 
insulin resistance, partly mediated by depressed plasma adiponectin levels, therefore 
contributes to increased fatty acid flux from adipose tissue to the liver and may induce the 
accumulation of fat in the liver. Elevated plasma glucose can further increase hepatic fat 
content through multiple pathways, resulting in overproduction of VLDL particles and leading 
to the characteristic dyslipidemia associated with type 2 diabetes. Thus, adiponectin may be a 
mediator between adipose tissue and the liver, influencing both glucose and lipid metabolites. 
Interestingly, animal studies144 have shown that administration of adiponectin to rodents with 
fatty liver has been shown to resolve the condition.  
 
 
Muscle depot 
Fat can be found stored within muscle cells - intramyocellular lipids (IMCL) as well as situated 
between the muscle bundles - intermuscular adipose tissue (extramyocellular lipid - EMCL). 
The IMCL storage reserve increases as a response to endurance training and physical 
activity, along with mitochondrial density and increased insulin sensitivity. This training 
response is linked to greater availability of substrate. However, increased amounts of this 
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(IMCL) ectopic depot are also seen in obese individuals or type 2 diabetics, and have been 
linked insulin resistance87,155. IMCL measurements using magnetic resonance spectroscopy 
(MRS) have been found to correlate well with markers of insulin resistance and visceral 
adiposity156-159, and have shown this depots accumulation to be associated with obesity and 
the development of skeletal muscle insulin resistance and T2D160,161. This suggests a 
potential way that fat distribution could influence metabolic risk alongside IAAT and well-
established risk factors for morbidity and mortality54.  
 
Other ectopic stores  
While beyond the scope of this thesis, there are other ectopic fat depots that need mention for 
the purpose of context.  These other depot sites are the pancreas and the heart. Owing to the 
difficulty in imaging the pancreas, this is an area of investigation that is still developing. 
Additional factors that influence the deposition of fat in these different locations include age, 
gender and ethnicity. These may also be important confounding factors in the relationship 
between adiposity stores and metabolic risk162. Ethnicity is known to effect fat and AT 
distribution 76,163, and additionally the association of fat distribution with insulin sensitivity also 
varies by ethnicity164,165. As an example South Asians, despite their slimness, are 
predisposed to fat disproportionately accumulating in the abdominal cavity166,167, which is 
thought to increase insulin resistance.  Genetic influences may also contribute to this complex 
area.  
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1.3. The Obesity Phenotype   
 
For many decades Body Mass Index (BMI) has been the ubiquitous tool to define an 
individual as lean, overweight or obese, and also to get a surrogate measure of body 
adiposity. At population level BMI has served extremely well as a tool to uncover the 
relationship between obesity and some life-threatening disorders, however there is mounting 
evidence questioning its utility and applicability to various populations168. Since its 
introduction, BMI has been known to have considerable limitations, especially at the extremes 
of BMI, in children, athletes and for different ethnic and age groups168,169. Based on the 
assumption that changes in body weight reflected changes in body fat, BMI was proposed as 
an estimate of obesity. However, obesity is defined as excess body fat rather than body 
weight (regardless of its composition) and differences in body weight do not always go hand 
in hand with changes in body fat170.  For example, body builders and power athletes (rugby, 
boxing, wrestling, shot put etc) may have a low percentage body fat, but their BMI would 
classify them as overweight or obese because of their greater lean (muscle) mass. Variations 
in muscularity represent a major confounding factor and demonstrates the low sensitivity of 
BMI.  In the case of mortality and ageing, it is well known that there is a greater loss of 
muscle mass (sarcopenic obesity) in women as they age compared to men. This increased 
loss of muscle in women exacerbates the misclassifications of BMI171,172. Also, since ageing 
men lose less muscle than ageing women (i.e. that they suffer from sarcopenia less than 
women do), the men’s BMI should take this fact into account more.  In men, there is an 
inverse relationship between muscular strength and mortality, which may be missed using 
BMI as a measure of adiposity173.   
 
In recent years there has been a slow, but inexorable move towards the acquisition of more 
detailed phenotypic information from overweight/obese individuals, both for scientific 
purposes, as well as to provide better advice to those trying to avoid or reverse the effects of 
increased body adiposity.   
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A more Accurate Assessment of Adiposity 
Many techniques have been developed over the years to provide a more detailed measure of 
body adiposity than can be obtained using BMI. Most recently imaging techniques (CT and 
MRI) have been used to assess body fat content and distribution. The applicability of the 
former to the study of fat in human volunteers has been hampered by the fact that ionising 
radiation is required during the acquisition of the images, while the relative cost of a MRI 
examination has limited its applicability to large population studies. Despite this, magnetic 
resonance spectroscopy (MRS) and MRI have become the gold-standards in the field of 
obesity174-176. Applying these advanced techniques to specific populations, for whom BMI may 
be particularly unreliable, will enable more accurate phenotyping of their potentially differing 
fat distributions. Such populations include: the metabolically healthy obese (MHO)177-179, the 
metabolically obese-normal weight (MONW) and its linked sub-group the “thin on the outside-
fat on the inside” (TOFI). While both MONW and TOFI individuals share a normal BMI (ie, 18-
25 kg/m2) and normal weight, the MONW individuals have a cluster of metabolic 
characteristics that may increase the risk of developing the metabolic syndrome. TOFI 
population is distinguished from the population in that TOFIs do not have any overt 
cardiometabolic disease (i.e. normal metabolic profile and normal insulin sensitivity) but may 
be at increased risk of developing obesity-related diseases.    
 
 
Metabolically Healthy Obesity  “Fat-Fit”  
It has been reported, for well over two decades, that some obese participants do not present 
the common cardiometabolic risk factors of elevated blood pressure, elevated triglycerides, 
C-reactive protein, insulin resistance, elevated glucose levels/diabetes, or decreased HDL, 
despite their excess body fat177.  Research groups in Europe and the USA have estimated 
that a significant number of overweight/obese participants (20%-35%) are “metabolically 
healthy obese” (MHO) individuals180-183.  In this sub-phenotype, there is a clear dissociation in 
the well-established relationship between body fat content and metabolic risk factors; in that 
despite a BMI of > 30 kg/m2, MHO individuals possess a favourable metabolic profile of: high 
insulin sensitivity, a healthy lipid profile (high HDL, low triglycerides), low visceral fat and no 
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hypertension. While there is little understanding of the complex factors that constitute this 
protective profile, it is believed to be related to the lower amounts of visceral fat in the 
presence of high total body adiposity.  A related sub-phenotype has also been reported, 
known as the “fat-fit”. In this phenotype individuals, like the MHO, show a similar dissociation 
between body fat content and metabolic risk factors184-186 but whose increased activity levels 
may be providing the protection from metabolic disturbances associated with obesity.   
 
Metabolically-obese but normal-weight  (MONW) 
Interestingly an opposite phenotype to the “MHO/Fat-Fit” has also been reported. In this 
phenotype, participants with a BMI <25 kg/m2 were seen to have disproportionally high levels 
of many risk factors associated with the metabolic syndrome. These participants have been 
defined as “metabolically-obese but normal-weight” (MONW)187. This syndrome (often in 
young individuals) is characterized by a normal body weight and BMI, but display a cluster of 
obesity-related abnormalities such as premature signs of insulin resistance, hyperinsulinemia 
and dyslipidaemia, high visceral fat, high liver fat and a high fat mass (usually greater than 
30%)188,189. There is uncertainty about the factors involved in this phenotype, but it is believed 
that body composition and body fat distribution abnormalities may be important factors in their 
metabolic complications190.  Several studies have shown that young MONW individuals have 
a lower fat-free mass and a tendency for a greater central (intra-abdominal) fat mass191,192. It 
has been hypothesized that MONW individuals may have decreased fat storage in adipose 
tissue – leading to greater ectopic storage130. Interestingly the MONW phenotype may be 
similar to phenotypes reported in different ethnic groups including Japanese and South Asian.  
 
Ethnicity – ‘Asian Indian’ Phenotype 
‘Asian Indians’ are often incorrectly grouped together as one homogeneous region on the 
basis that they share similar cultural, social and linguistic characteristics. South Asians 
(individuals from Pakistan, Bangladesh, Nepal and Sri Lanka) in particular represent an ethnic 
sub-group that exhibit the so called ‘Asian Indian Phenotype’, where individuals present with a 
‘normal’ BMI, indicating less generalized obesity, but have a disproportionately large waist 
circumference owing to greater central (abdominal) obesity193-195.  
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With such a global increase in obesity and its related disease risks it needs to be 
remembered that prevalence of obesity in a population is crudely determined as the 
proportion above a BMI cut-off. This is thought to represent the number of individuals with 
excess amount of body fat196. However, the relationship between BMI and total adiposity 
varies with different populations197 and South Asians in particular, have a different BMI-
adiposity relationship compared to Caucasians and African Americans.  A substantial 
proportion of South Asians are found to have an increased risk of type-2 diabetes (T2D) and 
CVD at BMI values lower than the proposed WHO cut-off point of 25 kg/m2 used to define in 
individuals as overweight198 199.  BMI can therefore differ significantly among populations of 
the same age, gender and body adiposity200. As a consequence, revised BMI cut-off points to 
define obesity have been suggested for several ethnic groups including populations from 
South Asia, China and Native Australia201 to reflect the fact that CVD risk factors occur at a 
much lower BMI than those individuals of European origin201. For instance individuals of Afro-
Caribbean origin exhibit more subcutaneous fat for a given BMI compared to 
Caucasians76,202-204, whereas Japanese populations are more prone to the accumulation of 
intra-abdominal fat 199,205. 
 
South Asians have been identified as a particular at risk ethnic group as they are predisposed 
to insulin resistance, the metabolic syndrome and type 2 diabetes mellitus206-208. South Asian 
men in particular may also be genetically predisposed to premature CVD209,210 as it is widely 
reported that this ethnic group has a significantly higher CVD mortality rate from the condition 
than other ethnicities 211-214 along with increased CVD risk seen in childhood.  
In England and Wales, compared to the general population, mortality from CHD is 50% 
higher in South Asians214. The pathology of this increased susceptibility is yet to be fully 
explained. Conventional risk factors, including type 2 diabetes and central obesity, insulin 
resistance parameters, or metabolic syndrome criteria (as currently defined) do not 
adequately explain their excess risk compared to other populations. One key factor is that 
current definitions of the metabolic syndrome by the National Cholesterol Education Program 
(NCEP) and the WHO give an inconsistent picture of cardiovascular disease risk when 
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applied to different ethnic groups within the UK. Rates of smoking, hypertension and levels of 
low-density lipoprotein (LDL) cholesterol tend to be similar or lower in South Asians, although 
diabetes is more prevalent215. It is possible that with South Asians, their increased 
predisposition for central obesity and insulin resistance, accompanied by raised triglyceride 
and lowered high-density lipoprotein (HDL) cholesterol concentrations, are contributing 
factors to their elevated vascular risk207,210,216,217 and further categorize them as metabolically 
obese, normal weight individuals. 
   
This ethnic group faces additional health risk as it has been found that migrants South Asians 
are more predisposed to developing CHD210,218. With increasing numbers of young South 
Asians now settling abroad, there is a very strong possibility of increased obesity related 
health risks, along with the associated increased healthcare burden in this “at risk” population. 
The U.S. South Asian population grew 38% (almost 15 times the national growth rate) in the 
years 2000-2005 and by 53% in 2007 according to the American Community Survey of the 
U.S. Census Bureau. South Asians are among the fastest growing ethnic groups in the U.S. 
(3rd largest ethnic group after Chinese Americans and Filipino Americans). In the UK, British 
South Asians make up approximately 6% of the population (50% of the UK’s non-European 
population) and therefore would benefit from focused research linked to their possible ethnic 
predisposition to health risk. However, it is unknown at this time if generational differences 
may be diluting or amplifying these existing risk predispositions. 
A greater knowledge of South Asian adiposity may be key to understanding this ethnic 
group’s predisposition to numerous health risks owing to adiposity’s obvious commonality and 
strong causal relationship to many of the related factors (hypertension, CVD, type-2 diabetes 
etc).  As with studies between Afro-Caribbean and Caucasian populations165, where similar 
levels of BMI appeared to differentially affect the metabolic syndrome, differences in fat 
distribution partially explained some of the observed ethnic differences.  It is proposed that 
this may also be the case with South Asians. 
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1.4. Body Composition Measurement  
 
 
 
In order to accurately assess adiposity and obesity related health risk we must be able to 
accurately measure body composition and particularly fat distribution. With the exception 
perhaps of cadaver dissection, a ‘true’ value of body fat content is not attainable. For in vivo 
quantification of body composition, we must therefore rely on a criterion (reference) with high 
accuracy in order to be able evaluate and utilise other less accurate methods. However, 
because the human body can be quantified at numerous levels, the criterion can vary.  Body 
composition assessment can be at the atomic level (carbon, calcium, potassium, and 
hydrogen); at the molecular level (water, protein, and fat); at the cellular level (total cell mass, 
extracellular fluid, and extracellular solids) and at the tissue or systems level (based on 
functional arrangement of 4 tissue types: connective, epithelial, muscular, and nervous). The 
choice of criterion should however, be chosen based on its avoidance of major assumptions 
and its degree of maximal precision. Depending on the criterion involved the numerous 
methods available for measuring body composition in vivo can be classified as either direct, 
indirect, and doubly indirect219.  
 
1.4.1. Direct methods 
Direct methods as indicated, directly measure amounts of chemical elements in the body, 
from which information about body components of interest can be obtained.  Apart from 
cadaver studies220-227 an example is in vivo neutron activation analysis  (IVNAA), where body 
content is measured at the elemental level228.  After exposure to a neutron field, gamma 
output is measured as the cell nucleus relaxes and returns to its pre-exposed state. However, 
worldwide, very few laboratories use this method, and it is used mainly for clinical purposes. 
The expose to high levels of neutron radiation is a concern with this technique and therefore 
limits its use in large-scale population research. 
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1.4.1. Indirect methods 
Indirect methods, such as, deuterium oxide dilution, dual-energy X-ray absorptiometry (DXA) 
and densitometry measure body components (fat mass, FM; fat-free mass, FFM; water etc.) 
and rely on certain assumptions that might not always be true.  This component approach to 
body composition has developed over the years from a two-component model (2-C), where 
tissue is categorised as either fat mass or fat free mass, to multi-component models, where 
the various components measured depend on the methods used.  Wang et al. 228 
summarised these methods in a proposed five-level model for body composition research 
(Figure 1.2).  
Dilution based techniques use 2-C model to predict the FFM and FM components by 
measuring total body water (TBW) volume using an isotope.  Based on the fact that water 
maintains a stable relationship to FFM dilution techniques can predict the FFM and FM (i.e, 
FM =  body weight - FFM).  This technique is limited in obesity studies as it is based on an 
assumed average proportion of TBW in FFM of 73%229, with 15-30% present in adipose 
tissue230. However, the FM proportion of TBW increases with obesity causing estimate 
inaccuracies231. Additionally, disease states such as diabetes further affect the variation in 
TBW distribution, increasing estimate error further.      
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Figure 1.2: The five levels of human body composition (adapted from Wang et al.,1992). 
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A chemical four-component model is generally regarded as the best choice to measure body 
composition.232 In a four-component model the amount of minerals, protein, and water in the body is 
measured, and body fat (fourth component) is calculated by difference. The number of assumptions in 
such a four-component model is small, and consequently the possible bias is small. While the four- 
component model is recommended as the method of choice in population studies, it is expensive and 
time-consuming and few laboratories have the capacity for using it since densitometry or IVNAA, 
deuterium oxide dilution, and DXA must also be available for measurement of the component parts 
(i.e. compartments).  
 
The standard model most widely used today is the four-component model comprising of adipose 
tissue, body cell mass, extracellular water and the skeleton. This model extended the basic 2-C 
underwater weighing (UWW) model to four components using more accurate measurements of body 
protein mass and bone mineral mass alongside assumed densities of body protein (1.34 kg/L) and 
bone mineral density (3.075 kg/L)233. The two additional measurements of neutron activation analysis  
(NAA) for body protein mass and dual-energy DXA for bone mass can themselves be used to provide 
an accurate estimate of the body fat mass without the need for UWW measurement234-236. 
 
2-C Densitometric Model 
Most widely available body composition methods are currently based on the simplest two-component 
(2C) chemical model with the human body partitioned into the fat mass (FM) and the fat-free mass 
(FFM)200,237, where fat mass is estimated indirectly using body density. All such measurements focus 
on distinguishing between relatively inert components of the body and those that are metabolically 
more active. The fat mass (FM) component with a density very close to 0.900 g/mL has a relatively 
constant composition238-240 and consists primarily of triglyceride.  The fat-free mass (FFM) component 
is estimated to be 1.100 g/mL241, as there is no direct measurement available. However, there is 
known variability in the fat-free density measure242,243, as verified by bone mineral density (BMD) and 
cadaver studies220,222,223,225. Additionally, this measure was also found to vary with respect to 
ethnicity244. 
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Equation 1.1. 245 for predicting percent body fat (%BF) from body density is derived from the above 
principles. 
 
  BF% = 1
bD
×
( fd × ffmd )
( ffmd − fd )
− fd
( ffmd − fmd )
× 100 (1.1)  
 
BF% = 495
bD
− 450 (1.2)  
 
In equation 1.1 :  
Df = density of fat mass (FM), Dffm = density of fat free mass (FFM), Db = Body density 
 
In equation 1.2, Siri’s equation246 for percent body fat is derived when the known respective values for 
FM and FFM densities, detailed earlier, are used. 
 
 
Densitometry  
Densitometry refers to the general procedure of estimating body composition from body density, and 
is based on the assumption that the density of any material is the function of the proportion and 
densities of its components. Measurement of whole-body density (Db) for the 2-C model has 
traditionally been derived from hydrodensitometry (more commonly known as ‘underwater weighing’, 
but also called ‘hydrostatic weighing’) and is the classic approach to determining body composition, 
based on Archimedes’ principle. This principle states that when a body is immersed in water, it is 
buoyed up by a force, which is equivalent to the weight of the volume of water displaced.   Therefore 
the weight of water displaced by a submerged individual is equal to their weight in air minus their 
weight in water. When this value is divided by the density of water it provides the individual’s gross 
volume. This volume must then be corrected for lung volume and gastrointestinal gas (usually taken 
to be 100mL). Ordinarily, the underwater weight is obtained when the individual has exhaled 
completely (residual volume), then this value must be subtracted from the gross volume instead (as 
indicated in equation 1.3, Chapter 2 - General Methods section ). 
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Although body volume for determination of body density has primarily been assessed by UWW 
and Archimedes’ principle, an alternative method using air displacement plethysmography (ADP) 
is available in the Bod Pod (Life Measurement Instruments Inc., Concord, California). The Bod 
Pod addresses some of the technical difficulties involved in water submersion and displacement 
measurement. While ADP makes corrections for surface area, lung volume and clothing it 
appears to be less accurate than UWW. However, ADP is prone to the same error as UWW when 
using equations to convert body density to percent body fat. Densitometry and any subsequently 
derived methods of predicting percentage body fat are therefore prone to similar errors owing to 
questions relating to constancy of the FFM density.  Additionally, since the original values were 
derived from limited reference cadaver data from a small number of Caucasians, the equations 
employed are therefore specific to a Caucasian population244,247.  In some cases conversion 
formulae have subsequently been derived for different populations248,249 to improve accuracy. One 
such example is in Afro-Caribbeans, who were found to have a denser fat-free mass than 
Caucasians250,251.  There is, however, very little comparable information on the density of FM and 
FFM in the South Asian population, so it is unknown whether body composition values obtained 
via the 2-C model are truly accurate for this ethnic group. Owing to uncertainty regarding 
constancy of such values and the potential errors that can result from a reliance on densitometry, 
validation against medical imaging (MRI, CT, DXA) should improve accuracy.  
 
 
1.4.1.3. Doubly indirect methods 
Doubly indirect methods rely on a statistical association between easily measurable body variables 
and a measure of body composition, usually obtained by an indirect method. Examples of doubly 
indirect methods are anthropometry (multiple skinfold thicknesses), bioelectrical impedance analysis 
(BIA), waist circumference, and BMI-based prediction equations for the percentage of body fat. Thus, 
they are no more than a prediction based on mathematical functions, and the bias at an individual 
level, and at a population level, can be substantial. The mathematical functions employed normally 
involve regression analysis where other parameters such as age or sex may be included. Such 
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methods indirectly measure body density and body water and have been mainly validated against 
UWW. A good example is BIA for which equations are available to calculate total body water or fat 
free mass.  Alternatively, the mathematical function may make use of known properties or ratios 
within tissues, for example the ratio of total body water to fat free mass is known to be constant at 
about 0.73.  Therefore, if total body water is measured using a labelled water technique, fat free mass 
can be calculated (see dilution method earlier in this chapter). 
However, to be accurate, these relatively easy to perform field methods require validation against a 
criterion method with minimal error 252 and being doubly indirect they are vulnerable to the errors and 
assumptions associated with UWW as well as those from their own technique. The use of deuterium 
dilution method (D2O) or DXA (with its rise in acceptance) as the criterion methods is improving the 
accuracy of these methods but underlying validity issues remain.  
These indirect methods do not relate to the different proportions of fat in the different storage depots. 
Skinfold measurement assume that the compressed double layer of skin and subcutaneous adipose 
tissue is representative of an uncompressed single layer of adipose tissue; that skin thickness is 
either negligible or constant and that subcutaneous adipose tissue compresses predictably. However, 
it has been found that skin thickness varies between individuals and between sites253, as well as that 
compressibility varies with age, gender, site and tissue hydration.  
The BIA method has the same ‘criterion’ method related errors as well as the fact BIA devices tend to 
be population specific with generally poor characteristics of fit for a large heterogeneous population. 
BIA has been shown to overestimate individuals with low percent fat and underestimated individuals 
with high percent fat254. The inclusion of anthropometric measures improves BIA fat prediction 
somewhat, but additional measurement errors from hydration, electrode placement, prior exercise and 
temperature can still influence the measurement. 
 
1.4.2. Magnetic Resonance Imaging (principles) 
Although there may be high correlations between many of the different measurement techniques – 
there is generally poor agreement between the imaging and non-imaging techniques255. Medical 
imaging technologies, Computerised Tomography (CT) and Magnetic Resonance Imaging (MRI), 
provide more accurate estimation of different body tissues from cross-sectional images of the body. 
Adiposity can be quantified using multiple consecutive scans to determine areas of subcutaneous and 
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internal adipose tissue that can then be converted to volumes as the distance between consecutive 
slices is known. The underlying principles of this method are briefly outlined here. 
MRI utilises hydrogen nuclei (1H), principally from water and fat, as described above.  Hydrogen is 
one of the most abundant NMR active nuclei in the body, and it is distributed widely throughout most 
tissues.  This means the radio waves, emitted from 1H after excitation, are sufficient to be converted 
into a detailed image.  The intensity of the signal is relative to the number of hydrogen atoms present, 
and this enables different tissue types to be identified.  However, the number of 1H alone cannot 
distinguish between all tissues, fat and muscle for example, do not have markedly different amounts 
of hydrogen. 
To differentiate between fat and muscle, a MR property known as ‘relaxation time’ (T1) is used.  This 
is the time it takes for the nuclei to release the energy they have absorbed from the applied radio 
frequency pulse, and return to their natural state.  The T1 for 1H in fat and muscle tissue are different, 
thus, T1 can be used to distinguish these tissues from each other within an image. 
The detection of different T1 times can be maximised by adjusting the time interval between each 
radio frequency pulse (Time to repeat=TR) and the time to detect the induced signal (Time to 
echo=TE).  This process is called the pulse sequence, and each specific sequence is developed to 
provide the optimum image, in the minimum scan time, for the particular tissues under investigation. 
MRI images are acquired in ‘slices’, so the whole body or a particular section is scanned in a series of 
fixed width slices.  The scan produces a series of cross-sectional images that together make up the 
body or segment.  Each image must be analysed individually and then tissue area calculated.  As the 
slices are of a known width the tissue relative volume or weight can also be calculated. 
 
MRI has been validated for measurement of both muscle and fat content in phantoms, animals and 
human cadavers.  It has been shown to accurately measure adipose tissue content in vivo, 
demonstrating good agreement with the values produced by dissection and chemical analysis256,257.  
MRI has also been shown to be reliable and reproducible, with the coefficient of variation ranging from 
0.3 – 2.3% for reproducibility and approximately 2% for reliability257. 
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Choice of Body Composition Measurement Technique 
It is important to understand that anthropometric-based measures such as BMI, waist circumference 
(WC), and waist-to-hip-ratio (WHR) estimate fat mass at different locations and may therefore reflect 
different etiological perspectives, and thus do not assess identical phenomena258. Waist 
circumference for instance, tends to reflect both total and abdominal adiposity; whereas BMI may 
represent fat-free mass or fat mass but does not account for the wide variation in body fat distribution 
at any given level of body size1,259. As such, these indirect surrogate measures are at present 
insufficiently precise, as there can for example be individuals with a moderately high BMI that have a 
low fat mass; as well as individuals with a low BMI and a disproportionately high fat mass.  Therefore, 
in order to develop more reliable and accurate surrogate measures to allow easier and more 
accessible methods to be used in field situations, an accurate quantification of body fat is an essential 
starting point.  Advances in medical imaging means newer and more sophisticated techniques, such 
as magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS) and computerised 
tomography (CT) that offer high resolution and sensitivity260,261, can now be used to measure specific 
tissues and importantly their regional distribution, for example subcutaneous and intra-abdominal fat.  
 
 Such issues underpin the importance of a sensitive assessment of the “excess fat mass” to better 
identify obesity and related health risks and also to fully investigate the extent to which generalized 
and/ or regional obesity are associated with the different health risks seen. 
It is clear to see that studies investigating the association between intra-abdominal adipose tissue and 
disease require an accurate and reliable measure of the different adipose depots. IAAT is a particular 
case in point. Owing to the considerable variability in IAAT for both men and women IAAT requires 
direct measurement for accurate quantification262,263.  Even within a narrow (2 cm) range of either 
sagittal diameter or BMI, there can be an approximate three-fold variation in total IAAT264. Even 
though a similar level of BMI appears to affect metabolism or metabolic syndrome components 
differently between populations, differences in fat distribution partially explain some of these.  
 
The purpose of the current research was to fully quantify adiposity in various populations with 
predicted phenotypic differences including a comparison between South Asian and Caucasian 
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participants, and also both lean and obese populations with documented differences in their physical 
fitness.  
1.5. Aims of the thesis 
 
The aims of this thesis are: 
 
1. To examine the relationship between BMI and regional adiposity using whole body MRI & 
regional MRS.  
 
2. To evaluate the accuracy of 2-C body composition measurement techniques (UWW, 
BodPod, bioimpedence, skinfold) for assessing adiposity in non-obese men.  
 
3. To examine the relationship between BMI and adiposity in the MONW phenotype.  
 
4. To examine the relationship between BMI and adiposity in the Fat-Fit phenotype.   
 
5. To determine whether the relationship between BMI and adiposity differs with ethnicity 
(specifically in South Asians vs Caucasians).  
 
 
Hypotheses 
 
Study 1 hypotheses: 
Hypothesis 1:     2-C methods (UWW, ADP, BIA, skinfolds) are a valid alternative to MRI for 
adiposity quantification.  
Hypothesis 2:     The Viscan BIA device is an accurate intra-abdominal adiposity proxy 
measurement method. 
Study 2 hypotheses:    
Hypothesis 1: The established TOFI index can identify individuals with adverse fat distribution 
within the normal BMI range (18.5<25 kg/m2). 
Hypothesis 2:    Established proxy (anthropometric) measures are able to successfully identify 
MONW individuals within a large cohort of healthy Caucasians.  
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Study 3 hypothesis:     Fitness results in reduced IAAT and ectopic fat, regardless of overall adiposity. 
 
Study 4 hypotheses:  
Hypothesis 1:   South Asians have greater internal and ectopic adipose stores than age and 
BMI matched Caucasians of the same gender. 
Hypothesis 2: The established TOFI index can identify South Asian MONW individuals with 
adverse fat distribution within the normal BMI range (18.5<25 kg/m2). 
Hypothesis 3:   Established proxy (anthropometric) measures are able to successfully identify 
South Asian MONW individuals. 
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Chapter 2.  General Research Methods and Procedures  
 
 
This chapter describes the experimental detail of all the measurement techniques used for each 
investigation in the thesis.  
 
Personal contribution to research presented in thesis. 
Owing to the fact that there have been collaborative projects published from aspects of the data 
included in this thesis, it is necessary to outline my personal involvement and contribution to the work 
being presented. The background to the research environment is that my research was a sub-
component of a larger ongoing research program in the group.  
During my time as a PhD student I was directly involved in the scanning of all the participants  
included. My role was to set up the magnet for each of the participants:  
- calibration of magnet with phantom 
- participant consenting & metal checking 
- scan room database entry and image transfer (for backup) 
- explanation of procedure to participant (health & safety, protocol etc)  
- repositioning  (for each different scan in sequence) and centering of participant in magnet 
- accompaniment during scan sequence (if necessary) – for extremely anxious individuals 
- trained in voxel localization by radiographers 
I also performed all the following :  
- anthropometry : height, weight, skinfolds, limb and body segment girths 
- Viscan measurements (abdominal BIA device) 
- UWW, BodPod, BIA, measures (Bedford Campus lab) 
- VO2 max tests at Hammersmith Hospital Unit 
- Analysis of own data (with help from statisticians listed  - where necessary)  
I was not permitted to do the MRI analysis as data analysis was outsourced for reliability (see details 
in this chapter), but I was mentored and trained by Dr Louise Thomas to inform my work and 
understanding. While MR spectroscopy required one trained analyst (for reliability) I was trained MR 
spectroscopy analysis and my work quality checked by Dr. Thomas before I subsequently performed 
MRS analysis on my data and other studies when Dr Thomas was maternity leave. During that time I 
maintained the database used for data management and recruitment.  
During the course of the research, I personally recruited approximately 110 participants using email, 
newspaper articles (with correspondence details listed), flyers and posters. The remaining subjects 
from the cohort presented here were from other studies in the group, to which I was granted access 
due to my contribution to data acquisition and analysis.  
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2.1. Ethics 
Ethical approval for this study was obtained from the main Research Ethics Committee (REC) of 
Hammersmith and Charing Cross Hospital, London (Rec: 07Q04011/173) as well as additional site-
specific assessment (SSA) ethical approval from Bedfordshire REC, Essex (Ref: 08/H0309/56) for the 
University of Bedfordshire site (Appendix 1). All volunteers gave informed written consent for the 
study. Informed consent was obtained as follows: The study was discussed with each volunteer 
individually to explain the study procedures in detail, the potential benefits of participation, any 
potential risks and the rational for the study itself. After this discussion the individual was given the 
study information sheet and the study consent form (Appendix 1).  The volunteers were given the 
opportunity to ask questions about the study and were subsequently given at least 24 hours to 
consider whether they wished to participate.  Any objection to participating was accepted, and the 
volunteers did not need to provide a reason for a refusal to take part.  The participants were assured 
that they were not obliged to enrol in the study and additionally, should they wish to, they could 
withdraw from the study at any time without giving a reason and without penalty. 
2.2. Participants 
Inclusion criteria required that participants be ambulatory with no medical conditions that could 
potentially affect any of the variables under investigation. Only self-reported, healthy participants, 
without any diagnosed medical conditions, were enrolled in the studies. All participants completed 
detailed screening to ensure suitability for inclusion (Appendix 1) Detailed participant information 
appropriate to each study can be found in the relevant chapter. 
2.2.1. Recruitment 
All participants were recruited randomly from the general public using various advertising media 
resources (email, poster, published newspaper article contact, television program research 
contribution contact, commercial radio research interview contact etc.) as well as from local 
community groups, public festivals and from any existing research volunteer databases.  
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2.3. Assessment protocol 
All participants were asked to attend the Robert Steiner MRI Unit (Hammersmith Hospital, London.) 
on the morning of their booked assessment. Participants were asked to fast from midnight the night 
before testing. The sequence of assessment was:  
1. Check for completion of medical history and general information documents (sent to all 
volunteers in advance of first visit). Witnessed signing of consent and metal check documents 
(Appendix 1). 
2. Participants asked to change into hospital issue theatre garments (‘scrubs’ = trousers and 
top) provided for them, retaining only underwear (pants). All jewellery/metal objects were to 
be removed. 
3. Baseline anthropometric measures were then performed as well as, where indicated, 
additional body composition techniques. 
4.  MRI scan pre-check was completed to ensure that no metal was being taken into magnet 
area. This included a verbal confirmation from the participant, to myself and the senior 
radiographer, that their signed metal check was accurate. A final physical check (hair clips, 
removable dentures, jewellery etc) was also conducted. 
5. MRI whole body scan & MRS of calf muscle and liver were performed.  
6. Post-scan aerobic capacity test undertaken (in appropriate study only).  
2.4. Anthropometric methods 
Body mass (kg), height (cm), waist circumference (WC) (cm) and hip circumference (cm) were 
measured in each participant. From these values, BMI (kg/m2), waist-to-hip ratio (WHR) (waist/hip) 
and waist-to-height ratio (WHtR) (waist/height) were calculated.  To minimise measurement error and 
increase accuracy and reliability of anthropometric measures, I personally performed all 
measurements using established, standardised protocols, thereby reducing any potential error.   
 
2.4.1. Standing height (Stature) measurement protocol 
Standing height (stature) was measured against a wall-mounted stadiometer (Seca, Birmingham, 
U.K.) employing the stretch stature method265. This method requires the participant to stand unaided 
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(barefoot) looking straight ahead with their feet together and their heels, buttocks and upper part of 
the back touching the measurement scale. The head when placed in the Frankfort plane need not be 
touching the scale. The Frankfort plane is achieved when the orbitale (lower edge if the eye socket) is 
in the same horizontal plane as the tragion (the notch superior to the tragus of the ear). When aligned 
the vertex is the highest point on the skull.  During positioning my hands were placed along the 
participant’s jaw (under their mandible) with my fingers reaching to the mastoid process. Keeping the 
head in the Frankfort plane, I stretched the participant by applying gentle upward lift through the 
mastoid processes while the participant took (and held) a deep breath. The stadiometer headboard 
was then lowered firmly on the vertex, gently compressing the participants’ hair as much as possible. 
Stature was measured to the nearest 0.1 cm. This measurement was repeated a second time. Owing 
to the fact that there can be diurnal variation in stature266, with participants being taller in the morning 
and shorter in the evening, all measures were taken in the mornings.  
2.4.2. Weight measurement protocol  
Weight was measured using a calibrated digital platform scale (TANITA electronic Scale WB-110MA, 
Tanita Corporation, Tokyo, Japan) with participants wearing only light clothing (hospital issue theatre 
‘scrubs’ – provided), barefoot, and with an empty bladder. Weight was recorded to the nearest 100 g. 
The scale was standardized to zero before each use and regularly calibrated using standard 
procedures. 
2.4.3. Waist & Hip circumference measurement protocol 
Standing waist circumference was measured at 4 different sites with a non-flexible anthropometric 
tape, and recorded to the nearest 0.1cm.  The sites included: midpoint (at the midpoint between the 
lower costal margin and the iliac crest), the umbilicus (at the level of the umbilicus), the minimal waist 
(the observed minimal waist as viewed anteriorly) and iliac crest (at the level of the iliac crest).  In 
addition, supine waist circumference was also measured at the level of the umbilicus.  All waist 
measurements were taken at the end of a normal expiration, with the tape held snuggly against the 
skin (ensuring its horizontal position), without pulling the tape too tightly so as to avoid compressing 
the underlying tissues.   
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Hip circumference was measured in the standing position at the level of the greater trochanter and 
incorporated the maximal circumference over the buttocks. From these measures waist to hip ratio 
(WHR) and waist to stature ratio (WSR) were calculated.  
 
2.4.4. Skinfolds measurement protocol 
 
Prior to taking skinfold measurements the exact location of each skinfold was measured and marked 
using standardised guidelines267, based on identifiable anatomical landmarks. This was to ensure 
accuracy and reproducibility of the measurements268. The designated skinfold locations should ideally 
be marked because the measurements are made from multiple successive cycles of all sites. The 
rationale for ‘cycling’ the measurement sites is that subcutaneous adipose tissue at each site, once 
measured, must be allowed to ‘relax’ to its pre-test state so that successive measurements are not 
subject to cumulative tissue compression. This method ensures that all measures are made on fully 
“relaxed” tissue at identical anatomical locations.  
 
The skinfold measures were taken on the right side of the body (irrespective of limb dominance) in 
accordance with standardised measurement sites and techniques267,269 using calibrated Harpenden 
skinfold calipers (CMS Instruments, London, U.K.). The accuracy of the calipers used was routinely 
checked using calibration blocks (precision cut brass blocks of known widths) and a high precision 
Vernier caliper set to a series given widths (10mm, 20mm, 30mm). Manufacturer recalibration was 
also an option had calibration errors were experienced. It must be mentioned that there is no 
consensus for body side recommendation in anthropometric research; mainly owing to the fact that 
the minor differences seen between left and right-sided measurements owing to handedness were so 
small compared to the measurement error involved as to be considered trivial270,271. I chose to adopt 
the right-sided measures so as to align my work with the majority of large population studies (e.g. the 
National Health Examination Surveys – NHES, and the National Health and Nutrition Examination 
Surveys -  NHANES272,273) in the United States, which form the basis of worldwide reference data, and 
took measurements on the right side. However, in Europe and also in many developing countries the 
general practice is to take measurements on the left side as recommended by the International 
Biological Program274. Skinfolds for the chosen sites were made using the flat surfaces of my thumb 
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and forefinger to pull a fold of skin away from the underlying muscle. Care was taken to ensure the 
fold was not under tension or compression at the point where it was to be measured and in line with 
standard practice the calipers were applied perpendicular to the fold being measured. Constant 
tension of the calipers was made 1 cm from my fingers and at a point where the edges of the skinfold 
were parallel (a depth about equal to the thickness of the fold). Each fold was then held during the 
measurement process and readings were made to the nearest 0.1mm four seconds after the 
complete release of the caliper trigger. After all the required sites had been measured once, the 
sequence was repeated twice more, in the same order, and the mean of the three readings was 
recorded. Values that differed from each other by more than +/- 10% were repeated until this criterion 
was met268. If there was any doubt about the presence of muscle tissue, the participant was asked to 
make a voluntary contraction of the muscle involved to ensure that only subcutaneous adipose tissue 
was being measured. 
 
In the past a number of different skinfold profiles have been used, with up to 10 sites in some 
profiles274. The International Society for the Advancement of Kinanthropometry (ISAK)267 defines a 
standard skinfold profile as incorporating 7 skinfolds sites. The 7 sites measured are detailed on the 
following pages. The skinfold values measured can be summed to provide simplistic comparative 
values or they can be incorporated into equations to compute estimates of percentage adiposity. The 
exact number of skinfold values required for adiposity prediction varies depending on which particular 
equation is being employed. There are over 100 equations for predicting adiposity from skinfold 
measurements, based on requirements of different numbers of skinfold sites as well as different 
combinations of skinfold sites. This diversity is owing to the fact that the equations are population-
specific and are based on the criterion value used in their specific validation study.  
In my study I used a four site equation suitable for both males and females. The Durnin and 
Womersley275 sum of four skinfolds formula uses skinfold values from biceps, triceps, subscapular 
and suprailiac (Iliac crest) sites. Like many others, this formula was validated using densiometry so it 
only predicts total body density (TBD) from the sum of four skinfolds. The computed value for TBD 
can then be converted to a predicted percentage body fat (%BF) value using Siri’s equation 246,276.  
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Equations.  
Where ∑4 = sum of 4 skinfolds : bicep, tricep, subscapular, iliac. 
Body density  = 1.1610 – 0.0632 log ∑4 (men) 
Body density  = 1.1581 – 0.0720 log ∑4 (women) 
! 
% Body fat (BF) (Siri, 1956) = [(4.95 / body density) – 4.5] x 100 
 
       
Skinfold sites and measurements. 
 
1. Triceps 
This skinfold was raised on the marked posterior mid-
acromiale-radiale line (approximately midway between the 
top of the shoulder and the elbow joint). The fold is vertical 
and parallel to the line of the upper arm. With the participants 
arm relaxed, the skinfold was taken on the most posterior 
surface of the arm over the triceps muscle.  
       
            
 
          Figure 2.0.A  Triceps skinfold measure. 
 
2. Subscapular 
Participants were asked to stand with their arms by their 
sides. The inferior angle of the scapula was palpated to 
determine the lowermost tip of the shoulder blade. The 
skinfold was raised 2 cm along a line running laterally and 
obliquely downwards from the landmark (approximately 45o) 
following the natural fold lines of the skin. 
Figure 2.0.B  Subscapular skinfold measure. 
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3. Biceps 
This skinfold was raised on the mid-acromilae-radiale line so 
that the fold ran vertically i.e. parallel to the axis of the upper 
arm. The participant stood with the arm relaxed, the shoulder 
joint slightly externally rotated and the elbow extended. The 
fold was located on the most anterior aspect of the right arm.  
 
 
                
         Figure 2.0.C  Biceps skinfold measure. 
 
 4. Supraspinale (Iliocristale) 
This fold was raised approximately 5-7 cm above the anterior 
superior iliac spine on a line from the anterior axillary border 
to the spinale.  The fold runs diagonally (medially) following 
the natural cleavage lines of the skin.                      
      
 
 
Figure 2.0.D  Supraspinale skinfold measure. 
5.  Iliac Crest (Suprailiac*) 
With the participants arm abducted to 90 degrees to the 
horizontal and the trunk erect, the most lateral superior edge 
of the ilium was palpated and the identified edge of the ilium 
was marked in line with the imaginary line made to the mid-
line of the axilla. This skinfold was raised immediately at this 
landmark above the iliac crest. The fold is directed diagonally 
(anterior and downward) in line with the natural fold of the 
skin.  
Figure 2.0.E  Iliac Crest skinfold measure. 
* NB. This was referred to as the Suprailiac by Durnin and Womersley. 
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6. Abdominal 
This is a vertical* fold raised 2 cm lateral (right) to the centre of 
the omphalion (mid-point of the navel). The initial grasp is firm 
and broad since often the underlying musculature is poorly 
developed. This is a standard guideline to avoid any 
underestimation of the thickness of the subcutaneous layer of 
tissue267.  
* NB. Vertical fold used for Jackson & Pollock equations; horizontal fold used with 
other equations.  
             Figure 2.0.F  Abdominal skinfold measure. 
 
 
7. Medial Calf 
With the participant either seated or with the foot on a box 
(knee at 90o) and with the calf relaxed, the vertical fold was 
raised at the pre-marked location, on the most medial aspect 
of the calf at its maximal circumference.  
  
 
 
 
              
Figure 2.0.G  Medical Calf skinfold measure. 
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2.5. Indirect Adiposity quantification:  2-C model methods 
Participants had their body composition measured by 2C model methods on one day and were 
scanned by MRI on a separate day within the same week following identical preparation (i.e. fasted 
from midnight on night before test and no vigorous exercise in previous 48 hours). As all 2C model 
methods were tested on the same day, it was important to ensure underwater weighing (UWW) was 
the last technique used as excess moisture on the skin can affect the accuracy of the other 
measurements. The testing order was as follows: skinfolds, bioelectrical impedance (Tanita, Bodystat 
Quadscan and 1500 devices), air displacement plethysmography (ADP / BodPod) and UWW. 
Protocols for use of all devices were as per manufacturers guidelines.  All 2-C measures were 
conducted at the Sport and Exercise Science laboratory, University of Bedfordshire (Polhill, Bedford 
Campus), Hertfordshire. 
 
 
2.5.1. Bioelectrical impedance analysis (BIA) using Tanita (BC-413 MA) 
 
Participant information (gender, height and age) was entered manually into the device via the main 
control panel according to the manufacturers guideline. Wearing minimal clothing the participant was 
required to step onto the platform at the base of the device, carefully placing their feet on the 
electrode plates. The participant was asked to stand still while a measurement of weight was 
acquired. The participant then grasped the handles of the Tanita device, one in each hand, ensuring a 
tight grip around the electrodes of the handles. While standing still, with their arms by their side 
slightly abducted from the body, an unperceivable micro-current was passed through the hands and 
feet around the body, for approximately 5 seconds. Body composition data from the device printout 
were recorded on each participant’s data sheet. 
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(Original image.) 
Figure 2.1  Tanita BC-413 MA impedance analyser  
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Figure 2.2 Four-surface electrode BIA technique applies current via one pair of distal (injector) electrodes, while 
the proximal (detector) electrode pair measures the potential across the conducting segment.   (from Lippincott 
Williams & Wilkins, 2001.)  
 
2.5.2. Bioelectrical impedance analysis (BIA) using Bodystat devices 
 
These bioelectrical impedance devices (Bodystat 1500 and Bodystat Quadscan 4000) were used 
according to the manufacturer’s instructions (Bodystat, Douglas, Isle of Man.).  
The participant was laid in a supine position for a standardised 5 minutes prior to testing to ensure 
body fluids had static and stable. During this time the participant was prepared for measurement. 
Disposable, single-use sensor (proximal) electrodes were placed on the dorsal surface of the wrist 
with the upper border of electrode bisecting the styloid process of the ulna and radius, and on the 
dorsal surface of the ankle with the upper border of electrode bisecting the medial and lateral malleoli.  
Source (distal) electrodes were placed at the base of the second or third metacarpal-phalangeal joints 
of the hand and foot as per the manufacturers guidelines (Appendix 2). 
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Figure 2.3.  Proximal and distal electrode placement for whole-body BIA (adapted from Heywood and 
Wagner, 2004) 
 
The electrode sites were cleaned with an alcohol wipe and were shaved to remove excess hair (if 
required) to maximise skin contact and conductivity. The participants arms and legs were comfortably 
abducted (35-40°) as recommended277, ensuring no contact between the thighs, and the arms and 
trunk to prevent any “short circuit” of the path of the electrical current, and affecting the impedance 
value.  I then manually entered baseline participant information (height, weight, gender, age, and self-
reported activity level) into the device setup according manufacturer guidelines. One setup was 
complete I activated the device to allow delivery of a micro-electrical current through the participant 
(approximately 5 seconds duration). As with other devices, results from the device were recorded on 
each participant’s data sheet. Due to the fact that a micro-current is used in such BIA devices, a 
contraindication to use is if the participant has a pacemaker or is pregnant. These conditions were 
exclusion criteria in the study.   
Proximal 
Distal 
5 cm  
 54 
 (Original image) 
Figure 2.4.  Bodystat Quadscan 4000 for whole-body BIA showing 2 sets of leads attached; one pair 
for upper limb and one pair for ipsilateral lower limb (red = proximal, black = distal)..  
 
2.5.3.  Bioelectrical impedance analysis (BIA) of the trunk (VISCANTM ) 
 
Abdominal fat content was measured using a VISCAN body fat analyser. During measurements, 
participants were instructed to lie supine wearing the theatre garments provided for MRI scanning. The 
standard test position was supine, with arms by sides (slightly abducted, elbows flexed at 90 degrees, 
with hands interlocked and resting on lower portion of rib cage), with clothing moved to allow full 
visualisation of the umbilical area (i.e. no undergarments impinging on test area. Participants were 
instructed to relax and breathe normally. Arm positioning was standardised to aid repeatability and 
prevent participants from placing their hands behind their neck to support their head and thereby 
potentially distorting resting abdominal dimensions by unnecessary potential elevation of rib cage and 
visceral (abdominal) region or contraction of abdominal muscles. 
Protocol 
• According to the manufacturer’s (Tanita Corporation, Tokyo, Japan) guidelines, the fully 
charged base unit was placed over the exposed umbilical area.  
• With the power on, the infrared positioning light was aligned at the navel, and participant 
gender was selected on integral control panel.  
• On activating the device ‘start’ button, the participant waist circumference was measured non-
invasively using the ViScan measurement system comprising an infrared beam projected over 
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the waist at the umbilical sagittal plane, detected by eight in-built infrared sensors on either 
side of the base unit. The result was then displayed on the unit control panel.  
• With the participant still supine, impedance was measured, using the ViScan system. The 
electrode belt holding four sensors (essentially a tetrapolar impedance method involving two 
pairs of injecting and sensing electrodes manifested as a wireless measurement “belt”) was 
then placed, in the sagittal plane, on the exposed midriff at the umbilicus, which had been 
lightly dampened (using moistened paper towel) to ensure optimum contact (Figure 2.5). 
Correct positioning of the electrode belt was ensured using systems infrared (laser line) 
positioning line, which was then confirmed by a short auditory beep.   
    
For participants with a very large waist circumference (> 130 cm), where the base unit could 
not be placed over the abdomen –the electrode belt was placed on the abdomen as usual 
(waist <130 cm), and then the base unit was positioned near, but not over the individual being 
tested. The “waist circumference > 130cm mode” was selected. The trunk and visceral fat 
measurements were taken as before and transmitted wirelessly to the base unit for display.      
• The manufacturers dual frequency BIA technology then allows the electrical signal to be 
passed through the abdominal area providing the visceral and trunk fat results (displayed on 
unit control panel).  
• These ViScan abdominal body composition values are derived from extrapolation of 
impedance measures  (at 6.25 KHz and 50KHz) using inbuilt software. 
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(Original image.) 
Figure 2.5    ViScan measurement system in operation.  
 
ViScan abdominal body composition values are sub-divided into:  total abdominal adiposity (i.e. IAAT 
+ ASAT), expressed as % trunk fat (range 0-75%), whereas IAAT is expressed as “visceral fat” 
(arbitrary units ranging from 1 to 59).  The ViScan also rates these 2 measures using arbitrary band 
ratings of “low”, “average” and “high” for % trunk fat and “average”, “high” and “very high” for visceral 
fat.   
 
2.5.4. Underwater weighing (UWW) 
 
Underwater weighing (UWW) determines body fat values from body density. Body density (D) is the 
ratio of body mass to body volume  (ie. Mass / Volume). It is based on the whole-body principle of 
Archimedes, which states that an object’s loss of weight in water equals the weight of the volume of 
water it displaces278. All participants were required to wear minimal clothing, i.e. tight fitting pair of 
swimming briefs along with a weighted diving belt to stop the participant from floating to the surface of 
the tank, this is particularly important for individuals with more adipose tissue, as excess fat will make 
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the participant more buoyant. (Care is taken to exclude the additional weight of the diving belt from all 
final participant values and calculations.) 
Before the underwater measurement was made, each participant had their dry weight and lung 
volume (forced vital capacity - FVC) measured. FVC was measured using a calibrated volume 
displacement spirometer (Vitalograph Gold Standard 2150, Vitalograph Ltd. Buckingham, U.K.) 
according to the manufacturers established protocol guidelines. The spirometer was calibrated before 
all testing sessions using a known volume (3L) calibration syringes. (The 3L calibration syringe is 
regularly volume checked using a calibrated water displacement method in addition to being serviced 
and checked by the supplier – Cranlea Ltd, Birmingham, UK.)    
   (Original image.) 
Figure 2.6. Vitalograph Gold Standard 2150 used for spirometry.  
 
UWW Test procedures :  
1. An appropriate bathing suit was to be worn (i.e. one that did not add to buoyancy by trapping 
air - preferably nylon). 
2. Participants were asked to have showered before the procedure in order to be devoid of 
excess body oils. Additionally, they were asked to have urinated and defecated, if possible, 
as well as to have removed all jewellery. 
3. Normal hydration was requested and participants were asked to be 3-12 hours post-
absorptive state (in this case fasted from midnight before test). 
 58 
4. The underwater weighing tank used should ideally be as small and as controlled as possible. 
The temperature was maintained between 33-36 oC, as the density of the water is determined 
based on its temperature (eg.  38 oC water density = 0.99296).  
5. Participants were weighed pre-immersion (dry land weight) in as little clothing as possible.  
6. A weight (diving) belt was attached to each participant to assist submersion. 
7. The participant’s underwater weight was recorded several times. Each weight was measured 
after a deep, full expiration. Participants needed to be fully submerged and at residual volume 
(5-10 seconds). The movement of the apparatus under the water was kept to an absolute 
minimum at the time of recording and UWW was recorded to the nearest 0.01 kg.  
8. On exiting the UWW tank, the water temperature is recorded as well as the weight of the 
diving belt and accessories (eg. chains used etc) to ensure the participants weight was the 
only one recorded. 
 
On entering the filled UWW tank care was taken to ensure participants did not disrupt the water 
unduly, and also avoided contact with the suspended seat attached to the load cell. In preparation for 
testing each participant was familiarised with the UWW technique by instructions to slowly submerge 
themselves fully under water and gently using their hands to eliminate any trapped air on the skin, 
hair and swimsuit.  
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  (Original image.)  
Figure 2.8.A. Underwater weighing (UWW) system used in study.  
 
Before measurements were undertaken each participant was recommended to practice the technique 
of fully exhaling before they submerged their head under water. Participants were then asked to 
practice gradually expelling any residual air left in their lungs while fully submerged. Once competent 
with this technique participants were required to sit on the suspended “button” chair - this too required 
familiarisation before the participant could balance on the seat. Once comfortable and balanced on 
the seat, the participant was instructed to repeat the exhalation and submersion process, avoiding 
contact with the sides of the tank, so not to produce a false underwater weight. During the seated 
submersion trials (once they had fully expelled any remaining air in their lungs) participants were 
instructed to remain still for as long as they could comfortably do so (approximately 10 seconds 
maximum) in order to allow the underwater weight to be recorded with minimal fluctuation.  
Once the weight was recorded the participant was instructed to ascend from under the water so they 
were not holding their breath unnecessarily long and instructed to breathe normally between trials. 
This process was repeated until 3 readings were within 100g of each other.  The mean of 3 final 
values was used as the underwater weight. The recorded values were used along with the 
participants’ pre-test, dry (land) weight in the calculation of body density (used to estimate body 
composition) using established formulae (1.3):   
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BD  =               mass(g)        (1.3)  
    volume (cm3) 
 
BD =                        mass of body in air (g) 
               Mass of body (g) – mass of body in water (g)  
 
BD =                                    mass of body in air (g) 
                        Mass of body (g) – mass of body in water (g)         _  residual volume 
                                       Density of water 
   
 
 
2.5.5.  Air displacement plethysmography – ADP (BodPod®)  
 
Before the measurement procedure all participants were instructed to completely void their bowels 
and bladder. In line with the manufacturers guidelines (to standardise the exclusion of trapped air in 
body hair) all participants were requested to remove all items of jewellery and to wear only a tight 
fitting swimsuit and swimming cap.  Baseline calibrations of the empty chamber with and without a 
standard phantom (40.995 L metal calibration cylinder) were performed before each participant as per 
the manufacturers guidelines. Once weighed on the integrated (calibrated) digital weighing scales, the 
participant was seated in the BodPod® (ADP) chamber and instructed to sit in the centre of the seat 
resting their back against the rear wall of the chamber with their feet in the centre of the base of the 
BodPod, with legs apart and their hands on their lap and instructed to remain still and breath normally. 
For safety reasons each participant was shown the emergency stop button (located inside the 
chamber), which releases the door if required for any reason. With the chamber door shut the test 
initiation activates magnetic door locks. Following each 50 seconds measurement, the BodPod 
chamber door was opened fully in order to avoid any potential feelings of claustrophobia by the 
participant. During these standardised door open intervals, participants were asked if they are ready 
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for the next test and happy to proceed. Once confirmed the door was gently shut and the second test 
was undertaken.  
If the repeat measurements disagreed by more than 150 mL, a third test was performed. If no two 
tests were in agreement by 150 mL, the entire process including calibration was repeated until two 
test values met the required accuracy. The resultant (accepted) test values were averaged and used 
in the calculation of raw body volume. The calculation of a body volume, height and weight must be 
used to estimate body surface area.  Predicted thoracic gas volume was also used in this calculation. 
Body surface area is required to account for the negative volume produced by the isothermal air 
surrounding the surface of the body. According to manufacturers guidelines, thoracic gas volume 
(TGV) was also accounted for owing to the isothermal air in the lungs and airway. Raw body volume, 
surface area artefact and TGV are used to produce a corrected body volume. This resultant value 
was used to estimate body density, which was then used to estimate percentage body fat. 
 
 
 
Figure 2.7  General arrangement of Bod Pod® front (test) chamber containing participant and rear 
(reference) chamber separated by a diaphragm mounted in common wall. Electronic oscillation of the 
diaphragm during testing produces minute (± 0.5cm H20) complimentary pressure changes in the 
chambers allowing derivation of an unknown volume from the direct pressure measurement. 
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Figure 2.8  Bod Pod™ Air Displacement Plethysmography (ADP) system used in study.  
(Original images.) 
 
2.6.  Direct Adiposity quantification: assessment by MRI and MRS  
2.6.1.  MR setup protocol  
On a single visit, participants underwent total body MRI scanning and in vivo proton (1H) magnetic 
resonance spectroscopy (MRS) of their liver and their calf muscles.  
Calibration 
The MR equipment was calibrated each day according to manufacturers guidelines using a 
standardized phantom to detect drifts in measurements. Additionally, equipment servicing and 
upgrading was performed regularly.  
 
Participant positioning & safety. 
Participants lay in a prone position with arms straight above the head, and were scanned from 
fingertips to toes. All participants were screened (Appendix 1) before scanning to ensure no metallic 
items were taken into magnet field – to avoid personal injury as well as any radiographic artefacts that 
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could compromise the MR images and the subsequent image analysis. Standard health and safety 
protocols were followed for all scanning. These included:    
1. Participants being provided with hospital issue theatre garments to wear during scanning to ensure 
removal of all personal clothing that might pose a risk / alter scan images, 
2.    Participants being instructed to lie very still during scanning to avoid image artefact. Sandbags 
and foam pads were used to support / brace limbs and ease muscle tension or unnecessary 
discomfort. 
3.  Ear defenders were worn at all times during scanning – manufacturers headphones or in-ear foam 
plugs, 
4. All cables in contact with participant were shielded and positioned according to strict MR safety 
guidelines to provide maximum protection.   
5. Participants were given an emergency buzzer to hold at all times to alert operating staff to any 
problems. As well as being fully instructed on scanning procedures beforehand – participants were 
reassured and communicated with at all times using a built-in open channel audio system 
(microphone and speaker) between the scanner room and the operators observation room (equipped 
with behind magnet video capability to monitor all aspects of the procedure).  
6. All staff entering the magnet area were appropriately trained in magnet safety and duly observed all 
departmental MR safety protocols.  
 
Figure 2.9  Phillips Achieva 1.5T MRI scanner used in all studies.  
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2.6.2. MR assessment of adiposity  
 
MRI of total body and regional adipose tissue 
Whole-body magnetic resonance (MR) images were obtained using a 1.5T multinuclear scanner 
(Phillips AchievaTM, Philips Medical Systems, Best, Netherlands) using established protocols 
previously described in detail by Thomas et al. (1998)279. The images were acquired using a whole 
body axial T1-weighted spin echo sequence and a Q body coil, without respiratory gating (typical 
parameters: repetition time (TR) 560ms; echo time (TE) 18ms; slice thickness 10mm; interslice gap 
10mm; flip angle 90 degrees; number of excitations 1). Initially coronal and sagittal whole body views 
were obtained to allow planning of the transverse images (Figure 2.10). 
  
Figure 2.10 .Sample coronal and sagittal MR images. (Original image.) 
  
Transverse images were then acquired as nine equal stacks of 12 slices at the isocentre of the 
magnet. A typical dataset is shown in Figure  2.11 
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Figure 2.11 Sample MRI image dataset from transverse acquisition sequence. (Original image.) 
!MRI Adipose tissue quantification (data analysis methods) 
  
As part of this research I was mentored and trained by Dr Louise Thomas in the use the commercially 
available software specifically designed for image analysis (SliceOmatic: Tomovision, Montreal, 
Quebec, Canada). This extensive training was to inform both my work and my understanding.  Using 
this software, each image was segmented into subcutaneous and internal adipose tissue, and the 
relevant pixels coded accordingly. This process is summarised in Figure 2.12. However, since my 
data and research was part of a much larger research program involving many projects, I was not 
permitted to perform the MRI analysis and the data analysis was outsourced for reliability purposes. 
All outsourced images were quantified, using the above method, by an independent data analysis 
company (Vardis Group, London, U.K.), who were blinded to the specific participant and project 
details.  
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Figure 2.12 The grey scale image was initially processed using mathematical morphology to segment 
the subcutaneous and internal fat. These were labelled (Tagged) with specific colour codes for each 
depot. In these studies, subcutaneous fat was coded green and internal fat coded red. Manual editing 
was then applied to remove pixels incorrectly assigned to fat, such as those arising from motion or 
bowel contents. 
 
The adipose tissue volumes (cm3) of each compartment were calculated by summing the number of 
pixels and multiplying by the known pixel dimensions (in cubic centimetres). Adipose tissue volume 
for the whole body was then calculated by multiplying the adipose tissue volumes of each slice by the 
sum of the slice thickness (10 mm) and interslice distance. 
 
Total and regional adipose tissue volumes were subsequently recorded in litres (L). These consisted 
of total adipose tissue (TAT), subcutaneous adipose tissue (ASAT) and internal adipose tissue (TIAT).  
These depots were further refined to enable measurement of abdominal adipose tissue depots. The 
abdominal region was defined as the images between the slice containing the femoral heads to the 
slice containing the top of the liver or the bottom of the lungs, usually between 15–17 images in most 
individuals279. The adipose tissue within the abdomen was therefore separated into intra-abdominal 
adipose tissue (IAAT) and abdominal subcutaneous adipose tissue (ASAT). Outside the abdominal 
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regions, adipose tissue was separated into non-abdominal subcutaneous adipose tissue (NASAT) 
and non-abdominal internal adipose tissue (NAIAT) as previously described by members of research 
group279. An additional quantification of abdominal adiposity as a whole, was derived from the sum of 
IAAT and ASAT, and termed “trunk” fat. 
 
 In summary: 
1. Total Adipose tissue = Subcutaneous AT + internal AT 
2. Subcutaneous AT (SAT) = abdominal subcutaneous AT (ASAT) + non-abdominal 
subcutaneous AT (NASAT): SAT = ASAT + NASAT. 
3. Total internal AT (TIA) = intra-abdominal AT (IAAT) + non-abdominal internal AT (NAIAT): 
Internal = IAAT + NAIAT. 
4. Total Trunk AT = IAAT + ASAT. 
 
Regular quality control duplicate datasets were also used to verify the accuracy of the outsourced 
image analysis. This involved internal reanalysis of randomly chosen sets of data - the results of 
which were then compared to the respective outsourced data results. In these datasets adipose tissue 
areas were estimated by a single trained observer (Dr. Louise Thomas) to minimise operator error 
(and variability) and maximise reliability. The coefficient of variation of these methods is low, ranging 
from <1% for total fat to 5% for visceral fat 280.  
 
Adiposity data were expressed in three ways;  
1) Absolute volume (L): adipose compartment volume in litres;  
2) Percentage of body mass (%kg): the total mass of each deposit (kg) was obtained by multiplying its 
volume in litres with the density of fat, which was taken to be 0.9gm/cm3 281. Percentage adiposity 
values for each fat compartment were calculated by dividing the body mass in kg by the appropriate 
fat store (% adiposity = fat (kg) / body mass (kg) x 100);  
Absolute volume provides information on the total volume of an adipose compartment, %kg data is 
useful as it includes information about fat mass relative to lean body mass.   
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MRS of liver and muscle adipose tissue 
During the same scanning session, 1H MR spectra were also acquired at 1.5T, using a flexible body 
coil. Participants were positioned supine, arms resting by their side, and legs supported with the hips 
slightly flexed using a foam wedge (to prevent lumbar discomfort from flat surface of scanning table) 
as in Figure 2.13.  
(Original image.) 
Figure 2.13 Supine positioning for MR spectroscopy acquisition.   
 
Liver MR Spectroscopy: 1H MR spectra were acquired at 1.5 T from the right lobe of the liver using a 
PRESS (point-resolved spectroscopy) sequence (TR 1500 ms/ TE 135 ms) without water saturation 
and with 128 signal averages. The right lobe was chosen owing to its larger size and its ease of 
imaging owing to it being closer to the centre of the magnet. As part of my research and to inform my 
work I underwent extensive training with experienced members of the research team (radiologists: 
Julie Fitzpartick and Giuliana Durighel, and senior researcher - Dr Louise Thomas) in order to be able 
to position participants in the magnetic field correctly and locate the voxel in the area of interest 
accurately. Transverse images of the liver were acquired and used to ensure accurate positioning of 
the (20x20x20 mm) voxel in a representative region of the liver, avoiding blood vessels, the gall 
bladder, and fatty tissue. Typical images and corresponding spectra from participants with high and 
low levels of liver fat infiltration are shown in figure 2.14 
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 Figure 2.14 Typical in vivo 1H magnetic resonance spectra from the livers of volunteers with (a) low 
fat infiltration and (b) high fat infiltration.  (Original image.) 
 
Muscle Spectroscopy: Intramyocellular lipids (IMCL) were measured in the soleus (S-IMCL) and 
tibialis (T-IMCL) muscles by obtaining proton MR spectra (1H MRS) from the respective muscles of 
the left calf of all participants, using the same PRESS sequence described above. For each of my 
data measurements I placed the voxel in a representative region of tissue that avoided visible streaky 
fat and main blood vessels.  
 
Figure 2.15 Typical in vivo 1H magnetic resonance spectra from soleus muscle Cho, 
choline-containing compounds (carnitine + glycerophosphocholine); Crtot, creatine + 
phosphocreatine; IMCL, intramyocellular lipid; EMCL, extramyocellular lipid. 
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This ability to select volumes if interest at different regions within a given tissue is a distinct advantage 
to using MRS for such analysis. While there are other methods for measuring muscle lipids, such as 
electron microscopy and morphometry282-284 or biochemical assay285-287, these and invasive and 
require a tissue biopsy. MRS has a high correlation (0.934) with EM morphometry, thus negating such 
invasive procedures; but has a low correlation (0.47) with biochemical, which additionally has less 
sensitivity to distinguish IMCL from EMCL288.  
A typical image and corresponding spectrum obtained from the soleus muscle of the left leg is shown 
in figure 2.15. Lipid resonances (IMCL) were quantified with reference to the total muscle creatine 
signal, in accordance with protocols previously published by the research team 289.  
 
The coefficient of variation for these methods is approximately 7% for IHCL290 and 2% for IMCL291. 
MRS data (IHCL, S-IMCL and T-IMCL) were presented as the geometric mean, while statistical 
analysis was performed on log10-transformed variables, owing to the positively skewed distribution of 
these data-sets 292. 
 
 
MRS analysis 
Following acquisition I then analysed the 1H MR spectra for my research subjects to determine the 
concentration of both IHCL and IMCL using spectral fitting applications (jMRUI / AMARES). The MRUI 
(jMRUI = Java based version) software is a graphical user interface (GUI) that allows time-domain 
analysis of in vivo MR data. Quantification of the reconstructed signals was performed in the time-
domain. AMARES293, as included in the jMRUI software package294, uses Fourier analysis to fit all 
relevant metabolites using established prior knowledge in the software setup. I used the AMARES 
algorithm to resolve the components of my acquired spectra based on the stored prior knowledge for 
the tissue and metabolites. AMARES is essentially a non-linear least square, fitting algorithm 
operating in the time domain and allows the inclusion of a large amount of prior knowledge through a 
so-called singlet approach. Intrahepatocellular lipids (IHCL) were measured relative to liver water 
content, according to previously published research295 and were expressed as a percentage ratio of 
the CH2 lipid peak area relative to the water peak area after correction for T1 and T2 relaxation. 
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Typical examples of the fitting process applied to the liver and soleus muscle are shown in figures 
2.16. A and 2.16. B respectively.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.16.    1H spectrum of the liver (A) and soleus muscle (B) processed by AMARES.  
a: Measured spectrum.  b: Fitted spectrum. c. Individual components. d. Residue. 
 
 
 
2.7. Fitness Assessment: VO2max 
Aerobic fitness was assessed via oxygen consumption (VO2) measurement using an automated, 
breath-by-breath gas analyser (Metalyser 3B, CORTEX Biophysik GmbH, Leipzig, Germany), this is 
an on-line cardiopulmonary gas exchange system. This ‘indirect calorimetry’ is used to calculate 
values for oxygen uptake from the difference between ambient gas composition and the expirate. The 
system comprises three major components: gas analysers for carbon dioxide (infrared) and oxygen 
(paramagnetic), a turbine or ‘triple-V’ sensor for recording gas flow (and hence volume) and a central 
processing unit (CPU) and a monitor to integrate and display graphical information in real time.  
a 
b 
c 
d 
A B 
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(Original image.) 
 
Figure 2.17   Automated breath-by-breath gas analyser used for aerobic fitness testing.  
 
 
Calibration 
Prior to every trial the gas analysers were calibrated using known concentrations of CO2 and O2 
(Cranlea Ltd, Birmingham, UK) and the flow-volume sensor was calibrated using a 3-litre syringe 
(Cranlea Ltd, Birmingham, UK). The system contains hardware to allow the continuous measurement 
of ambient temperature and barometric pressure and automatically corrects values, made for expired 
air, to standard temperature (0 oC), barometric pressure at sea level (101.3 kPa) and dry gas (STPD). 
Measurements are all made at BTPS (body temperature and pressure saturated) under ambient 
conditions where gas water vapour saturation varies with changes in temperature, pressure and 
moisture in the air. BTPS measurements are converted to STPD. The gas is dried to remove water 
vapour pressure from the measurement, allowing greater ease of comparison.  
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Validation 
The accuracy of the computerized, breath-by-breath, metabolic system (Cortex Metalyser 3B) used 
was periodically compared against the criterion Douglas bag method, which is considered the “gold 
standard’ for cardiopulmonary gas exchange assessment, in order to check the validity of the on-line 
system in determining a number of cardiopulmonary parameters.  The Douglas bag method is an 
historic manual measurement method whereby large impermeable (non-diffusing) collection bags, 
linked in series, are used to collect expired gases over a known time period (eg. 1 minute). 
Subsequently, gas fractions of oxygen and carbon dioxide are measured offline from the contents of 
these collection bags using calibrated gas analysers (for O2 and CO2) for each respective gas. At the 
same time, expired gas volumes in these collection bags are measured using a dry gas meter and 
vacuum pump to ensure matching of the gas fractions with the ventilatory volumes. The summary 
coefficients of variation (i.e. the differences between Cortex Metalyser 3B and Douglas bags) in this 
study were:  VE 1.40%, VO2 0.60%, VCO2 0.10%, RER 1.20%. Most certifying organizations tolerate 
a maximal error of 4% in VO2 determination296. The British Association of Sport and Exercise 
Sciences (BASES)297 advises that less than a 2% difference for VO2 between Douglas bag and an on-
line gas analysis system is acceptable. The Cortex (Metalyser 3B) system used in this research was 
therefore deemed accurate and acceptable.   
 
VO2 max  
Maximal aerobic power, or VO2max, is the upper limit of the criterial standard of cardiorespiratory 
fitness, maximal oxygen uptake and is the maximum rate at which an individual can extract oxygen 
and then transport and utilize it in tissues while breathing air, at sea level298. In vivo, there exists a 
finite reactant supply and thus, at some stage, as external power is increased, there will be no further 
rise in VO2 299,300 . Thus, VO2 is a measure of 1) the maximal energy output by aerobic processes and 
2) the functional capacity of the circulatory system 301. Criteria for attainment of VO2max are generally 
accepted297 as being:  
 
1) an increase inVO2 <100 mL (2mL kg-1 min-1 ) between the final 2 workloads, and  
2) an increase in HR <5 bpm between the final 2 workloads, (or final heart rate within 10 beats 
min-1 of maximum value or predicted age-related maximum : 220-age) 
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3) a final respiratory exchange ratio (RER) greater than 1.15.   
VO2 max must, by definition, cause volitional exhaustion between 9 and 15 minutes 297.  
If the plateau in criteria 1) is not achieved (or the test lasts less than 9 minutes or more than 15 
minutes) then the resulting value is referred to as VO2 peak.  This is deemed a satisfactory index of 
aerobic power as there is usually less than 3% difference between a ‘max’ and a ‘peak’ value302.  
However, it is now becoming widely accepted that attainment of a true VO2max value requires a further 
verification phase (test) as in many cases individuals being tested may not exhibit a clearly definable 
VO2 plateau, despite giving a maximal effort303-305. It is well known that there are also concerns about 
using the term VO2 max when the exercise test does not incorporate the largest possible proportion of 
muscle mass (e.g. in cycling tests as compared to treadmill tests). With the exception of elite cyclists, 
most individuals undertaking a cycle test may experience a greater degree of local muscle fatigue 
during their maximal exertion and not elicit a true VO2 max.  In such cases where the primary criterion 
(1. listed above) for VO2max is not attained / evident (i.e. absence of definable VO2 plateau), secondary 
criteria (i.e. 2) and 3) listed above) would be used for confirmation. These secondary criteria have 
been criticised306,307 on the basis that these can in cases be satisfied at exercise intensities as low as 
73% of VO2 max. 308 . The physiological reasons for this greater degree of fatigue may be linked to the 
fact that cycling may require a greater force output than running and may cause greater fast twitch 
fibre recruitment – with a corresponding increased lactate production (through glycolytic metabolism) 
compared to the oxidative slow twitch fibres309.  Additionally, there may be reduced blood flow in the 
legs during cycling compared to running310, thus further increasing the local fatigue.     
Resulting values for VO2 max (or VO2 peak) are generally expressed as absolute terms (L. min-1). As 
there is a strong positive relationship between body size and absolute values (L. min-1), these can be 
divided by body mass to yield a relative value (mL.kg-1 min-1) in an attempt to overcome the effects of 
differences in body mass when comparing values. In weight bearing sports / activities the relative 
value is more commonly used and in non-weight bearing sports / activities the absolute value is more 
often used. Maximal oxygen consumption (VO2 max) was expressed in absolute terms (L.min-1) and 
relative terms (mL.kg.min-1).  
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Heart rate (HR) measurement 
Heart rate was measured before, during and after exercise tests. Heart rate (HR) was monitored 
using a Polar (Polar Electro, Finland), telemetry system (chest strap transmitter & watch monitor) as 
well as by a telemetry receiver linked to the on-line gas analyser (Metalyser 3B, CORTEX Biophysik 
GmbH, Leipzig, Germany). The manufacturer quotes accuracy for heart-rate measurement of 1% per 
minute for steady-state conditions. The resultant heart rate data was digitally processed in real-time 
and integrated simultaneously with the on-line gas analysis data using inbuilt proprietary software 
(Metasoft 3, CORTEX Biophysik GmbH, Leipzig, Germany).  
 
(Original image.) 
Figure 2.18  Integrated cardiopulmonary exercise testing components used. 
 
 
VO2max protocol 
Cardiovascular fitness was measured with an incremental (ramp) exercise protocol. The incremental 
cycle test was performed using a calibrated electronically braked ergometer (Lode Corival, Lode, 
Germany) employing an automated incremental increase in workload of 15 watts / min until voluntary 
exhaustion. All participants started from 50 watts. Participants were requested to maintain a constant 
pedal frequency of 60-70 rpm throughout the test (rpm rate displayed to participant on cycle 
ergometer digital display). To aid the timing of the cycling tempo, a digital metronome with an acoustic 
beep (set to 60 beats / minute) was also used so that participants could maintain the requested 
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constant pedal frequency more easily than just viewing the ergometer visual feedback display.  
Standardised (scripted) verbal cues were given to all participants to encourage a maximal effort.  
Cycle ergometry was the chosen mode of exercise: 
1) owing to limited available space in hospital location for a treadmill installation and use,  
2) to accommodate participants that may be unfamiliar with treadmill use (and therefore require 
prior familiarization sessions) and to avoid unnecessary risk,  
3) to accommodate participants that may be non-exercisers,  or participants of a very low fitness 
level who could be disadvantaged owing to skill needed for effective treadmill use.  
 
With all tests there are safety concerns, but with maximal fitness testing these relate to the fact that 
the test is difficult and stressful. Many individuals with chronic disease or disability, do not achieve a 
‘true’ VO2max. Instead, they reach a point at which they cannot continue because of limiting factors 
such as mental fatigue, fear, lack of motivation or symptoms such as chest pain and light-headedness. 
In these cases, the individuals are said to have reached ‘symptom-limited exhaustion’ and this is 
referred to as VO2 peak. A further issue with cycle tests, as opposed to treadmill tests, is that 
individuals can often reach a point of peripheral fatigue, before central (cardiorespiratory) fatigue that 
prevents them reaching a ‘true’ VO2max. This can happen when the test workloads are increased by 
too big an increment at any point. This is due to the fact that cycling demands a greater power output 
than running, which causes increasing recruitment of more fast twitch (glycolytic) fibres as the test 
progresses. This increasing recruitment of predominantly glycolytic metabolism results in increased 
lactate production, leading to fatigue, decreasing power output and reduced blood flow the legs310. 
This series of events often happens before long before any limitations in the supply of oxygen.  In 
such cases the final value should be referred to as VO2 peak. Additionally, it is the job of the test 
supervisor to observe the person exercising at all time in case the participant experienced discomfort 
or showed signs they were becoming unwell during a test. In the absence of cardiac (ecg) monitoring, 
observing for signs of poor perfusion (cyanosis or pallor), ataxia, dizziness or discomfort would be a 
priority. Standard guidelines311 do exist for detailing ‘absolute’ and ‘relative’ indications for stopping a 
test.    
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2.8. Statistical Analysis 
 
Statistical calculations were performed using SPSS software (version 17.0, SPSS Inc, Chicago, IL, 
U.S.A.) throughout this thesis. Statistics appropriate to each study can be found in the relevant 
chapter. Additional statistical advice and support was provided during aspects of the thesis by 
Caroline Dore (MRC Clinical Trials Unit, London. UK) and Mr. Peter Sheard (Faculty of Health and 
Social Sciences, University of Bedfordshire, Beds. UK).  
 
! !
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Chapter 3. Comparison of body composition techniques. 
3.1. Introduction 
One of the key issues in the quantification of adiposity is the method of measurement. While many 
studies have reported that different populations have greater body fat depots than others 197,312-314, the 
studies have used a variety of measurements – not all of which give the greatest accuracy and may 
therefore have limited applicability. Studies exclusively measuring body composition with 
anthropometric measures such as waist-to-hip ratio (WHR) and body mass index (BMI) could 
potentially miss valuable data owing to low predictive accuracy. For instance using a methodology 
such as MRI, which enables accurate quantification of regional adipose tissue depots such as internal 
fat, may influence the outcome of a clinical study. This is particularly the case for certain populations 
in whom it is known that simple anthropometric measures under predict adiposity315. 
 
As an example, despite its convenience, BMI fails to account for the composition of body weight, 
which is comprised of mainly fat, lean tissue and bone mineral. Previous studies have confirmed that 
the relationship between BMI and relative body adiposity varies considerably by age, gender, and 
race/ethnicity 200,316,317. Additionally, the waist-to-hip ratio is also a poor indicator of regional adipose 
tissue distribution since it is influenced by a number of factors such as frame size and skeletal muscle 
mass 318.  
Since obesity is technically characterized by excess fat mass, a measure of whole body adiposity (% 
body fat) only provides an estimate of relative adiposity or leanness. Such proxy measures do not 
account for the heterogeneity that is inherent in human body composition, especially since body fat and 
its distribution are known risk factors for metabolic abnormalities53,54,104.  The risks associated with 
excess adiposity have consistently been shown to be a function of regional fat distribution, rather than 
overall fat volume53,54 owing to the stronger associations with physiological and pathological 
processes55-58.  
 
While various methodologies exist to measure overall body adiposity319,320, available methods for 
measuring regional adiposity are more limited. Simple anthropometry is often used as a predictor of 
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abdominal adiposity, for example, an increased waist circumference has been shown to be an effective 
predictor of abdominal obesity321.   
 
Abdominal obesity relates to excess adiposity at the abdomen and is known to predispose individuals to 
diabetes and cardiovascular disease83. Adipose tissue in the abdomen is found in several 
compartments, the ones that can typically be measured using MRI include abdominal subcutaneous 
adipose tissue (ASAT) and intra-abdominal adipose tissue (IAAT).  Elevated IAAT, (also referred to as 
“visceral fat”) is associated with insulin resistance, dyslipidemia, systemic inflammation, diabetes, 
hypertension, myocardial infarction, and all-cause mortality85,91,322,323. While proxy measures such as 
waist circumference may reflect actual measured abdominal adiposity it is not in itself a direct measure 
of either ASAT or IAAT and may not be sufficiently sensitive to detect changes in abdominal body 
composition324.  This is further complicated by that fact that abdominal subcutaneous and intra-
abdominal fat compartments may expand independently of each other and there is no simple metric 
relationship between IAAT and total adiposity 325-327.  
 
Magnetic resonance imaging (MRI) and computed tomography (CT) are the ‘gold standard’ methods 
for measurement of ASAT and IAAT176.  However, both are high cost techniques, labour intensive, 
non-portable and of limited availability for wide application.  
 
This study aimed to assess the accuracy of several different whole body composition methods 
(devices) to accurately measure/predict adiposity with reference to the different AT depots as well as 
an assessment of regional body composition measurement methods. For the comparisons made, 
MRI-based techniques of body fat distribution and ectopic fat content were used as the gold standard 
criterion measurement.  
 
Therefore in this chapter I have compared body fat measures derived from hydrodensitometry, bio-
impedance and anthropometry, to measures of adiposity from MRI in a heterogeneous group of male 
and volunteers. MRI-based techniques were used to determine the criterion range of all adiposity 
stores for all participants in the cohort.  The study was divided into 2 parts: 
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Part A – Comparison of general (total) body composition methods  
Part B – Comparison of abdominal adiposity measurement methods 
 
In doing so the study aimed to use assess the feasibility of these different devices (techniques) to 
provide accurate, and relatively more affordable measures of adiposity. 
 
Objectives:  
1. Quantify adiposity stores in a cohort of healthy volunteers using MRI and MRS. 
2. Part A: To evaluate the accuracy of four different 2-C body composition measurement 
techniques (UWW, BodPod, BIA, skinfolds) in a group of 21 non-obese men (10 South Asian, 
11 Caucasian) against the criterion (gold standard) magnetic resonance imaging (MRI).  
3. Part B: Assess the accuracy of abdominal adiposity proxy measurement methods to predict 
regional adiposity derived from MRI in a group of 74 adults Caucasians (40 females and 34 
males. 
 
 
Study Hypotheses:  
 
Hypothesis 1:   2-C methods (UWW, ADP, BIA, skinfolds) are a valid alternative to MRI for adiposity 
quantification.   
 
Hypothesis 2:  The Viscan BIA device is an accurate (internal) abdominal adiposity proxy 
measurement method.   
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3.2. Methods 
 
Recruitment issues. 
During Part A of this study, involving comparison of multiple 2-C devices (UWW, BodPod, BIA, and 
skinfolds), there was a low participant number (N= 21) as there was extreme difficulty recruiting 
sufficient willing volunteers to all tests conducted. The low number recruited was due to several 
factors. The first major obstacle to recruitment was participant reluctance to give up half a day (at 
maximum – including travel) for the battery of tests that were involved.  Whilst most of these 
individuals would volunteer for the MRI component, the additional measurement techniques were 
usually the limiting factor. This may have been because participants perceived there was intrinsic 
benefit in the medical (MRI) scanning component as opposed to the other ‘non-medical’ techniques.  
However, it is widely accepted that with UWW a major limitation is that it requires a highly motivated 
participant who is willing to don bathing attire, complete effective spirometry, is willing and capable of 
exhaling prior to submersion in a water tank and can be confident in that tank for a period of 
approximately 30 seconds. In some cases, it was discovered that subjects that were successfully 
recruited and willing, subsequently found they were not comfortable with or were unable to 
successfully complete the submerged component. Another aspect of the additional techniques that 
hampered recruitment was that obese individuals are les inclined to want to undertake such testing 
that requires minimal attire, let alone, close fitting swim-type costumes that are necessary for the 
UWW and ADP measurements (to prevent air being trapped that may influence results adversely).  
The ADP measurement, whilst not involving water, involves sitting in a close fitting sealed chamber, 
which can feel claustrophobic (despite the chamber having a perspex viewing window) and may feel 
especially so for large framed and obese individuals.  The state of undress and need for close fitting, 
minimal clothing with the addition of a swim cap (to prevent air trapped in hair confounding results) 
can put volunteers off. 
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Participants 
Written, informed consent was acquired from all volunteers. Ethical approval permission for this study 
was obtained from the Research Ethics Committee of Hammersmith and Queen Charlotte’s and 
Chelsea Research Ethics Committee Hospital, London (Rec: 07Q04011/19). In total, 84 volunteers 
(44 male: 34 Caucasian, 10 South Asian; 40 female Caucasian) were recruited. All participants were 
aged 20-70 years. Self-reported exclusion criteria included participants suffering from chronic disease 
including diabetes, cardiovascular or liver disease, metabolic conditions, claustrophobia, and anyone 
taking prescribed medication and women on the contraceptive pill.  
 
Anthropometric measurements 
Body mass (kg), height (cm), midpoint328 waist circumference (WC) (cm) and hip circumference (cm) 
were measured in each participant as detailed in the General Research Methods and Procedures 
section (Chapter 2). From these values, BMI (kg/m2), waist-to-hip ratio (WHR, waist/hip) and waist-to-
height ratio (WHtR, waist/height) were calculated. As previously mentioned, BMI grouping 
corresponded to the following ranges; 1: 18.5<25 kg/m2, 2: 25<30 kg/m2, 3: 30<40 kg/m2, 4: 40+ 
kg/m2. 
 
Measures of Adipose Tissue Content 
Part A 
On a single visit, a sub-group of 21 male participants, underwent: whole body MRI scanning, total 
body fat measured using bioelectrical impedance (BIA), air displacement plethysmography (ADP or 
the BodPod), underwater weighing (UWW) and skinfold anthropometry according to the methods 
described in Chapter 2. 
 
Part B  
On a single visit, a sub-group of 74 male and female participants (33 males, 40 females), underwent: 
whole body MRI scanning, abdominal body fat measured using an abdominal adiposity device 
(Viscan BIA), and anthropometry according to the methods described in Chapter 2. 
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Statistical Analysis 
Part A 
In order to assess the validity of the five predictor variables were compared to the criterion. The 
relationship between MRI, ADP, BIA UWW and SKF percent body fat estimates was examined using: 
repeated measures ANOVA to assess the differences of the mean percentage body fat scores both 
within and between Caucasian and South Asian male groups. Correlation coefficients and multiple 
linear regression analysis were used to assess the linear relationship between the criterion and 
predictor variables and agreement between body composition estimates was examined by calculating 
the 95% limits of agreement as explained by Bland-Altman329. 
The use of multiple regression allowed for the prediction of MRI body fat from one or more predictor 
variables. Potential bias between MRI percentage body fat and the predictor variables was assessed 
using residual plots. For all analysis the alpha level set for statistical significance was P<0.05, using 
SPSS software (version 17.0 SPSS, Chicago, IL, USA).  Satistical advice was provided during this 
study by Mr. Peter Sheard (Faculty of Health and Social Sciences, University of Bedfordshire, Beds. 
UK). 
 
Part B 
Agreement between methods of umbilical waist measurement (i.e. ViScan vs. manual measurement) 
was assessed according to Bland-Altman329 and systematic bias between methods was assessed via 
paired sample t-test.  As the units of the ViScan and MRI were not the same, Bland-Altman plots could 
not be constructed to compare the different measures of abdominal adipose tissue compartments.  
Pearson’s correlation coefficients were calculated to assess the association between MRI derived 
abdominal fat compartments and VISCAN BIA estimates.  Significant differences in MRI derived total 
abdominal fat between the ViScan trunk fat bandings and between IAAT and the ViScan visceral fat 
bandings were assessed using a one-way ANOVA.  Associations between other anthropometric 
measures and MRI derived abdominal fat compartments were also assessed using Pearson’s 
correlation coefficients.   All statistical analyses were performed using SPSS software (version 17.0 
SPSS, Chicago, IL, USA).  Level of significance was set at p<0.05.  
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3.3. Results 
3.3.1. PART A. Assessment of 2 Component (2C) measurement systems  
 
Descriptive Statistics 
This aspect of the study compared five 2-component (2C) model methods of estimating percentage 
body fat in 21 Caucasian and South Asian male participants. The group characteristics are 
summarized in Table 3,0. The Caucasian participants were older, taller (1.79 m ± 0.08 m vs 1.70 ± 
0.04 m, p=0.003) heavier (83.85 kg ± 9.30 vs 73.21 kg, p=0.025) and had a greater BMI compared to 
the South Asian participants. 
 
Table 3.0.  Characteristics of Caucasian and South Asian participants included in technique 
comparison study. 
  
All participants (n=21) Caucasian (n=11) South Asian (n=10) 
Mean ± sd range Mean ± sd range Mean ± sd range 
Age (years) 30.24 ± 9.94 31.00 33.36 ±11.67 30.00 26.80 ± 4.61 18.00 
Height (m) 1.75 ± 0.08 0.25 1.79 ± 0.08 0.25 1.70 ± 0.04 0.13 
Weight (kg) 78.78 ± 11.15 49.80 83.85 ± 9.30 34.20 73.21 ± 10.70 37.10 
BMI (kg m²) 25.81 ± 25.81 13.19 26.19 ± 3.34 11.13 25.38 ± 3.85 13.17 
Data expressed as mean ± SD. 
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Table 3.1 Comparison of adiposity measurements by five different methods (using six devices) 
in Caucasian and South Asian participants.  
  Caucasian (n=11) South Asian (n=10) Between groups difference 
Skinfolds 19.57 ± 1.48 26.53 ± 1.86  6.95 ± 2.37* P = 0.010 
BIA-Bodystat 15.98 ± 1.23 19.01 ± 1.54** 3.03 ± 2.37 P = 0.144 
BIA-Tanita 16.08 ± 1.51 22.00 ± 1.89** 5.92 ± 2.42* P = 0.026 
ADP 20.36 ± 1.97 30.09 ± 2.47 9.73 ± 3.16 P = 0.007 
UWW 18.91 ± 1.81 27.64 ± 2.27 8.74 ± 2.91* P = 0.008 
MRI 17.18 ± 1.88 30.29 ± 2.35 13.11 ± 3.01* P = 0.000 
 
Data expressed as means ± standard error, results of a repeated measures ANOVA.. Where BIA – 
bioelectrical impedance, ADP - air displacement plethysmography, UWW - underwater weighing and 
MRI - magnetic resonance imaging. * = between groups mean difference is significant (P<0.05), ** = 
within groups significant mean difference compared to MRI(P<0.05) 
 
MRI was taken to be the criterion, based on its acceptance as a direct method to measure body fat 
content and distribution. Within group comparison of Caucasians revealed no significant mean 
difference between the MRI and the five other methods of measuring adiposity (Figure 3.1). ADP 
overestimated MRI percent body fat by the greatest degree (3.19%), while both BIA devices, Bodystat 
and Tanita provided the closest measurement to MRI in the Caucasian group, underestimating 
percent body fat by 1.20% and 1.10%, respectively. UWW was ranked as the third closest measure to 
MRI, and skinfolds was fourth closest.  
 
However, within the South Asian group, there were significant differences between body fat measured 
by MRI and both BIA devices (Tanita and Bodystat). In contrast to the Caucasian group, in this 
population, BIA (Bodystat and Tanita) significantly underestimated % body fat by 11.27% and 8.29%, 
respectively. Unlike the Caucasian group, ADP exhibited the least difference to MRI percent body fat 
with a 0.20% underestimation, UWW was the second closest measure to MRI and skinfolds were 
ranked third.  
Comparing the different methods for measuring body fat content, all methods measured a higher 
percentage body fat in South Asian compared to Caucasian participants. Indeed, significant 
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differences in percentage body fat content between South Asian and Caucasian participants were 
detected using skinfolds (p=0.004), BIA-Tanita (p=0.026), BodPod (p=0.002) HW (p=0.016) and MRI 
(p=0.0001). Whereas no significant differences could be detected using BIA-Bodystat. The greatest 
measurable difference in % body fat between South Asian and Caucasian was obtained using MRI 
measured adiposity (Table 3.1).  There was significantly less variation in body fat percentage 
measured by the different techniques in Caucasian compared to South Asian participants (8.30 ± 2.82 
vs 12.95 ± 3.93, p<0.01), figure 3.0B. 
Figure 3.0A. Total body fat content of Caucasian and South Asian male participants measured 
by 6 different devices using 5 different techniques (all subjects).  
 
Data expressed as mean and SD. 
UWW – underwater weighing 
MRI – magnetic resonance imaging 
BIA – bioelectrical impedance analysis 
BodPod (ADP) – air displacement plethysmography 
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Figure 3.0B.  Total body fat content of Caucasian and South Asian male participants measured 
by 6 different devices using 5 different techniques (grouped by ethnicity).  
 
 
Data expressed as mean and SD. 
UWW – underwater weighing 
MRI – magnetic resonance imaging 
BIA – bioelectrical impedance analysis 
BodPod (ADP) – air displacement plethysmography 
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Figure 3.1 Mean differences and 95% confidence intervals for 2C devices (SKF, BODYSTAT 
(BIA), TANITA (BIA), ADP, HW and MRI) minus MRI  
 
Mean differences and 95% confidence intervals (CI) between MRI and the five predictor estimates of 
percent body fat are shown. The mean MRI % body fat value was subtracted from the mean % body 
fat value of each 2C device to produce a mean difference for both ethnic groups, the dashed zero line 
indicates MRI measured % body fat. The error bars representing the 95% confidence interval show 
that ADP in the Caucasian group is close to being significantly different from MRI, because the error 
bars only just cross zero. (a = Caucasian, b = South Asian) 
 
 
In the Caucasian group, all estimates of % body fat, with methods other than BIA (Bodystat and 
Tanita) overestimated % body fat compared to that measured by MRI. In contrast, in South Asian 
participants % body fat was underestimated by all 2C methods.  
 
 
Correlation analysis 
In the Caucasian participants, all 2-C methods (other than Bodystat), had a significant, positive linear 
relationship with MRI (Table 3.2). The strongest positive, linear relationship (r= 0.878, P≤0.0001), 
between ADP and MRI, was also found in this group.  
In the South Asian participants, all 2C methods, other than Tanita (BIA), had a significant, positive 
linear relationship with MRI. The strongest positive, linear relationships with MRI were demonstrated 
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by the South Asian comparisons with tricep skinfold thickness (r = 0.852, P = 0.004) and the skinfold 
analysis method (r = 0.821, P= 0.007). In the South Asian group, skinfold thickness measurements 
(bicep SKF, tricep SKF and subscapular SKF) all had stronger correlations (r = 0.807) with MRI % 
body fat compared to the Caucasian group correlation (r = 0.647). However, suprailiac skinfold 
thickness correlation with MRI body fat was similarly low in both ethnic groups (Caucasian:  r = 0.647, 
P = 0.020 and South Asian: r = 0. 610, P = 0.041). 
 
Table 3.2 Correlation coefficients (r) of five 2C model methods of estimating % body fat  
(including four individual skinfold sites) compared to the criterion MRI measure. 
  
Correlation coefficients (r) 
Caucasian (n = 11) South Asian (n = 10) 
MRI vs Skinfolds 0.721 P = 0.006 0.821 P = 0.007 
MRI vs BIA-Bodystat 0.508 P = 0.666 0.666 P = 0.050 
MRI vs BIA-Tanita 0.767 P =  0.003 0.529 P = 0.111 (n=7) 
MRI vs ADP 0.878 P ≤ 0.0001 0.796 P = 0.010 
MRI vs UWW 0.808 P = 0.001 0.748 P = 0.020 
MRI vs Bicep SKF 0.584 P = 0.030 0.807 P = 0.009 
MRI vs Tricep SKF 0.556 P = 0.038 0.852 P = 0.004 
MRI vs Subscapular SKF 0.626 P = 0.020 0.810 P = 0.008 
MRI vs Suprailiac SKF 0.647 P = 0.016 0.610 P = 0.041 
*= P<0.05, **=P<0.01.  
Where BIA – bioelectrical impedance, ADP - air displacement plethysmography,  
UWW - underwater weighing and MRI - magnetic resonance imaging 
 
There was also no significant correlation between Bodystat (BIA), tricep skinfold thickness and bicep 
skinfold thickness with MRI % body fat in the Caucasian group (table 3.2). Therefore, these variables 
were excluded from the subsequent multiple regression analysis (Table 3.3). This was also the case 
in the Asian Indian group for Tanita (BIA) and suprailiac skinfold thickness. 
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Regression analysis 
 
Regression analyses using a stepwise multiple regression produced, one model in the Caucasian 
group and two models in the South Asian group (Table 3.3). In the Caucasian participants ADP % 
body fat could predict 77.1% of the variance in MRI % body fat. The estimated coefficient of 
determination for the population (adjusted r²) reveals that 74.6% of the variance in MRI % body fat is 
associated with changes in the variable ADP in the population tested.  The final equation produced 
from this was MRI% BF =  0.757 + (1.76 × ADP% BF) 
 
Table 3.3  Regression analyses to predict MRI % body fat in Caucasian and South Asians. 
 
Model Intercept (A) Slope (B) r r² Adjusted r² s.e.e. P 
Caucasian 
1. (ADP) 0.757 1.76 0.878 0.771 0.746 3.274  0.000 
South Asian  
1. (Tricep SKF) 17.327 0.926 0.852 0.726 0.687 3.11  0.004 
2. (Tricep SKF) 0.757 0.716 0.962 0.926 0.901 1.75  0.000 
(UWW) 0.476 
Where s.e.e = standard error of the estimate 
 
In the South Asian group, two models were produced: the first including tricep skinfold thickness as a 
predictor. This could predict 68.7% of the variance in MRI % body fat resulting in the prediction 
equation: MRI% BF = 17.327 + (0.926 × tricep SKF). Interestingly the s.e.e was 3.11, similar to that 
produced in model 1 for the Caucasian group. The adjusted r² in the South Asian participants was 
greatly improved by the addition of the predictor variable UWW. In the revised equation combining 
tricep skinfold thickness and HW, 90.1% of the variance in MRI could be accounted for. The improved 
s.e.e (1.75) suggests that this model was the best predictor for MRI % body fat.  
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Agreement between measurement methods 
 
To further assess the validity of the models produced by the multiple regression analyses, Bland-
Altman329 plots were employed. Residual body composition scores of the included devices were 
analysed against those of MRI to determine the 95% limits of individual agreement. Agreement 
between MRI and ADP in Caucasian participants showed a mean difference (MRI-ADP %BF) of -3.19 
± 3.60 %, producing % body fat 10.39% below and 4.02% above that of the MRI measurement, 
suggesting significant agreement between the two methods. 
 
Figure 3.2  Bland-Altman plot showing bias of agreement between Caucasian MRI and ADP %BF 
scores (difference between MRI and ADP against their mean). Central line is group mean difference 
and the outer lines represent ± 2 standard deviations. 
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Similarly the Bland-Altman plot (Figure 3.3) for agreement between UWW and MRI shows a mean 
difference (MRI-UWW %BF) of 4.05 ± 3.99 %). Therefore, UWW results in a % body fat values 3.93% 
below and 12.04% above that of MRI measured % body fat.  
 
Figure 3.3. Bland-Altman plot showing bias of agreement between MRI and HW %BF scores 
(difference between MRI and UWW against their mean). Central line is group mean difference and the 
outer lines represent ± 2 standard deviations. 
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Reliability of 2C devices and MRI 
 
Repeated measurements of the different methods of measuring % body fat had a typical error less 
than 0.71% BF. After MRI, both BIA devices tested had the lowest coefficient of variation (COV), 
suggesting they were the most accurate methods, and could be used to reliably detect the small 
differences/changes. 
 
Table 3.4. Mean typical error of measurement (TEM) and mean TEM as coefficient of variation 
for each 2C device (95% limits of agreement) 
 
 CoV (%) and (95% CI) 
BIA-Tanita 2.8% (2.2-3.6%) 
BIA-Bodystat 2.2% (1.8-2.9%) 
ADP 4.0% (3.2-5.3%) 
UWW 4.0% (3.2-5.2%) 
MRI 1.0% (0.6-2.1%) 
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3.3.2  PART B - Assessment of abdominal adiposity measurement device – Viscan BIA. 
 
Descriptive Statistics 
The characteristics of the population used to assess the validity of the Viscan analyser to measure 
abdominal fat content compared to MRI measurements of visceral fat are summarised in Table 3.5. 
Taking the study population as a whole, body mass, and height were significantly greater in the male 
participants (P<0.001), whereas %BF was significantly greater in the females (P<0.001), with no other 
significant gender differences in the group (P≥ 0.06).  Participant characteristics and summary body 
composition compartments (MRI and ViScan) are shown in table 3.5, by gender and BMI group (lean 
vs. overweight/obese).  
  
 
Pearson’s correlation coefficients relating to MRI derived abdominal fat compartments in the whole 
population are shown in table 3.6.  The ViScan derived % trunk fat most strongly associated with MRI 
derived total abdominal fat (IAAT + ASAT) expressed as a percentage of body weight (r=0.938, 
P<0.001), explaining 88% of the variance in total abdominal fat.  This relationship is shown in figure 
3.4A. Lower correlations were shown with total abdominal adiposity and manual anthropometric 
measures that singularly explained between 23% and 68% of the inter-individual variance.  ViScan 
derived % trunk fat was the strongest single correlate with ASAT (r=0.884, P<0.001), explaining 78% of 
the inter-individual variance (this relationship is shown in figure 3.4B).  Other anthropometric measures 
individually explained between 16% and 72% of the variance. 
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Table 3.5 : Measured participant characteristics and body composition compartments, split by BMI (lean group represents BMI ≤  25 kgm-2, the overweight/obese 
group represents individuals with a BMI above 25 kgm-2). 
 Lean Overweight/obese† 
 males (n=13) females (n=18) males (n=21) females (n=22) 
Age (y) 36.7 ± 13.0 29.3 ± 10.4 42.1 ± 14.6 49.1 ± 15.1 
Body Mass (kg) 71.0 ± 7.2 58.8 ± 5.4* 91.4 ± 11.8 82.7 ± 14.2* 
BMI (kgm-2) 22.7 ± 2.0 21.5 ± 1.8 29.2 ± 3.3 32.0 ± 3.6 
Mid waist circumference (cm) 81.4 ± 6.5 71.8 ± 5.1* 97.0 ± 12.0 99.6 ± 12.3 
WHR 0.86 ± 0.07 0.76 ± 0.04* 0.92 ± 0.07 0.90 ± 0.09 
Truncal fat (mm) 
 
15.3 ± 4.0 13.8 ± 4.9 21.1 ± 7.9 26.1 ± 4.7* 
MRI     
total body fat (%) 19.8 ± 5.7 28.1 ± 6.4* 24.8 ± 8.0 47.0 ± 4.8* 
total abdominal fat (IAAT + ASAT) (kg) 4.5 ± 1.8 4.2 ± 1.3 8.3 ± 4.0 13.4 ± 3.7* 
ASAT (l) 3.1 ± 1.3 3.8 ± 1.1 5.9 ± 3.1 10.8 ± 3.1* 
IAAT (l) 1.9 ± 1.1 0.9 ± 0.4* 3.3 ± 2.0 4.2 ± 1.9 
IAAT:ASAT ratio 0.65 ± 0.35 0.23 ± 0.07* 0.58 ± 0.3 0.39 ± 0.18 
IHCL (%) 
 
0.8 ± 1.0 0.4 ± 0.7 6.4 ± 9.2 10.6 ± 13.8 
ViScan (BIA)     
ViScan % trunk fat (%) 20.2 ± 5.2 24.1 ± 7.3 28.9 ± 9.1 45.2 ± 4.6* 
ViScan visceral fat (no units) 6.8 ± 1.8 3.6 ± 1.3* 13.2 ± 6.2 10.9 ± 2.4* 
 
WHR= waist hip ratio.  Truncal skinfold measurements calculated as mean of repeated skinfold measures at 4 sites, namely subscapular, supraspinalae, iliac crest and abdominal; IAAT, intra-
abdominal adipose tissue,: ASAT, abdominal subcutaneous adipose tissue: IHCL, intra-hepatocyte lipid.  
* Significant gender difference within the same BMI group (P<0.05)  † All variables significantly different from lean group of the same gender (P<0.05) 
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Table 3.6: Pearson’s correlation coefficients for associations with MRI abdominal fat compartments.   
 
      IAAT ASAT IHCL Total abdominal 
fat (kg) 
Total abdominal 
fat  
 (% of body weight) 
ANTHROPOMETRY       
Waist (mid)  0.844 0.690 0.630 0.821 0.651 
Waist (umbilicus)  0.805 0.765 0.582 0.861 0.697 
Waist (supine umbilcus) 0.796 0.773 0.597 0.860 0.698 
Hip   0.613 0.846 0.461 0.844 0.670 
WHR   0.783 0.400 0.601 0.583 0.480 
WSR   0.82 0.798 0.606 0.889 0.825 
BMI 0.702 0.843 0.520 0.875 0.733 
Trunkal skinfold thickness 0.592 0.773 0.473 0.799 0.762 
VISCAN       
ViScan % Trunk fat  0.688 0.884 0.447 0.899 0.938 
Viscan Visceral fat   0.731 0.622 0.567 0.725 0.742 
 
Abbreviations: Waist (mid), midpoint between lower rib and greater trochanter; Waist (umbilicus), waist circumference at the level of the umbilicus; Waist (umbilicus supine),  
waist measured at the level of the umbilicus with the participant laying supine;  ; WHR, waist hip ratio,; WSR, waist-stature ratio; truncal skinfold, mean of repeated skinfold 
measures at 4 sites, namely subscapular, supraspinalae, iliac crest and abdominal.  IAAT, intra-abdominal adipose tissue,: ASAT, abdominal subcutaneous adipose tissue: 
IHCL, intra-hepatocyte lipid. All variables correlated at a significance of P<0.001 unless otherwise stated. 
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Figure 3.4A: Relationship between MRI derived total abdominal adipose tissue (IAAT + 
ASAT) expressed as a % of body weight, and % trunk fat as measured by the ViScanTM 
Measurement system 
 
 
 
 
As well as attempting to quantify abdominal fat compartments, the ViScan also categorises 
individuals into bandings of adiposity both for % trunk fat (“low”, “average” or “high”) and for 
visceral fat (“average”, “high” or “very high”).    How these categories relate to MRI measured 
adipose tissue compartments are represented as boxplots in figure 3.5 for both total abdominal fat 
(figure 3.5A) and IAAT (figure 3.5B). Following one way ANOVAs there was a significant 
difference in MRI derived total abdominal fat between the three ViScan categories of % trunk fat 
(P<0.001), with the “low” group significantly less than the “average” group (P<0.001) and the 
“average” group significantly less than the “high” group (P<0.001).  There was also a significant 
difference between ViScan visceral fat categories in terms of MRI derived IAAT (P<0.001).  
However, following post-hoc tests IAAT was only significantly different between the “average” and 
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the “high” groups (P<0.001) with no differences seen between the “high” and the “very high” 
groups. 
 
Figure 3.5:  Resultant boxplot s to show the ViScan derived banding of individuals in terms 
of abdominal fat compartments and MRI derived abdominal adipose tissue (n=74) 
 
Figure 3.5A: ViScan categorised percentage trunk fat 
 
Figure 3.5B: Viscan categorised visceral fat.    
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A further factor that was investigated in reference to the comparison between MRI and ViScan 
measures of visceral fat was the presence of fat in the liver. Participants were divided into two 
groups according to their liver fat content; High liver fat >2% (n=30) and Low liver fat <2% (n=44). 
The correlation between MRI and ViScan measures of visceral fat was stronger in the participants 
with low liver fat content (r=0.83, p<0.001) compared to those with high liver fat content (r=0.69, 
p<0.001). 
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3.4. Discussion 
 
Part A - Assessment of 2-Component (2C) measurement systems 
 
There have been very few studies comparing how conventional 2-C methods for measuring body 
composition compare with reference methodology (such as MRI) in different ethnic groups. The 
2C devices tested in this part of the study (Part A) were less sensitive in detecting difference 
between groups, generally overestimating Caucasian adiposity and underestimating South Asian 
adiposity (depicted in Figure 3). BodPod (ADP) was closest to MRI values in South Asians.  BIA 
was better at measuring % body fat in Caucasians while all other devices overestimated. Both BIA 
devices tested would be unsuitable for estimating South Asian adiposity, owing to the significant 
difference between their values and MRI. The remaining 2C devices could be valid tools.   
It is acknowledged that the rather modest sample size in this part of the study makes 
generalization of the prediction equations somewhat limited.  A larger sample population that 
considers obesity level and type would be required to confirm the prediction accuracy and enable 
generalisation to the wider community. However, there is no escaping the fact that even in this 
healthy, non-obese group there was considerable disagreement between the methods tested.  
When all participant data are considered (Figure 3.0A) the disagreement is however not as great 
as when the group are split by ethnicity (Figure 3.0B). The apparent polarisation of the results by 
ethnicity clearly demonstrates the limitations of assuming such different devices can be used for 
interchangeably for all groups.  
Possible reasons for the lack of agreement in methods point to the principles of 2-C models. The 
main criticism of the 2-C methods in body composition is that they are doubly indirect methods 
(discussed in Chapter 1) and are therefore based on assumptions that may not be entirely correct. 
The main assumption is that the fat-free mass (FFM) component is estimated to be 1.100 g/mL 241 
as there is no direct measurement available. Unsurprisingly, there is known variability in this fat-
free density measure242,243 as verified by bone mineral density (BMD) and cadaver 
studies220,222,223,225. Additionally, this measure was also found to vary with respect to ethnicity244. 
Within commercial measurement methods, like some of those tested in this study, the algorithms 
used to quantify % body fat were derived from a small number of Caucasians, and as such the 
equations employed are specific to the Caucasian population250,251. There is very little comparable 
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information on the density of fat and fat free tissues in the different ethnic populations, so it is 
unknown whether body composition values obtained via the 2C model are truly accurate for these 
groups. 
 
While it is well known that impedance based measures are influenced by age, gender and body 
water distribution219, body build is also believed to be a confounding factor. It has been shown in 
various studies that the contribution of the limbs to total body impedance is disproportional to the 
amount of water in these segments330,331. Population groups are known to differ in build. Malays 
and Chinese have relative short arms and short legs compared to their body height332 and Indians 
and Australian Aboriginals have relatively long legs333. Some studies report the impact of relative 
leg length on the relationship between BMI and %BF334-337. The same holds for slenderness as 
more slender individuals are reported to have less bone mass, less connective tissue and less 
muscle mass for the same height, resulting in higher %BF at the same BMI as a more stocky build 
person336,337. Also within ‘homogeneous’ ethnic populations, the bias in predictive body 
composition has been reported to depend on body build factors336.  
The errors seen in predicting body composition in this study may be linked to variability in body 
build between ethnic groups338, as variation in the relative distribution of weight and impedance 
amongst the limbs and trunk may confound body impedance algorithms that basically treat the 
body as a single cylinder.  The interrelated variation in body fat distribution also becomes a factor 
as this impacts on body geometry and is seen to vary with different ethnic groups and populations.   
 
The use of 2-C methods to accurately measure adiposity is problematic owing to the fact that such 
devices make indirect measurements of combined adipose depots that are not constant and vary 
differently between individuals and ethnic groups.  Accepting the fact that 2C methods can 
measure adiposity reasonably satisfactorily, the problem arises when they cannot account for 
ethnic / racial differences. There have already been specific correction factors developed for black 
participants based on their higher fat-free mass 244 but none yet exist for South Asians. The poor 
reliability of field devices to quantify adiposity points to the development of better ethnic specific 
corrections or algorithms. The fact that such affordable devices cannot yet distinguish between 
various internal adipose depots is a problem that will not be easily solved. Such methods are 
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more sophisticated than purely anthropometric surrogates of adiposity (BMI, circumference 
measures and their respective ratios) but are not significantly improving the quantification of 
adiposity for accurate health risk reduction.  A prime example being the larger areas of visceral 
adiposity seen in Japanese men compared to Caucasian men with the same waist 
circumference205.  
 
 
Part B - Assessment of Abdominal adiposity measurement device  
In this part of the study (Part B) comparisons between the ViScan and MRI were undertaken 
across a range of adiposity (i.e. obese and non-obese) to fully examine the influence of adiposity 
on ViScan measurement. In this study ViScan derived percentage trunk fat strongly and 
significantly related to TAAT and ASAT in both lean and overweight/obese individuals. 
Furthermore, ViScan derived “visceral” fat correlated significantly with IAAT but the strength of this 
relationship was much weaker in overweight/obese individuals. Similarly, the ViScan significantly 
overestimated waist circumference compared to manual measurement.   
 
In this cohort of adults ranging in body size, the ViScan appears to systematically overestimated 
waist circumference in comparison to manual measurement (both standing and supine) by 4-6cm. 
This is far in excess of the within-participant variation of manual waist measurement, shown to be in 
the order of 5-9mm 339.  This difference in waist circumference measurement between methods is 
likely explained by the fact that the ViScan is in reality a predicted measure using a patented “waist 
circumference calculator” technology. This method calculates a waist circumference of the human 
participant on the basis of the abdomen width, itself determined by the distance of each side of the 
abdomen from the two infrared sensors either side of the base unit.  Waist girth is more than likely 
then calculated based on a correlation between abdomen width and waist circumference stored in 
the memory of the machine.  It is unclear as to the potential impact this demonstrated error in waist 
prediction will have on the BIA derived body composition of the trunk by the ViScan.  Previous 
models of assessing whole body fat from BIA have used anthropometric data such as height and 
body mass to improve the predictive accuracy and reproducibility340 and one could speculate that 
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waist circumference is incorporated into the ViScan prediction equations to potentially give an 
estimate of the cross sectional area of the trunk (e.g. crudely as waist circumference squared).   
 
The ViScan method is a direct measurement of the transimpedance at the abdominal region, and 
therefore should better reflect the immediate local tissue compartments, particularly fat. In terms 
of total abdominal fat, % trunk fat as derived by the ViScan did show an excellent relationship to 
MRI total abdominal fat.   A strong relationship between ViScan measured % trunk fat, and DXA 
derived FM of the trunk has been reported previously by authors associated with the 
manufacturers341.  My study represents the first time this association has been independently 
confirmed against the “gold standard” for adipose tissue measurement, MRI.  However, it is 
difficult to directly compare methods like for like for two reasons; the ViScan does not quantify 
adipose tissue in terms of absolute mass or volume, while MRI analysis cannot express 
abdominal fat as a % of trunk weight because the non-adipose weight of the trunk is not 
measured by this technique.  
 
The use of transimpedance may have advantages over traditional segmental multifrequency BIA 
(eg Tanita device used in Study A comparing BIA devices) which has been used by various 
authors to estimate regional fat mass, almost exclusively utilising predictive equations based on 
DXA 342,343.   This traditional use of BIA is dependent on modelling the body segments (e.g. the 
trunk) as distinct cylinders, and utilising the relationship between the resistance of these cylinders 
and the FFM of the segment344.  Fat mass of the segment is then derived by subtraction of FFM 
from total mass, assuming a constant hydration of FFM.   Moreover, FFM (and therefore FM) in 
the trunk are often estimated, by difference, from the FFM and FM of the total body and 
extremities. Additionally, the measurement of trunk composition is heavily influenced by electrode 
placement, which has differed between authors. 
If it is assumed, via a prediction model, that the transimpedance is only influenced by the IAAT and 
ASAT compartments in the abdominal region then this is assuming the other non-adipose structures 
are constant. This may not take into account differences in other factors such as musculature, tissue 
hydration, or intestinal contents (gaseous or solid). It is also unclear how big an influence 
gastrointestinal (GI) or bladder contents have on measurements as in my study all participants were 
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measured following an overnight fast and having voided their bladder. This is a standard procedure 
with BIA devices, as additional fluid volume will potentially influence conductance and the 
subsequent measurement.  
 
In this study a significant relationship was also found between the ViScan measures and IHCL 
(Table 3.8), suggesting a possible influence of organ mass/composition on transimpedance. 
Moreover, measurement of visceral fat using the ViScan may relate to increased liver volume. I 
found that participants with elevated liver fat content had a lower correlation between the MRI and 
ViScan measures of visceral fat. Since increasing liver fat content is closely associated with 
increasing liver volume176,  it may be inferred that the greater contribution of liver to the abdominal 
contents also affects the ability of ViScan to accurately measure visceral fat.  I am not suggesting, 
based on this correlation that the Viscan can be used to detect/measure liver fat in any way. 
Moreover, liver fat helps support the notion that liver size may be influencing the prediction of 
abdominal adipose tissue compartments when using transimpedance. Further studies using MRI 
or CT need to be undertaken to investigate the influence structural differences, tissue hydration 
and musculature have on transimpedance measurements using the ViScan or similar devices. 
Assuming constancy of non-adipose components, the ratio of ASAT:IAAT may itself influence the 
measurement as increased ASAT would lead to “deeper” IAAT and hence could influence its 
contribution to the transimpedance.  In this study ASAT:IAAT ratio was significantly higher in women 
than men (P<0.001), as has demonstrated by other authors57,345,346.  This gender influence on 
abdominal adipose tissue compartments may need to be taken into account when interpreting 
transimpedance.   Although the operator must select the participant’s gender as part of the ViScan 
measurement, it is unclear how this is factored into to the interpretation of the subsequent 
transimpedance.  
 
Taking this argument further, it is likely the absolute amount of ASAT (litres) is exhibiting an 
influence on the contribution that the deeper IAAT may have on the transimpedance; hence 
influencing the ability of the ViScan to predict visceral adiposity.  In this study the cohort was 
separated according to obesity status and by ASAT and I observed weaker relationships in the 
obese participants and those with higher ASAT. This finding is particularly relevant when 
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assessing abdominally obese individuals, particularly female abdominally obese using the ViScan. 
In very obese individuals with large abdominal adiposity it may be increasingly difficult to 
distinguish IAAT and ASAT as these compartments may be “bridged” with each other 
anatomically, a further explanation for increasing difficulty of interpreting BIA in the very obese. 
 
Another possible influence on the ViScan’s ability to predict adipose tissue compartments may be 
in the relative placement of the electrodes.  Nagal et al. (2008)347, in a similar model to the 
ViScan, noted that the electrode placement would determine how much ASAT influences the 
impedance, and that to determine deeper structures there should be a greater distance between 
injecting and sensing electrodes.  In the ViScan system, the distance between electrodes is fixed, 
being housed within a measurement “belt” placed at the level of the umbilicus.  Nevertheless, the 
relative positions of these electrodes, compared to anatomical landmarks may be slightly different 
in the abdominally obese compared to leaner individuals, i.e. a leaner individual (with a smaller 
waist circumference) will have electrodes spanning proportionally more of the abdomen that an 
abdominally obese individual (with a larger waist circumference).  Linked to this is the fact that 
there are reported gender differences observed in abdominal fat distribution that may influence 
IAAT and ASAT measures. In men there is believed to be a steady increase in IAAT from 5cm 
below L4-L5 to 10cm above L4-L5, whereas in women, total IAAT peaks below or at L4-L5 346,348. 
 
Taking all these factors into account, the ViScan may be a better predictor of IAAT in leaner 
individuals than in the abdominally obese. In the current cohort, this would explain the greater 
inconsistency in the categorising of individuals in terms of IAAT compared to categorising 
individuals in terms of total trunk fat.  This potential influence of relative adiposity on prediction 
using the ViScan is one factor that has not been highlighted in the original Japanese development 
study349 as these measurements were conducted mainly on lean individuals.  As discussed here, 
reasons for differences could be firstly that leaner individuals would tend to have lower ASAT, and 
hence any IAAT is anatomically nearer to the surface electrodes; and secondly a lower waist girth 
could mean the placement of the electrodes is more evenly spread across the whole abdomen. 
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In conclusion, the ViScan measurement system may be a simple and useful tool for the estimation 
of total abdominal adiposity.  However, the use of this system to distinguish visceral fat (i,e, IAAT) 
remains limited. More studies are needed to investigate the reliability of this measurement, and 
more importantly the ability of the ViScan to detect changes in abdominal fat compartments. 
Nevertheless, the ViScan system may still prove to be a useful motivational device for the health 
practitioner, despite limitations as a diagnostic or monitoring tool.     
 
 
Conclusion 
 
 
Part A. Findings from this part of the study have demonstrated that, when compared to the 
criterion (MRI), the 2-C body composition measuring devices tested were less accurate. Groups 
looking for a more available and cheaper alternative to MRI for percentage adiposity 
quantification, would need to give additional consideration to the ethnicity of their test population. 
In this study (Part A), Caucasian adiposity was overestimated (up to 3%) and Asian adiposity was 
underestimated (up to 11%) by the 2-C devices. Based on a sample size (N= 21), the hypothesis 
for this current study: that 2-C methods (UWW, ADP, BIA, skinfolds) are a valid alternative to MRI 
for adiposity quantification is rejected. 
 
 
Part B. Findings from this part of the study have demonstrated that a BIA device (ViScan) 
developed for measuring abdominal adiposity was not able to conclusively measure intra-
abdominal adipose tissue (IAAT) in obese males and females.  The hypothesis for this current 
study: that the Viscan BIA device is an accurate intra-abdominal adiposity proxy measurement 
method is rejected.  
 
 
 
  
 107 
Chapter 4. The “Thin Outside Fat Inside” (TOFI) phenotype. 
!
4.1 Introduction 
 
Body mass index (BMI) is the current benchmark for obesity classification, but like all 
anthropometric measurements, it only offers a proxy measure of body adiposity168. Furthermore, 
at any given body size, there is significant variation in adipose tissue content and distribution 
which cannot be predicted by standard anthropomorphic characteristics; such as skin-fold 
measurements, body mass index (BMI), or waist-to-hip ratio (WHR)99,176,350. Measuring body fat 
content and distribution directly is essential as the contribution of adipose tissue to disease is 
differentially related to disease. As mentioned in chapter 1, deposition of adipose tissue internally 
within the abdomen, or in lean tissues such as the liver (hepatic fat, IHCL) and muscle 
(intramyocellular lipids, IMCL) is associated with greater risk of metabolic disease such as, type 2 
diabetes, obesity and insulin resistance, more than elevated stores of subcutaneous adipose 
tissue 108-111.  
 
In research, surrogate measurements of adipose tissue content are common, particularly of 
‘central fat or abdominal fat’, which is often taken to be a proxy of visceral fat content. Waist 
circumference (WC) is widely used and often quoted in papers as a measure of abdominal fat. 
While easily obtainable, it is unable to distinguish between IAAT and abdominal subcutaneous 
adipose tissue (ASAT) deposition52. Similarly, many publications report abdominal fat content 
using DXA188,351-353, which while providing more information than waist circumference, still cannot 
distinguish between different abdominal adipose tissue depots. Given their different contributions 
to disease there is an essential need for any measurement of abdominal fat content. 
 
Recently it has become apparent that there are populations in which the risk of metabolic disease 
cannot be adequately explained from measures of adiposity alone. Indeed there have been 
several reports of lean individuals (BMI < 25 kg/m2) who demonstrate reduced insulin sensitivity, 
increased abdominal adiposity, a more atherogenic lipid profile, and raised blood pressure, similar 
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to that usually observed in overweight or obese individuals. These changes are usually 
accompanied by reduced physical activity and a low VO2max. The combination of these factors is 
thought to predispose these individuals to an increased risk of type 2 diabetes and CVD 354-356. 
These individuals have been referred to as being ‘metabolically obese but normal-weight’ 
(MONW)177,187. The etiology of this phenotype is not fully understood, but may in part be related to 
adipose tissue distribution and ectopic fat content. Further understanding of this phenotype is 
important since it poses a potentially serious hidden risk. 
 
This chapter describes the relationship between anthropometric measurements, individual 
adipose stores and ectopic fat in a heterogeneous group of male and female Caucasian 
volunteers. MRI-based techniques were used to determine the “normal” range of abdominal 
adiposity stores (IAAT and ASAT) in a defined healthy active subset of the cohort.  In doing so the 
study aimed to use the ratio of intra-abdominal (IAAT) and subcutaneous (ASAT) adipose tissue 
to generate a potential clinical index of abdominal obesity, which could be used in future to identify 
individuals at increased metabolic risk. 
 
Objectives:  
1. Quantify adiposity stores in a large cohort of healthy Caucasian volunteers using MRI and 
MRS. 
2. From the large cohort, identify a healthy, active, control sub-group in order to establish a 
normal range of abdominal adipose tissue (IAAT/ASAT ratio). 
3. Identify MONW individuals within the main cohort’s lean (BMI 18.4 – 25 kg/m2) category 
based on the clinical index developed and assess the relationship between their adiposity 
and established proxy (anthropometric) measures.   
 
Study 2 Hypotheses: 
Hypothesis 1:  The established TOFI index (identify) can identify individuals with adverse fat 
distribution within the normal BMI range (18.5<25 kg/m2). 
Hypothesis 2:  Established proxy (anthropometric) measures are able to successfully identify 
MONW individuals within a large cohort of healthy Caucasians.  
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4.2. Methods 
 
Participants 
Written, informed consent was acquired from all volunteers. Ethical approval permission for this 
study was obtained from the Research Ethics Committee of Hammersmith and Queen Charlotte’s 
and Chelsea Research Ethics Committee Hospital, London (Rec: 07Q04011/19). In total, 477 
Caucasian volunteers (243 male, 234 female) were recruited. All participants were aged 17-71 
years. Self-reported exclusion criteria included participants suffering from chronic disease 
including diabetes, cardiovascular or liver disease, metabolic conditions, anyone taking prescribed 
medication and women on the contraceptive pill. Volunteers underwent anthropometric 
assessment, total body MRI scanning and in vivo proton (1H) magnetic resonance spectroscopy 
(MRS) of liver and calf muscle. 
 
Anthropometric measurements 
Body mass (kg), height (cm), midpoint328 waist circumference (WC) (cm) and hip circumference 
(cm) were measured in each participant by myself, as detailed in the General Research Methods 
and Procedures section (Chapter 2). From these values, BMI (kg/m2), waist-to-hip ratio (WHR, 
waist/hip) and waist-to-height ratio (WHtR, waist/height) were calculated. As previously 
mentioned, BMI grouping corresponded to the following ranges; 1: 18.5<25 kg/m2, 2: 25<30 
kg/m2, 3: 30<40 kg/m2, 4: 40+ kg/m2. 
 
MRI scanning: Total body and regional adipose tissue content 
On a single visit, participants underwent total body MRI scanning and in vivo proton (1H) magnetic 
resonance spectroscopy (MRS) of their liver and their calf muscle as described in the General 
Research Methods and Procedures chapter (Chapter 2). 
The adiposity data obtained was expressed as previously described (Chapter 2 - section 2.5.1.3).  
 
MRS of liver and muscle fat 
During the same scanning session, 1H MR spectra were also acquired at 1.5T, and analysed 
using methods described earlier (Chapter 2).   
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Control Group – “normal” range of abdominal adiposity.  
A healthy, active control group was identified within the main cohort in order to classify the ‘normal’ 
fat distribution. The following criteria were used to define Caucasian individuals as healthy, active, 
controls:  
1) Absence of disease/metabolic condition;  
2) BMI: 18.5 < 25kg/m2 (WHO guidelines1);  
3) WC: male ≤ 94cm, female ≤ 80cm (WHO guidelines1);  
4) WHR: male ≤ 0.90, female ≤ 0.80357;  
5) Age: male (18-50yr), female (18-39yr): the younger age group in female participants was 
chosen in order to eliminate the effects of menopause from our control group, as there is a 
significant increase in obesity related-metabolic disorders after menopause, which has been 
linked to alterations in body adiposity, notably an increase in IAAT358.  
6) Activity level: sedentary participants were excluded following physical activity classification, 
determined using Baecke359 and/or I-PAQ360 questionnaires (Appendix 2). Both tests calculate 
weekly physical activity, classifying individuals into low, moderate or high categories based on 
specific criteria; I-PAQ assesses the duration and frequency of walking, moderate intensity and 
vigorous intensity activity. Participants with a high or moderate score in the "healthy" definition 
were included, as this level of activity was considered sufficient to maintain cardiovascular health 
while individuals reported in the "low" physical activity group from either test were excluded. 
 
The advantage to using such validated activity scoring methods is that each has a robust checklist 
for assessing categories of activities and therefore cover the spectrum of intensities that make up 
discreet aspects of everyday living.  The two questionnaires also encompass a ‘scripted ’ protocol 
for verbal instructions to ensure reliability, as well as to ensure interviewers assess the activity 
pattern accurately. The I-PAQ has additional benefits in that it has been translated into several 
languages and has telephone ‘scripts’ too for non face-to-face interviews too. Choosing the 
appropriate activity assessment method was critical so that the reliability was high and the scoring 
was relatively straight forward in terms of ease of calculating and subsequent logging. The 
physical activity assessments I used also require the researcher to complete them using a 
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structured interview technique (hence the need for a standard  questioning script and protocol) 
rather than the participant completing it themselves.  
 
Statistical Analysis 
Gender differences were analysed using the Student’s t-test. Significance was taken as p<0.05. 
All data are presented as mean ± standard deviation. Data which were found not to be normally 
distributed (IHCL and IMCL) are presented as a geometric mean, while statistical analysis was 
performed on log10 transformed variables.  Associations between variables were investigated 
using Pearson partial correlation r values. The statistical analysis was performed using SPSS 
software (version 17.0; SPSS, Inc., Chicago, IL, USA). Satistical advice was provided during this 
study by Caroline Dore (MRC Clinical Trials Unit, London. UK). 
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4.3. Results 
 
Descriptive Statistics 
The mean age of all participants was 37yrs (range 18 – 71yrs) with 25.0% of all participants 
classified as overweight (32.6% of men, 17% women, BMI: 25<30), 24.7% qualifying as obese 
(26.8% of men, 22.6% of women, BMI: 30<40) and 2.9% morbidly obese (2.1% of men, 3.8% of 
women, BMI: 40+). Gender specific characteristics are shown in Table 4.0. Males had a 
significantly greater weight, WC, height and WHR, than females (P < 0.001 for all). Overall, female 
participants were found to have significantly more TAT, SAT, ASAT, NASAT, and significantly 
lower levels of internal, IAAT and a lower IAAT/ASAT ratio than males participants (P < 0.001 for 
all). Ectopic fat content in both the liver and soleus muscle were also found at significantly lower 
levels in female compared to male participants (p<0.001). There were no significant differences in 
the tibialis muscle. 
 
  
 113 
Table 4.0  Gender specific variable data. 
 
 MALE  (n=243) FEMALE (n=234) p 
 Mean ± SD Range Mean ± SD Range M vs. F 
Age (yrs) 40.3 ± 13 17 - 70 34.5 ± 12.4 17 – 71 <0.001 
Weight (kg) 87.6 ± 16.2 59.0 - 146.6 71.4 ± 17.6 40.7 - 146.8 <0.001 
BMI (kg/m2) 27.3 ± 4.8 18.6 - 44.5 26.2 ± 6.6 15.5 - 57.3 <0.05 
WC (cm) 95.4 ± 13.3 70.0 - 131 81.4 ± 13.8 56.5 – 131 <0.001 
Hip (cm) 103.5 ± 8.4 85.4 - 136 102.3 ± 10.7 76 – 134 0.23 
Height (cm) 179 ± 7.3 143 - 199 165.2 ± 6.6 145.5 - 182 <0.001 
WHR 0.92 ± 0.07 0.75 - 1.11 0.8 ± 0.07 0.58 - 1.04 <0.001 
WHtR 0.53 ± 0.08 0.37 - 0.85 0.49 ± 0.09 0 - 0.78 <0.001 
IHCL* 6.8 ± 14.0 0 - 89.6 2.8 ± 8.5 0 - 65.0 <0.001 
S-IMCL* 15.5 ± 9.7 2.9 - 100.1 11.5 ± 6.9 2.28 - 51.0 <0.001 
T-IMCL* 6.3 ± 3.8 0.25 - 30.5 6.7 ± 4.1 0.96 - 35.4 0.25 
TAT (l) 24.9 ± 10.9 6 - 67.7 31.2 ± 15.9 8.3 - 106.2 <0.001 
SAT (l) 18.6 ± 8.4 4.2 - 58.2 26.6 ± 13.5 7.3 - 90.5 <0.001 
ASAT (l) 5.3 ± 3.0 0.7 - 20.2 7.6 ± 4.9 1.5 - 29.7 <0.001 
NASAT  (l) 13.3 ± 5.6 1.3 - 38 19.0 ± 8.8 5.8 - 60.9 <0.001 
Internal (l) 6.3 ± 3.3 0.7 - 15.8 4.6 ± 2.8 1 - 15.7 <0.001 
IAAT  (l) 3.5 ± 2.1 0.2 - 9.4 2.3 ± 1.8 0.4 - 9.6 <0.001 
NAIAT  (l) 2.8 ± 1.4 0.5 - 7.9 2.4 ± 1.1 0.6 - 6.2 <0.001 
Trunk (l) 8.8 ± 4.7 1.0 - 25.5 9.9 ± 6.4 1.9 - 39.3 <0.05 
IAAT/ASAT 0.7 ± 0.3 0.18 - 1.64 0.3 ± 0.1 0.09 - 0.97 <0.001 
    
 
Mean and range variable data. WC: waist circumference; WHR: waist-to-hip ratio; WHtR: waist-to-
height ratio; IHCL:  intrahepatocellular lipid; IMCL: intramyocellular lipid (S - soleus, T - tibialis); 
Adipose tissue deposits are in litres (l); TAT: total adipose tissue; SAT: subcutaneous; ASAT: 
abdominal subcutaneous; NASAT: non-abdominal subcutaneous; Internal: total internal; IAAT: 
intra-abdominal; NAIAT: non-abdominal internal. * MRS data (IHCL (M: 234, F: 169), S-IMCL (M: 
239, F: 179) and T-IMCL (M: 239, F: 178)) is presented as the geometric mean, while statistical 
analysis was performed on log10 transformed variables. All data are presented as mean ± SD. 
Male versus female data were analysed by Student’s t-test.  
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Table 4.1 BMI group specific summary measures in male and female volunteers 
 
 MALE FEMALE 
BMI group 1 2 3 4 1 2 3 4 
(n) number 93 79 65 5 132 40 53 9 
Age (y) 34.4 ± 12 42.5 ±12.9 45.9 ± 11.5 45.6 ± 3.6 30.2 ± 9.3 36.8 ± 11.5 43.1 ± 15.4 36.1 ± 7.2 
Weight (kg) 74 ± 6.8 87.3 ± 9.0 104.3 ± 9.9 126.6 ± 21.2 60.3 ± 7.0 72.8 ± 7.4 89.3 ± 10.5 122.6 ± 11.7 
WC (cm) 82.8 ± 6.4 96.0 ± 7.6 107.8 ± 8.1 126.8 ± 3.2 73.2 ± 7.0 82.3 ± 6.9 98.5 ± 10.6 121.8 ± 13.1 
Hip (cm) 96.4 ± 5.1 103.8 ± 4.9 110.6 ± 5.9 125.5 ± 8.1 95.8 ± 6.6 104.8 ± 5.3 114.3 ± 7.7 132.5 ± 0.7 
Height (cm) 180.0 ± 6.3 178.4 ± 7.4 178.6 ± 7.2 172.8 ± 17.1 166.5 ± 6.1 164.3 ± 7.2 162.9 ± 6.5 163.8 ± 7.6 
WHR 0.9 ± 0.1 0.9 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 0.8 ± 0.01 0.8 ± 0.1 0.9 ± 0.1 0.8 ± 0.1 
WHtR 0.5 ± 0.01 0.5 ± 0 0.6 ± 0.01 0.7 ± 0.1 0.4 ± 0.1 0.5 ± 0.01 0.6 ± 0.1 0.7 ± 0.1 
IHCL* 0.9 ± 2.1 6.8 ± 14.4 12.6 ± 17.5 32.9 ± 16.9 0.4 ± 0.6 1.3 ± 2.3 10.2 ± 15.8 2.8 ± 8.5 
S-IMCL* 13.5 ± 12.0 15.2 ± 7.0 18.1 ± 8.1 23.8 ± 8.2 10.0 ± 6.1 12.1 ± 6.6 15.2 ± 8.2 16.2 ± 2.4 
T-IMCL* 4.9 ± 2.9 6.3 ± 3.4 7.8 ± 4.8 8.8 ± 2.8 6.1 ± 3.2 5.7 ± 2.7 8.9 ± 6.2 9.9 ± 3.8 
TAT  (L) 16.1 ± 6.0 25.0 ± 7.1 35.7 ± 7.8 47.8 ± 11.3 21.1 ± 5.6 31.8 ± 5.5 47.9 ± 8.6 79.0 ± 13.2 
SAT  (L) 12.2 ± 4.5 18.3 ± 4.9 26.6 ± 6.6 38.5 ± 11.2 18.1 ± 4.7 27.2 ± 4.8 40.3 ± 8.1 67.4 ± 11.2 
ASAT  (L) 3.0 ± 1.2 5.1 ± 1.8 8.2 ± 2.6 13.4 ± 4.0 4.5 ± 1.6 7.8 ± 1.9 12.4 ± 3.2 22.2 ± 3.8 
NASAT  (L) 9.2 ± 3.7 13.2 ± 3.4 18.4 ± 4.4 25.1 ± 7.4 13.6 ± 3.4 19.4 ± 3.3 27.8 ± 5.6 45.2 ± 7.7 
Internal  (L) 3.9 ± 2.0 6.7 ± 3.1 9.1 ± 2.8 9.4 ± 0.8 3.0 ± 1.2 4.6 ± 1.4 7.6 ± 2.3 11.6 ± 2.5 
IAAT  (L) 2.0 ± 1.1 3.8 ± 1.9 5.3 ± 1.8 5.7 ± 0.4 1.3 ± 0.7 2.1 ± 0.9 4.3 ± 1.5 6.4 ± 2.0 
NAIAT  (L) 2.0 ± 0.9 2.9 ± 1.3 3.8 ± 1.3 3.7 ± 0.6 1.7 ± 0.7 2.5 ± 0.6 3.4 ± 1.1 4.5 ± 1.7 
Trunk  (L) 4.9 ± 2.2 8.9 ± 3.1 13.4 ± 3.3 19.0 ± 3.7 5.8 ± 2.0 10.1 ± 2.5 17.2 ± 3.7 25.2 ± 10.7 
IAAT/ASAT 0.6 ± 0.3 0.8 ± 0.4 0.7 ± 0.3 0.4 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.4 ± 0.2 0.3 ± 0.1 
 
 
 
 
WC: waist circumference; WHR: waist-to-hip ratio; WHtR: waist-to-height ratio; IHCL: intrahepatocellular lipid; IMCL: 
intramyocellular lipid (S - soleus, T - tibialis); Adipose tissue deposits are presented as volume in litres (L); TAT: total 
adipose tissue; SAT: subcutaneous; ASAT: abdominal subcutaneous; NASAT: non-abdominal subcutaneous; Internal: 
total internal; IAAT: visceral; NAIAT: non-abdominal internal. * MRS data: (IHCL (M: 234, F: 169), S-IMCL (M: 239, F: 
179) and T-IMCL (M: 239, F: 178)) is presented as the geometric mean. BMI grouping corresponds to the following 
BMI ranges; 1: 18.5<25, 2: 25<30, 3: 30<40, 4: 40+. All data is presented as mean ± SD. 
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Figure  4.0  Abdominal subcutaneous (ASAT), intra-abdominal adipose tissue (IAAT) and 
IAAT/ASAT ratio by BMI group in male and female volunteers. 
 
 
 
BMI group specific variation in abdominal subcutaneous (ASAT) (A) and intra-abdominal adipose 
tissue (IAAT) (B) in male and female volunteers. Adiposity stores are presented in litres. The ratio 
of IAAT/ASAT is also presented by BMI groups (C). The graphs present the fitted mean curve, 
and the 2.5th and 97.5th centiles, calculated assuming normal errors. 
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Correlation Analysis 
Gender-specific correlation analysis for all anthropometric variables, adipose tissue (in litres) and 
ectopic fat stores (arbitrary units) are shown in Table 4.2 (men) and Table 4.3 (women). Apart 
from a few exceptions, all variables correlated with each other to a significant degree (p<0.01). In 
male participants, WC was the variable, which correlated to the greatest degree with individual 
adiposity stores (TAT: r = 0.92, SAT: r = 0.88, ASAT: r = 0.85, NASAT: r = 0.87, Internal: r = 0.80, 
IAAT: r = 0.82, NAIAT: r = 0.71, Trunk: r = 0.92, p<0.01, Table 4.2), while in female participants 
BMI had the strongest correlation with individual adiposity stores (TAT: r = 0.95, SAT: r = 0.94, 
ASAT: r = 0.94, NASAT: r = 0.93, Internal: r = 0.85, IAAT: r = 0.84, NAIAT: r = 0.78, Trunk: r = 
0.95, p<0.01, Table 4.3). 
 
Intrahepatocellular lipid (IHCL) correlated most strongly with WC in male participants (r = 0.71, 
p<0.01, Table 4.2) and WHtR in female participants (r = 0.64, p<0.01, Table 4.3). In male 
participants, WC was also the strongest correlate of S-IMCL (r = 0.50, p<0.01) and T-IMCL (r = 
0.39, p<0.01) (Table 4.2), while in females S-IMCL and T-IMCL correlated most strongly with BMI 
(S-IMCL: r = 0.45, T-IMCL: r = 0.27, p<0.01 for both, Table 4.3). Intra-abdominal adipose tissue 
was the depot, which correlated most strongly with ectopic fat in both genders (Male IAAT: IHCL r 
= 0.72, S-IMCL r = 0.47, T-IMCL r = 0.42, p<0.01 for all, Table 4.2; Female IAAT: IHCL r = 0.72, 
S-IMCL r = 0.51, T-IMCL r = 0.32, p<0.01 for all, Table 4.3). In both male and female participants, 
weight, BMI, WC and WHtR correlated more strongly with each other than individual percentage 
adiposity stores (Tables 4.2 and 4.3). 
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Table 4.2 Linear correlation analysis between anthropometric measurements, lipid stores and body fat stores in male participants. 
 
All data are presented as Pearson correlation r values. Bold typeface indicates a significant correlation; shaded boxes indicate the anthropometric variable with the strongest correlation. A 
Statistical analysis of IHCL (M: 234), S-IMCL (M: 239) and T-IMCL (M: 239) performed on log10 transformed variables; * = p<0.05, ** = p<0.01. Abbreviations: WC: waist circumference; WHR: 
waist-to-hip ratio; WHtR: waist-to-height ratio; IHCL: intrahepatocellular lipid and IMCL: intramyocellular lipid (S - soleus, T - tibialis); Adipose tissue deposits are in litres (l); TAT: total adipose 
tissue; SAT: subcutaneous; ASAT: abdominal subcutaneous; NASAT: non-abdominal subcutaneous; Internal: total internal; IAAT: intra-abdominal; NAIAT: non-abdominal internal.  
MALE AGE ANTHROPOMETRIC VARIABLE ECTOPIC FAT STORE A ADIPOSITY DEPOT (LITRES) 
n = 243 Age Weight BMI WC Hip Height WHR WHtR IHCL S-IMCL T-IMCL TAT SAT ASAT NASAT Internal IAAT NAIAT Trunk 
Weight 0.288**                   
BMI 0.378** 0.883**                  
WC 0.478** 0.881** 0.901**                 
Hip 0.311** 0.914** 0.841** 0.861**                
Height -0.124 0.352** -0.120 0.090 0.355**               
WHR 0.510** 0.603** 0.706** 0.856** 0.479** -0.108              
WHtR 0.493** 0.745** 0.912** 0.950** 0.766** -0.216* 0.885**             
IHCL 0.405** 0.551** 0.625** 0.712** 0.559** -0.070 0.663** 0.707**            
S-IMCL 0.389** 0.377** 0.378** 0.504** 0.437** 0.054 0.427** 0.463** 0.440**           
T-IMCL 0.314** 0.293** 0.343** 0.389** 0.300** -0.051 0.375** 0.384** 0.417** 0.590**          
TAT 0.376** 0.836** 0.832** 0.915** 0.863** 0.098 0.712** 0.855** 0.663** 0.427** 0.386**         
SAT 0.271** 0.836** 0.823** 0.878** 0.876** 0.116 0.632** 0.816** 0.590** 0.368** 0.338** 0.975**        
ASAT 0.231** 0.829** 0.841** 0.850** 0.858** 0.074 0.599** 0.806** 0.598** 0.358** 0.359** 0.922** 0.944**       
NASAT 0.280** 0.801** 0.775** 0.868** 0.862** 0.133* 0.632** 0.799** 0.567** 0.357** 0.311** 0.958** 0.984** 0.870**      
Internal 0.550** 0.635** 0.659** 0.804** 0.642** 0.028 0.750** 0.761** 0.692** 0.451** 0.414** 0.825** 0.678** 0.647** 0.663**     
IAAT 0.548** 0.629** 0.669** 0.815** 0.632** -0.004 0.779** 0.778** 0.716** 0.473** 0.417** 0.804** 0.659** 0.639** 0.639** 0.976**    
NAIAT 0.501** 0.585** 0.580** 0.714** 0.598** 0.075 0.638** 0.664** 0.589** 0.462** 0.370** 0.781** 0.642** 0.598** 0.637** 0.943** 0.847**   
Trunk 0.396** 0.822** 0.848** 0.919** 0.840** 0.047 0.740** 0.874** 0.711** 0.435** 0.421** 0.962** 0.911** 0.939** 0.854** 0.859** 0.865** 0.769**  
IAAT/ASAT 0.460** -0.026 0.012 0.187** -0.013 -0.071 0.369** 0.182** 0.330** 0.195** 0.169** 0.125 -0.064 -0.132* -0.024 0.571** 0.603** 0.467** 0.185** 
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Table 4.3 Linear correlation analysis between anthropometric measurements, lipid stores and body fat stores in female participants. 
 
All data are presented as Pearson correlation r values. Bold typeface indicates a significant correlation; shaded boxes indicate the anthropometric variable with the strongest correlation. A 
Statistical analysis of IHCL (F: 169), S-IMCL (F: 179) and T-IMCL (F: 178)) performed on log10 transformed variables; * = p<0.05, ** = p<0.01. Abbreviations: WC: waist circumference; WHR: 
waist-to-hip ratio; WHtR: waist-to-height ratio; IHCL: intrahepatocellular lipid and IMCL: intramyocellular lipid (S - soleus, T - tibialis); Adipose tissue deposits are in litres (l); TAT: total adipose 
tissue; SAT: subcutaneous; ASAT: abdominal subcutaneous; NASAT: non-abdominal subcutaneous; Internal: total internal; IAAT: intra-abdominal; NAIAT: non-abdominal internal. 
FEMALE AGE ANTHROPOMETRIC VARIABLE ECTOPIC FAT STORE A ADIPOSITY DEPOT (LITRES) 
n = 234 Age Weight BMI WC Hip Height WHR WHtR IHCL S-IMCL T-IMCL TAT SAT ASAT NASAT Internal IAAT NAIAT Trunk 
Weight 0.276**                   
BMI 0.357** 0.945**                  
WC 0.477** 0.862** 0.892**                 
Hip 0.350** 0.882** 0.874** 0.848**                
Height -0.261* 0.114 -0.208* -0.049 0.052               
WHR 0.456** 0.488** 0.530** 0.825** 0.405** -0.158*              
WHtR 0.462** 0.734** 0.832** 0.973** 0.801** -0.227* 0.832**             
IHCL 0.477** 0.501** 0.622** 0.623** 0.510** -0.309* 0.539** 0.644**            
S-IMCL 0.501** 0.397** 0.450** 0.436** 0.402** -0.133 0.333** 0.402** 0.404**           
T-IMCL 0.371** 0.196* 0.265** 0.278** 0.191* -0.162* 0.295** 0.239** 0.399** 0.448**          
TAT 0.292** 0.959** 0.951** 0.854** 0.879** -0.032 0.461** 0.762** 0.584** 0.426** 0.174*         
SAT 0.256** 0.959** 0.944** 0.834** 0.878** -0.013 0.431** 0.738** 0.532** 0.387** 0.138 0.995**        
ASAT 0.227** 0.945** 0.937** 0.845** 0.874** -0.038 0.455** 0.753** 0.545** 0.384** 0.151 0.970** 0.974**       
NASAT 0.266** 0.946** 0.927** 0.803** 0.852** -0.001 0.408** 0.706** 0.509** 0.378** 0.127 0.987** 0.992** 0.939**      
Internal 0.424** 0.821** 0.850** 0.772** 0.704** -0.117 0.532** 0.721** 0.686** 0.505** 0.299** 0.879** 0.828** 0.807** 0.822**     
IAAT 0.461** 0.796** 0.839** 0.787** 0.690** -0.165* 0.577** 0.745** 0.720** 0.506** 0.319** 0.852** 0.802** 0.799** 0.786** 0.974**    
NAIAT 0.322** 0.773** 0.777** 0.657** 0.643** -0.031 0.408** 0.596** 0.552** 0.445** 0.232** 0.828** 0.781** 0.734** 0.790** 0.935** 0.829**   
Trunk 0.302** 0.943** 0.949** 0.879** 0.874** -0.075 0.511** 0.797** 0.637** 0.448** 0.212** 0.978** 0.967** 0.986** 0.936** 0.887** 0.888** 0.792**  
IAAT/ASAT 0.446** 0.053 0.122 0.232** 0.075 -0.184* 0.335** 0.267** 0.373** 0.303** 0.304** 0.122 0.038 0.009 0.0535 0.509** 0.539** 0.409** 0.158* 
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The TOFI Phenotype 
In an attempt to refine the phenotype of individuals classed as MONW, the TOFI (Thin on the Outside Fat 
on the Inside) index was derived in order to identify individuals as having the most adverse fat distribution 
using MRI imaging. The index derived was based on the ratio of intra-abdominal to abdominal 
subcutaneous adipose tissue (IAAT/ASAT). This ratio was plotted against BMI. The values measured in 
the control group established a representative “normal” range of abdominal adiposity.  
 
Participants in the main group with a BMI range of 18.5 < 25 kg/m2 were then classified as TOFI if their 
IAAT/ASAT ratio was two standard deviations above the mean of healthy control individuals. The gender 
specific variable data from healthy, active individuals used to define the thin-on-the-outside fat-on-the-
inside (TOFI) phenotype (Table 4.4) shows the mean IAAT/ASAT ratio for healthy Caucasian individuals 
was 0.59 (male) and 0.25 (female). Two standard deviations above the mean IAAT/ASAT of healthy 
individuals (+2 SD male: 1.04, female: 0.45) were used to define the cut-off for TOFI classification. Thus 
individuals with a BMI 18.5 < 25kg/m2 with a IAAT/ASAT ratio above 1.0 (males: aged 18-50yr) and 0.45 
(females: aged 18-39yr) were classified as TOFI; this corresponds to 14.0% of men (15/106) and 12% of 
women (17/132) in the main cohort.  
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Table 4.4. Gender specific variable data for healthy, active individuals. 
 Male  (n = 57) Female (n = 54) P 
 Mean ± SD Range Mean ± SD Range M vs. F 
Age (yrs) 32 ± 10 17 - 50 26 ± 5 20 - 39 <0.001 
Weight (kg) 73.2 ± 7.3 59 - 91.6 59.5 ± 5.5 49.3 - 70.7 <0.001 
BMI (kg/m2) 22.6 ± 1.6 18.6 - 25 21.7 ± 1.6 18.6 - 24.7 <0.001 
WC (cm) 81.3 ± 5.3 70.5 - 90.5 71.6 ± 4.3 62.5 - 80 <0.001 
Hip (cm) 96.4 ± 5.3 85.4 - 107 95.3 ± 5.1 85 - 106 0.25 
Height (cm) 179.7 ± 6.4 164 - 192.8 165.5 ± 5.0 157 - 178.8 <0.001 
WHR 0.8 ± 0.01 0.76 - 0.9 0.8 ± 0.01 0.65 - 0.8 <0.001 
WHtR 0.5 ± 0.01 0.37 - 0.53 0.4 ± 0.01 0.37 - 0.48 <0.001 
IHCL* 11.0 ± 6.4 2.85 - 40.96 8.3 ± 5.6 2.28 - 39.16 0.02 
S-IMCL* 4.7 ± 2.4 1.31 - 12.48 5.2 ± 2.3 0.96 - 9.71 0.28 
T-IMCL* 0.8 ± 2.3 0.0 - 17.36 0.3 ± 0.5 0.0 - 2.74 0.15 
TAT 14.3 ± 4.5 6 - 26.2 20.1 ± 4.9 11.8 - 39.3 <0.001 
SAT 11.0 ± 3.4 4.2 - 20.4 17.6 ± 4.2 9.9 - 31.8 <0.001 
ASAT 2.7 ± 1.2 0.7 - 6.2 4.4 ± 1.3 2 - 7.2 <0.001 
NASAT 8.4 ± 2.4 3.5 - 14.4 13.2 ± 3.1 8 - 26.5 <0.001 
Internal 3.3 ± 1.5 0.7 - 7.7 2.5 ± 1.0 1.1 - 7.5 <0.001 
IAAT 1.6 ± 0.9 0.2 - 3.7 1.0 ± 0.4 0.4 - 2.7 <0.001 
NAIAT 1.7 ± 0.7 0.5 - 4.1 1.5 ± 0.6 0.6 - 4.9 0.12 
Trunk 4.3 ± 1.9 1.02 - 9.58 5.4 ± 1.5 2.47 - 8.93 <0.001 
IAAT/ASAT 0.6 ± 0.2 0.21 - 1.41 0.2 ± 0.1 0.11 - 0.52 <0.001 
 
 
WC: waist circumference; WHR: waist-to-hip ratio; WHtR: waist-to-height ratio; IHCL:  intrahepatocellular 
lipid; IMCL: intramyocellular lipid (S - soleus, T - tibialis); Adipose tissue deposits are a percentage of 
body mass (%kg); TAT: total adipose tissue; SAT: subcutaneous AT; ASAT: abdominal subcutaneous 
AT; NASAT: non-abdominal subcutaneous AT; Internal: total internal AT; IAAT: intra-abdominal AT; 
NAIAT: non-abdominal internal AT. * MRS data (IHCL (M: 57, F: 51), S-IMCL (M: 57, F: 51) and T-IMCL 
(M: 57, F: 51)) is presented as the geometric mean while statistical analysis was performed on log10 
transformed variables. All data are presented as mean ± SD. Male versus female data analysed by 
Student’s t-test. 
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Table  4.5. Gender specific variable data for TOFI and non-TOFI individuals.   
 
 MALE FEMALE 
 non-TOFI (91) TOFI (15) p non-TOFI (115) TOFI (17) P 
Age (y) 34.6 ± 11.8 46.8 ± 12.5 <0.001 30.0 ± 8.9 40.5 ± 15.8 <0.001 
Weight (kg) 73.0 ± 7.2 77.5 ± 6.8 <0.05 60.9 ± 6.7 59.8 ± 5.5 0.51 
BMI 22.7 ± 1.5 23.5 ± 1.6 0.076 22.0 ± 1.8 22.0 ± 2.2 0.97 
WC (cm) 82.4 ± 6.5 87.8 ± 8.3 <0.05 73.4 ± 6.5 76.2 ± 9.7 0.18 
Hip (cm) 96.2 ± 5.1 99 ± 5.4 0.10 96.2 ± 6.0 94.2 ± 8.1 0.29 
Height (cm) 179.1 ± 6.9 181.8 ± 7.2 0.16 166.3 ± 5.8 165.0 ± 8.6 0.45 
WHR 0.86 ± 0.05 0.89 ± 0.07 0.11 0.76 ± 0.05 0.81±  0.07 0.13 
WHtR 0.4 ± 0.17 0.44 ± 0.15 0.4 0.44 ± 0.06 0.47 ± 0.08 0.11 
IHCL* 0.86 ± 1.3 3.0 ± 4.6 <0.001 0.33 ± 0.52 3.76 ± 10.64 <0.01 
S-IMCL* 12.8 ± 11.5 19.8 ± 12.0 <0.05 9.25 ± 4.74 15.7 ± 10.1 <0.001 
T-IMCL* 4.9 ± 3.0 6.8 ± 2.8 <0.05 5.88 ± 2.95 8.3 ± 4.1 <0.01 
TAT 15.8 ± 6 19.5 ± 4.6 <0.05 21.3 ± 5.1 23.8 ± 6.6 0.07 
SAT 12.2 ± 4.7 12.6 ± 2.7 0.76 18.4 ± 4.4 18.9 ± 5.4 0.71 
ASAT 3.0 ± 1.2 3.2 ± 0.8 0.47 4.7 ± 1.6 4.6 ± 1.4 0.88 
NASAT 9.3 ± 3.8 9.4 ± 2.1 0.89 13.8 ± 3.1 14.3 ± 4.4 0.55 
Internal 3.6 ± 1.7 6.9 ± 2.1 <0.001 2.8 ± 1.0 4.9 ± 1.5 <0.001 
IAAT 1.8 ± 1 3.8 ± 1.1 <0.001 1.2 ± 0.5 2.4 ± 0.9 <0.001 
NAIAT 1.8 ± 0.7 3.1 ± 1.1 <0.001 1.7 ± 0.6 2.5 ± 0.8 <0.001 
Trunk 4.7 ± 2.1 7.0 ± 1.8 <0.001 5.8 ± 1.9 7.0 ± 2.2 <0.05 
IAAT/ASAT 0.6 ± 0.2 1.2 ± 0.2 <0.001 0.3 ± 0.1 0.5 ± 0.1 <0.001 
 
Anthropometric, and adiposity variable data for male individuals (BMI 18.5<24) and female volunteers (BMI 
18.5<24) classified as TOFI or non-TOFI. All data are presented as mean ± SD. * MRS data is presented as 
the geometric mean while statistical analysis was performed on log10 transformed variables. Data analysed 
by Student’s t-test.   
 
Significantly greater S-IMCL depots were observed in TOFI female volunteers. However, there was no 
difference between IHCL in either gender (Male IHCL: p=0.59; Female IHCL: p=0.95). Participants 
classified with the TOFI phenotype based on their IAAT, could not be predicted from BMI, WC, WHR or 
WHtR or trunk fat since there was no significant difference in these variables between TOFI and non-
TOFI healthy participants (Table 4.5).  
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Interestingly, MRI phenotyping also revealed participants with an identical waist circumference, and 
overall trunk fat content, who could therefore not be distinguished from anthropometric phenotyping, had 
different levels of IAAT. For instance, the images shown in Figure 4.1, shows two individuals both with 
12.8 litres of trunk fat. Participants A as 4.6 litres of IAAT, while participants B has 6.3 litres. 
 
Figure 4.1  Anthropometric variation in abdominal adiposity. 
 
 
 
WHR was the anthropometric variable, which correlated most with the IAAT/ASAT ratio in both men (r = 
0.37, p<0.01) (Table 4.2) and women (r =0.34, p<0.01) Table 4.3).  
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Figure 4.2 Typical images to visually demonstrate the TOFI phenotype.  
 
The male individuals shown in this figure are of similar age, BMI and percentage body fat but have 
different levels of visceral fat and therefore different disease risks. Participant (a) is a TOFI (BMI 25·8 
kg/m2; 3·3 litres of visceral fat); participant (b) is a healthy volunteer (BMI 26·5 kg/m2; 2·2 litres of visceral 
fat). 
 !
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4.4. Discussion 
 
There are well established differences in adipose tissue content and distribution between male and 
female participants. In this chapter my results confirmed these findings, with females demonstrating 
significantly higher percentage total and subcutaneous fat stores than the males. Male participants also 
had significantly greater IAAT compared to females. There were also gender differences in ectopic fat 
content, with male participants having significantly higher levels of IHCL and S-IMCL compared to 
females. Ectopic fat depots in the liver and skeletal muscle are implicated in the pathogenesis of insulin 
resistance, a key feature of the metabolic syndrome. The exact mechanism by which ectopic fat 
accumulation affects tissue and organ function is unknown, but possible theories include physical 
compression, altering local secretory profiles, and lipotoxicity83. The strong association between 
increased ectopic fat storage and obesity, type 2 diabetes mellitus, and insulin resistance is well 
established 74,83,361-363.  
 
Anthropometric variables as markers of fat deposition 
Anthropometric measurements are easily obtainable, inexpensive, and commonly used determinants of 
both obesity and the metabolic syndrome364,365. In this study, I found that anthropometric variables 
generally correlated with total and subcutaneous stores better than with internal depots or ectopic fat 
stores. Anthropometric variables such as WC and WHtR can give little indication of the proportion of IAAT 
or ASAT in seemingly “lean” participants and are therefore inappropriate for classifying individuals that 
may be at increased metabolic risk within a “normal” BMI range. Methods of measuring total abdominal 
obesity such as Viscan and DXA offer a faster, less expensive alternative to the MRI protocol 
implemented here366. However, while there is no doubt a strong correlation between abdominal fat and 
metabolic risk, these methods are unable to differentiate between subcutaneous and internal abdominal 
adipose stores. This was clearly illustrated in Figure 4.1. These two individuals have an identical amount 
of trunk fat and yet have entirely different amounts of IAAT and ASAT.  
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In this study the use of a ratio of IAAT and ASAT (IAAT/ASAT) is proposed to identify individuals at 
potentially increased metabolic risk. The study determined the range of IAAT and ASAT in healthy 
individuals in order to define the limits by which individuals with a disproportionally elevated IAAT, or 
TOFI (Thin Outside Fat Inside) phenotype could be identified. When considering the larger cohort, this 
healthy control group represents 10-20% of individuals; the same proportion of healthy individuals in the 
normal population367. The use of ASAT, as opposed to whole body SAT, allows a more accurate 
comparison of these two abdominal fat depots. For ease of reference, IAAT/ASAT developed ratios of 
greater than 1.0 in Caucasian male participants and 0.45 in Caucasian female participants are proposed 
to define this phenotype.  
 
Correlation analysis revealed relatively weak associations between the IAAT/ASAT ratio that was used to 
define TOFI individuals and other physiological characteristics. In fact age, a non-anthropometric variable, 
provided the strongest correlation to IAAT/ASAT. Furthermore, there was a notable lack of statistical 
difference in anthropometric, adiposity and ectopic fat depots between TOFI and non-TOFI individuals, 
except for changes in internal fat depots. These data suggest that MRI analysis is currently the only 
means of successfully identifying individuals with a disproportionately high amount of intra-abdominal fat. 
Given the previously reported significant positive relationship between liver fat and IAAT content110,350 and 
the fact that individuals with a phenotype opposite to that of the TOFI (i.e., FOTI, fat outside, thin inside), 
have reduced intra-abdominal and IHCL compared to weight matched individuals368, it was surprising that 
a significant difference in IHCL deposition was not detected between TOFI and “non-TOFI” individuals. 
This discrepancy could potentially be due to the fact that the cohort had a small number of individuals in 
the TOFI group, and the fact that the analysis of “non-healthy” individuals was limited to those within the 
age and BMI range used to define the cut-off values. It could also be possible that elevated IAAT is a 
precursor to later metabolic changes, which might include increased deposition of IHCL. However, as this 
is a cross-sectional study, only a subsequent longitudinal can confirm this.   
 
Incidence of ‘metabolically-obese but normal-weight’ has been reported to be between 13 and 18%177,354, 
which is similar to the incidence of TOFI found in this study (12% women, 14% men). When the proposed 
IAAT/ASAT cut-off values were applied to individuals with an increased BMI (greater than the 18.5<25 
kg/m2 range) it was found that 16% of females and 23% of males were identified as TOFI. This increase 
in male classification is likely to be a reflection of the increased proportion and deposition of visceral 
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adipose tissue at a higher BMI in males. Disproportionate levels of IAAT in overweight and obese 
participants are also thought to be problematic. Indeed, obese participants with a disproportionate 
accumulation of visceral fat have been reported to have an increased incidence of disorders of glucose 
and lipid metabolism 186. Further work will be required to characterise healthy control individuals within 
increased BMI ranges to accurately define those with excessive IAAT.  
 
In this study, the TOFI phenotype was attributed to 12-13% of Caucasian volunteers that fall within a 
normal BMI range1. Additional studies may also reveal the applicability of the TOFI index to additional 
ethnic populations given the established differences in body fat distribution between racial groups366,367. 
Currently, the TOFI index provides a quantitative means of comparing intra-abdominal fat deposition. 
Clearly, the utility of the TOFI phenotype to classify this “at risk” group of individuals will only be fully 
realised once it has been correlated with markers of the metabolic syndrome. Further work is required to 
determine the physiological basis for the wide variation in the abdominal fat partitioning reported here. 
The mechanism is likely to be complex, with a multitude of genetic, environmental and age related 
determinants369. However, the TOFI index provides an effective means of classification; addressing what 
is emerging as the key phenotype for metabolic risk.  
 
 
In summary, this study used the ratio of IAAT and ASAT in a defined “healthy” subset of this cohort to 
define the TOFI sub-phenotype - a potential means of evaluating abdominal obesity and identifying 
individuals at increased metabolic risk. Therefore the hypothesis (1) for this current study: that the 
established TOFI index (identify) can identify individuals with adverse fat distribution within the normal 
BMI range (18.5<25 kg/m2) is accepted. 
 
Additionally, the findings demonstrate that anthropometric measurements such as waist circumference 
(WC) and waist to height ratio (WHtR) are not appropriate for classifying the TOFI phenotype in a 
seemingly ‘lean’ individuals (i.e. in normal BMI range 18.5<25 kg/m2).  The hypothesis (2) for this current 
study: that established proxy (anthropometric) measures are able to successfully identify MONW 
individuals within a large cohort of healthy Caucasians is rejected.  
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Chapter 5. Aerobic fitness and adiposity.!
 
5.1.  Introduction 
There are instances in which excess body fat is not associated with metabolically adverse profiles such 
as increased risk of insulin resistance, glucose intolerance, type 2 diabetes and CVD85,370,371. There is 
increasing evidence to support the existence of ‘metabolically normal obesity’, the phenotypic opposite of 
the MONW individuals discussed in Chapter 4. The phenotype is typically referred to as metabolically 
healthy obese (MHO)177,180-183 and describes individuals with high body fat, but normal insulin sensitivity, 
blood pressure, high HDL and low plasma triacylglyceride (TAG) levels179 372.  
 
A similar phenotype, known as “fat-fit”, similar to the MHO has also been identified, but in this case it 
includes a measure of physical activity185,373. Blair and colleagues pioneered the notion that physical 
activity reduces the risk of chronic disease in the ‘fat-fit’ 374. In an early study, they found that 
cardiovascular disease risk was lower in 3,217 men who were fat, fit and active compared to 2,182 men 
who were fat, unfit and inactive375. Cardiovascular and all-cause mortality were also lower in men who 
were fat, fit and active than 1,852 men who were normal-weight, unfit and inactive375. In later studies, 
Blair and colleagues assessed physical fitness instead of physical activity because fitness can be more 
accurately measured and because fitness is largely the product of aerobic activity374,376. An interesting 
example of this phenotype is seen in Japanese Sumo wrestlers, who despite their elevated total fat 
content, have low levels visceral adiposity accompanied by high insulin sensitivity377,378  
 
It is unclear whether the MHO and fat-fit are indeed describing a single phenotype, since reports of this 
phenotype vary somewhat owing to there being no clear consensus regarding how they should be 
defined. Some authors rely on absence of (or presence of only one) cardiometabolic risk factors including 
elevated blood pressure, elevated TAG, C-reactive protein, insulin resistance, elevated glucose 
levels/diabetes, or decreased HDL379 while others rely solely on insulin sensitivity380. Studies of fat-fit 
individuals tend to include a measure of physical activity or assessment of fitness, while studies focused 
on MHO tend not to include any. 
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The relevance of these phenotypes demands attention, especially in light of the evidence that fat-fit 
individuals have substantially lower mortality risk than normal-weight unfit individuals185,381. Indeed Lee et 
al. 184 have shown that physical fitness reduces or eliminates the risks associated with obesity. Indeed 
with increasing levels of physical activity or fitness there is a linear reduction in all-cause mortality382.  
How much and what type of physical activity an obese individual might need to undertake to become ‘fit-
fat’ is unclear. Mortality was reported to be 20-30% lower at a threshold exercise energy expenditure of 
about 4200 kJ (1000 kcal) per week, with even lower mortality above 4200 kJ per week.  
 
!
Measurement of cardiorespiratory fitness.  
 
Both physical and health-related fitness are complex attributes, and thus there is no single measurement 
method for these parameters. Moreover, different methods are used to measure different components of 
fitness, such as motor skills, muscular strength, and agility. Cardiorespiratory fitness is one of the most 
important components of health-related fitness. It is usually measured by indirect calorimetry in a 
laboratory setting as maximal aerobic power or maximal oxygen uptake (VO2max), referring to the 
maximum rate at which an individual can take up and utilize oxygen while breathing air at sea level during 
heavy dynamic exercise383. Owing to difficulties in assessing a true plateau in maximal oxygen uptake, an 
allied measure of VO2peak is also used (i.e. the highest rate of oxygen uptake achieved during heavy 
dynamic exercise). Cardiorespiratory fitness can also be estimated from peak power achieved on a cycle 
ergometer, total time on a standard treadmill test, or submaximal tests by estimating age-predicted values 
from the heart rate response301,384-386.  (See Chapter 2 for full protocols and rationale.)  
 
The aim of this chapter study was to refine the MHO phenotype to include accurate measures of fitness in 
addition to accurate MRI/MRS measures of adiposity and ectopic fat content.  
 
Objectives:  
1. Identify 4 phenotypes relating to adiposity and fitness: 
1.1 Slim, fit and active (the slim-fit),  
1.2 Slim, unfit and inactive (the slim-unfit),  
1.3  Fat, fit and active (the fat-fit)  
1.4 Fat, unfit and inactive (the fat-unfit). 
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2. Investigate whether fat-fit results in a ‘healthier’ body composition than slim-unfit. 
 
Study 3 Hypothesis: 
Hypothesis : Fitness results in reduced IAAT and ectopic fat, regardless of overall adiposity. 
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5.2.  Methods 
 
Participants 
Fifty male volunteers aged 34–56 years were recruited. Hammersmith Hospital Research Ethics 
Committee approved this study and all participants gave written informed consent (REC reference 
number 04/Q0403/87). The study protocol conformed to the ethical guidelines outlined in the 1975 
Declaration of Helsinki.  
 
Adiposity, fitness and activity 
Waist circumference (minimal), fitness level and exercise habit were subsequently used to distinguish and 
categorize the participants as being: “fat”, “slim”, “fit” and “unfit”. Waist circumference was measured (as 
described in Chapter 2 – General Methods) using an inelastic tape, at the narrowest part of the torso387 , 
in the horizontal plane, and values ≤90 cm were used to identify and classify “slim” men and values ≥100 
cm were used to identify and classify “fat” men.  
 
Aerobic fitness was assessed by oxygen consumption measurement using a calibrated online gas 
analysis system during an incremental cycling test. A full description is given in the General Research 
Methods and Procedures chapter (Chapter 2).  
 
Maximal oxygen consumption (VO2 max) was expressed in absolute terms (L⋅min-1) and using previously 
established age-specific norms388 (Appendix 2),  men who scored ‘very poor’, ‘poor’, ‘fair’ or ‘average’ 
were classified as “unfit”;  and men who scored ‘good’, ‘very good’ or ‘excellent’ were classified as “fit”. 
In the knowledge that there could potentially be some very unfit, overweight participants being tested, I  
ensured that established safety guidelines were observed to ensure no unnecessary risk was 
encountered.  As maximal fitness testing is stressful, it can be necessary to terminate testing under 
certain circumstances311. Such circumstances would include dizziness, pain or significant discomfort, or 
other overt signs of becoming unwell as a consequence of increasing workload. During the course of this 
study, exercise tests were terminated at 80% of age-predicted maximum heart rate in three “fat-unfit” 
participants, to reduce their risk of cardiovascular injury. This decision was made based on their initial 
assessment and their physiological response to the early stages of their cycle tests.  In these three cases, 
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the participants’ VO2 max was subsequently estimated (using standardised methods) by extrapolating 
their 80% submaximal heart rate and oxygen uptake values.  During these tests cardiac (3 lead ECG) 
monitoring was utilised to record heart rate data and to provide additional safety criteria necessary in 
clinical exercise testing. As a registered nurse (intensive care speciality), experienced exercise 
physiologist, and Advanced Life Support qualified practitioner, I was able to provide the necessary 
appropriate support for such test scenarios and be able to recognise test termination points as required. 
The fitness tests were also undertaken in the hospital MR imaging unit where trained medical 
practitioners (who were part of the wider research team) were regularly in attendance to provide medical 
cover for research programs, and would routinely be informed that such exercise testing was taking 
place.    
 
In this study physical activity was assessed using the Five-City Project Physical Activity Recall 
Questionnaire389 (in addition to the previously mentioned Baecke questionnaire). These validated 
questionnaires ensured that an accurate and standardised method was used for this important data, by 
avoiding any ambiguity in participant questioning. I employed these, interviewer probe-type format 
methods, to minimise the potential for over-reporting.  Only unfit men who reported no regular moderate 
or vigorous activity in the previous two years and fit men who reported taking part in at least 60 minutes of 
vigorous aerobic activity per week in the previous two years were included in the study. This amount of 
activity is the minimum amount recommended to develop and maintain cardiorespiratory fitness390. 
Moderate-intensity activities are those ≈4 METs and vigorous-intensity activities are those ≥6 METs, 
where 1 MET is equivalent to the energy expended at rest 391,392.  
 
MRI scanning: Total body and regional adipose tissue content 
 
On a single visit, participants underwent total body MRI scanning and in vivo proton magnetic resonance 
spectroscopy (1H MRS) of their liver and their calf muscle. A full description is given in the General 
Research Methods and Procedures chapter (Chapter 2). 
 
Statistical methods 
Descriptive characteristics were compared using univariate general linear model analysis of variance 
(GLM-ANOVA) with Bonferroni post hoc tests. Magnetic resonance imaging and spectroscopy data were 
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compared using general linear model analysis of covariance (GLM-ANCOVA) with Sidak post hoc tests. 
Age and height were the covariates in the comparisons of the slim-fit, the slim-unfit, the fat-fit and the fat-
unfit. Age, height and BMI were the covariates in the comparisons of the fit-and-active and the unfit-and-
inactive men. Multiple linear regression was used to investigate if simple measures of fitness (VO2 max), 
adiposity (waist circumference) and activity (years of exercise) could predict total and regional adiposity 
measurements. The probability of F was used to retain (<.05) or remove (≥.10) predictors in backwards 
elimination models. Only one measure of fitness, adiposity and activity was used in each regression 
model because there was evidence of collinearity when two measures were included. All data were 
analysed using SPSS software (version 17.0, SPSS Inc., Chicago, Il, USA). All p values presented are 
two-tailed. 
 
 !
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5.3. Results 
 
Table 5.1 presents the descriptive characteristics of four different phenotypes identified for this study. 
Based on the results of the waist circumference and fitness testing there were: 13 slim-fit individuals, 12 
slim-unfit, 13 fat-fit, and 12 fat-unfit. Their characteristics are presented in Table 5.1.  
 
Slim-fit and slim-unfit individuals differed only in measures of fitness; there were no significant differences 
in any adiposity measures. In addition to reduced fitness, fat-unfit individuals also had a significantly 
greater waist circumference compared to fat-fit participants (p<0.05). 
 
Maximal oxygen uptake was significantly lower in unfit men. Self-reported vigorous activity ranged from 
2–13 hours per week and exercise history ranged from 2–33 years in the slim-fit and the fat-fit. Slim-fit 
and fat-fit men took part in aerobic exercise or a mixture of aerobic and resistance exercises. The slim-
unfit and the fat-unfit reported no regular moderate or vigorous activity in the last two years. 
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Table 5.1 Characteristics of the slim-fit, slim-unfit, fat-fit and fat-unfit groups 
 
 Slim-fit  
(n=13) 
Slim-unfit  
(n=12) 
Fat-fit  
(n=13) 
Fat-unfit  
(n=12) 
Age (years) 43 ± 5 43 ± 7 46 ± 6 47 ± 4 
Weight (kg) 80.7 ± 7.9 75.9 ± 6.5 112.6 ± 15.7*† 104.8 ± 12.3*† 
BMI (kg/m2) 24.4 ± 1.7 23.5 ± 1.5 33.7 ± 4.2*† 33.0 ± 3.9*† 
Waist circumference (cm) 83.7 ± 4.89 83.9 ± 4.3 110.8 ± 8.9*† 114.2 ± 9.3*† 
Hip circumference (cm) 99.0 ± 5.1 98.7 ± 3.5 115.6 ± 8.5*† 110.8 ± 5.6*† 
Waist-to-hip ratio 0.86 ± 0.04 0.85 ± 0.03 0.96 ± 0.04*† 1.01 ± 0.04*†‡ 
VO2 max (L·min-1) 3.87 ± 0.56 2.84 ± 0.42* 3.97 ± 0.32† 3.18 ± 0.77*‡ 
VO2 max (mL·kg-1·min-1) 48.1 ± 7.6 36.7 ± 4.8* 36.0 ± 4.3* 30.25 ± 6.4* 
Vigorous activity (h·wk-1) 6.0 ± 3.2 - 5.5 ± 2.9 - 
Years of exercise 16 ± 9 - 17 ± 13 - 
Data presented as mean ± SD. *Significantly different to slim-fit after adjustment for age and height, 
p<0.05. †Significantly different to slim-unfit after adjustment for age and height, p<0.05. ‡Significantly 
different to fat-fit after adjustment for age and height, p<0.05. 
 
 
Body Composition  
Differences in adiposity between the 4 groups are summarised in Table 5.2.  
Slim-fit vs slim-unfit: There were no significant differences in adiposity in either subcutaneous or 
internal depots between the slim-fit and the slim-unfit. The ratio of IAAT/ASAT (TOFI index) was 
significantly higher in the slim-unfit group. There were no significant differences in ectopic fat between the 
slim-fit and the slim-unfit groups. 
 
Fat-fit vs fat-unfit: There were no significant differences in TAT, SAT or ASAT between the fat-fit and fat-
unfit groups. However total internal adipose tissue, as well as IAAT and NAIAT were significantly higher in 
the fat-unfit compared to the fat-fit. The IAAT/ASAT was also significantly higher in the fat-unfit group. 
Similarly, IHCL was significantly elevated in the fat-unfit compared to the fat-fit, despite no significant 
differences in IMCL. 
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Table 5.2 Total and regional fat distribution in the slim-fit, slim-unfit, fat-fit and fat-unfit groups 
 
 Slim-fit  
(n=13) 
Slim-unfit  
(n=12) 
Fat-fit  
(n=13) 
Fat-unfit  
(n=12) 
TAT (L) 15.2 ± 4.0 17.6 ± 5.6 36.6 ± 11.2*† 38.3 ± 6.6*† 
SAT (L) 12.2 ± 3.4 12.7 ± 3.7 28.8 ± 10.4*† 26.2 ± 4.9*† 
ASAT (L) 3.0 ± 1.4 3.2 ± 1.2 9.2 ± 4.0*† 8.1 ± 1.8*† 
TIAT (L) 3.0 ± 1.1 4.8 ± 2.3 7.8 ± 1.5*† 12.1 ± 3.7*†‡ 
IAAT (L) 1.4 ± 0.8 2.6 ± 1.4 4.7 ± 1.1*† 7.5 ± 2.2*†‡ 
NAIAT (L) 1.5 ± 0.4 2.3 ± 1.1 3.1 ± 0.6* 4.5 ± 1.8*†‡ 
IAAT:ASAT 0.5 ± 0.2 0.8 ± 0.3* 0.6 ± 0.2 1.0 ± 0.3*‡ 
IHCL 0.4 ± 0.5 1.5 ± 1.4 5.5 ± 6.1 26.1 ± 24.2*†‡ 
S-IMCL 8.3 ± 3.6 11.0 ± 7.3 15.4 ± 5.7 14.7 ± 10.7 
T-IMCL 5.0 ± 2.7 6.3 ± 2.6 8.3 ± 7.3 9.3 ± 5.4 
Data presented as mean ± SD.  
*Significantly different to slim-fit after adjustment for age and height, p<0.05.  
†Significantly different to slim-unfit after adjustment for age and height, p<0.05.  
‡Significantly different to fat-fit after adjustment for age and height, p<0.05.  
 
TAT - total adipose tissue; SAT – subcutaneous; ASAT - subcutaneous abdominal; TIAT - Total internal; 
IAAT - Intra-abdominal adipose tissue; NAIAT - Non-abdominal internal; IAAT/SAAT (L). IHCL - 
intrahepatocellular lipid; IMCL - intramyocellular lipid (S - soleus, T - tibialis); IHCL and IMCL data were 
analysed as log data. Values are mean±SD.  
 
 
 
Fat vs slim: Interestingly, when the adiposity data are presented as a percentage of body weight, rather 
than in absolute volumes (as shown in Table 5.2), the proportion of internal fat was actually lower in the 
fat-fit compared to the slim-unfit group (Figure 5.1).  
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Figure 5.1. Internal fat expressed as a percentage of body weight in 13 slim-fit men, 12 slim-
unfit men, 13 fat-fit men, and 12 fat-unfit men. Data are presented as means ± standard 
deviations. *Significantly different to slim-fit after adjustment for age and height, p<0.05. 
†Significantly different to slim-unfit after adjustment for age and height, p<0.05. ‡Significantly 
different to fat-fit after adjustment for age and height, p<0.05. 
 
 
The percentage of IAAT was higher in the slim-unfit compared to the slim-fit though this did 
not reach significance (p=0.06). This was significantly higher in both the fat-fit and fat-unfit. 
(Figure 5.2).  
 
 
Figure 5.2. Intra-abdominal adipose tissue (IAAT) expressed as a percentage of body weight 
in 13 slim-fit men, 12 slim-unfit men, 13 fat-fit men, and 12 fat-unfit men. Data are presented 
as mean ± standard deviation. *Significantly different to slim-fit after adjustment for age and 
height, p<0.05. †Significantly different to slim-unfit after adjustment for age and height, 
p<0.05. ‡Significantly different to fat-fit after adjustment for age and height, p<0.05. 
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Combining the data from the fit group (slim-fit and fat-fit) as well as data from the unfit groups 
(slim-unfit and fat-unfit), created two groups comprised of 26 fit-and-active men and 24 unfit-
and-inactive men. Comparing these two categories showed the amount of IAAT and the 
amount of IHCL were significantly lower in the fit-and-active compared to the unfit-and-
inactive, independent of age, height and BMI (Figure 5.3). 
 
 
 
 
Figure 5.3. The amount of IAAT (top) and intrahepatocellular lipids (IHCL, bottom) in 26 men who were fit-
and-active and 24 men who were unfit-and-inactive. Data are presented as mean ± standard deviation. 
*Significantly different to fit-and-active after adjustment for age, height and BMI, p<0.01. 
 
 
 
 
 
A number of significant predictors of total and regional fat were identified in multiple linear regression 
models (Table 5.3). For example, waist circumference and years of exercise explained 84% of the 
variance in total fat, waist circumference and VO2 max explained 70% of the variance in IAAT, and waist 
circumference explained 25% of the variance in IHCL. Regression coefficients indicated that a 10 cm 
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increase in waist circumference was associated with a 7.3 litre increase in total fat and a 1.3 litre increase 
in IAAT. In contrast, a 0.5 L⋅min-1 increase in VO2 max was associated with a 0.5 L reduction in IAAT. 
 
Table 5.3 Fitness, adiposity and exercise history as predictors of total and regional fat in multiple 
linear regression models 
 
Outcome variables 
Significant predictor variables 
 
R2 Constant 
VO2 max 
(L⋅min-1) 
Waist 
circumference 
(cm) 
Years of 
exercise 
TAT (L) -44.02 - 0.73 -0.14 .84 
SAT (L) -35.29 - 0.56 - .75 
ASAT (L) -15.01 - .21 - .75 
TIAT (L) -5.44 -1.73 0.18 - .72 
IAAT (L) -5.02 -1.00 0.13 - .70 
NAIAT (L) -0.42 -0.73 0.06 - .61 
IAAT:ASAT 1.44 -0.22 - - .23 
S-IMCL -3.59 - 0.16 - .16 
T-IMCL -4.31 - 0.11 - .13 
IHCL -37.52 - 0.45 - .25 
 
Values are unstandardised coefficients derived from all participants. Predictors were included in the 
model if the probability of F was <.05. Outcome variables were measured in litres apart from IAAT/ASAT 
and IHCL. TAT - total adipose tissue; SAT – subcutaneous; ASAT - subcutaneous abdominal; TIAT - 
Total internal; IAAT - Intra-abdominal adipose tissue; NAIAT - Non-abdominal internal; IAAT/ASAT (L). 
IHCL - intrahepatocellular lipid; IMCL - intramyocellular lipid (S - soleus, T - tibialis); IHCL and IMCL data 
were analysed as log data. 
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5.4. Discussion 
 
In this chapter, I have shown that intra-abdominal adipose tissue and liver fat are lower in men who are 
fat, fit and active than men who are fat, unfit and inactive. This may help explain why the risk of chronic 
disease is lower in the ‘fat-fit’ than the ‘fat-unfit’ 184. It is important to explain how it is possible to be fat, fit 
and healthy because weight loss is difficult to achieve393.  
 
Several investigators have compared intra-abdominal adipose tissue in fit men and unfit men of different 
waist circumference or BMI394-396. Wong and colleagues395 obtained five to seven computed tomography 
(CT) images bordered by the L4–L5 and L3–L4 vertebral disc spaces and found that IAAT was lower in 
169 fit men than 124 unfit men of a given BMI (fit men were those in the highest two quintiles and unfit 
men were those in the lowest two quintiles of treadmill time). Lee and colleagues394 obtained a single CT 
or MR image at L4–L5 and found that IAAT was lower in 147 men who were fat and fit (BMI 26.9±3.2 and 
highest 40% of treadmill times) than 56 men who were fat and unfit (BMI 32.1±3.5 and lowest 20% of 
treadmill times). Fit men also had lower triglyceride and higher HDL cholesterol levels for a given waist 
circumference or amount of IAAT. Arsenault and colleagues396 obtained a single CT image at L4–L5 and 
found that IAAT was lower in 58 fit men than 58 unfit men matched for BMI (fit men were above the 50th 
percentile and unfit men were below the 50th percentile in submaximal cycling tests). The cardiovascular 
disease risk factor profile of fit men was also better than that of unfit men matched for BMI. Physical 
activity was not assessed in any of these studies and the authors could only speculate that physical 
activity was associated with lower levels of IAAT. 
 
Most fit men are active375, but around 2-40% of sedentary men perform well in fitness tests375,397. 
‘Naturally fit’ men were excluded from my study because the available evidence suggests that fitness 
does not reduce the risk of chronic disease in sedentary men. For example physical activity and physical 
fitness were assessed in 4,999 middle-aged men in the Copenhagen Male Study and coronary heart 
disease rates were comparable in those who were fit and sedentary and those who were unfit and 
sedentary during 17 years of follow-up397. In fact, coronary heart disease rates fell across fitness quintiles 
in active men and these data suggest that the protective effects of physical fitness are mediated through 
physical activity.  
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Men who were fat, fit and active were carefully identified in this study. Waist circumference was measured 
because large studies suggest it is a stronger predictor of disease than general adiposity398,399 and was 
part of the standard anthropometry protocol adopted in such studies within the research group. There is 
however, no consensus on waist circumference thresholds400, but a male waist circumference of 100 cm 
is associated with the accumulation of IAAT401. A waist circumference of 90 cm or less was used to define 
slim individuals to avoid misclassification. Maximal oxygen consumption is the ‘gold standard’ measure of 
aerobic fitness and ‘fit’ and ‘unfit’ men in my study were defined with reference to healthy, untrained men 
of the same age from established normative values402. These normative values used were themselves 
largely derived from cycling tests and VO2 max was expressed independent of body weight to avoid 
penalising heavier individuals. Vigorous activity is known to be recalled with greater accuracy403 and only 
fit men who reported taking part in at least 60 minutes of vigorous activity per week in the last two years 
were recruited. 
 
Waist circumference is believed to be a surrogate measure of IAAT404 and it has been suggested that 
waist circumference is a better predictor of cardiovascular disease risk than aerobic fitness405. Waist 
circumference was associated with IAAT in the present study, but there were no significant differences in 
waist circumference between the fat-fit and the fat-unfit despite significant differences in IAAT content. 
Waist circumference (cm) and VO2 max (L⋅min-1) explained 70% of the variance in IAAT in the present 
study and these findings suggest that waist circumference and aerobic fitness should be assessed in 
clinical practice.  
 
This is the first study of liver fat in men who were fat, fit and active. The expansion of adipocytes is 
associated with the accumulation of lipid in non-adipose cells in the liver, skeletal muscle and pancreas 
(ectopic fat), but some individuals with ‘metabolically benign’ obesity appear to have much lower levels of 
ectopic fat406. One possible explanation for the lower levels of IAAT and liver fat observed in the fat-fit 
than the fat-unfit in my study is that ectopic fat may be accumulating when there is lipid ‘overflow’ from 
adipocytes along with concomitant storage in non-adipose depots407,408. This overflow may be less likely 
to occur in the fat-fit participants owing to a capacity to store excess fat in insulin-sensitive subcutaneous 
adipose tissue408 as a consequence of them being ‘metabolically healthy’. Stefan and colleagues406 found 
that ectopic fat was significantly lower in 31 obese individuals who were insulin sensitive than 96 obese 
individuals who were insulin resistant (obesity was defined as a BMI ≥30 and insulin sensitivity was 
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assessed during oral glucose tolerance tests). Ectopic fat accumulation may also be less likely to occur in 
those individuals whose lean tissue is able to maintain and/or increase fat oxidation to accommodate 
normal and/or increased triglyceride levels407, such as the fat-fit. The presence of IMCL in fit men in the 
present study is probably a normal training adaptation that allows fat to serve as a readily available 
fuel409. 
 
It is interesting that the ratio of IAAT to ASAT (TOFI index – Chapter 4) was lower in the slim-fit and the 
fat-fit than the slim-unfit and the fat-unfit, and as discussed in previous chapters, IAAT is associated with 
greater risk of chronic disease than subcutaneous abdominal adipose tissue410. Furthermore, authors 
from the Framingham Heart Study suggest that subcutaneous abdominal adipose tissue may be a 
‘protective fat depot’ in those with higher levels of IAAT411. In men in the highest tertile of IAAT, for 
example, the prevalence of high triglycerides was 52.7% in those with the greatest levels of 
subcutaneous abdominal adipose tissue and 64.4% in those with the lowest levels of subcutaneous 
abdominal adipose tissue (p=0.03 for trend). Data from the Framingham Heart Study also indicates that 
IAAT levels are lower in those who lead a healthy lifestyle, including those who are physically active and 
those who follow dietary guidelines412.  
 
Cross-sectional data cannot be used to infer causality, but several randomised, controlled trials have 
found that endurance training is accompanied by preferential reductions in IAAT413. IAAT and liver fat 
vary considerably in healthy adults279,290 and the findings should be confirmed in a larger study with 
greater statistical power. This study of Caucasian men cannot be generalised to women, older adults and 
other groups. Blair 414 recently suggested that weight loss was the wrong goal because physical activity is 
beneficial to health whether or not an individual loses weight.  
 
The findings in this study have showed that intra-abdominal adipose tissue and liver fat are lower in men 
who are fat, fit and active than men who are fat, unfit and inactive. The hypothesis for this current study : 
that  fitness results in reduced IAAT and ectopic fat, regardless of overall adiposity, is accepted.  
 !
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Chapter 6. The “Asian Indian Phenotype” / (MONW) 
 
6.1. Introduction 
 
As discussed in Chapter 4, a significant proportion of lean individuals (BMI < 25 kg/m2) have been 
referred to as ‘metabolically obese but normal-weight’ (MONW)187,177 as a result of their increased 
abdominal adiposity. An example of this can be seen in the ‘Asian Indian Phenotype’ where individuals 
despite a body mass index (BMI) within the normal range have been reported as having increased waist 
circumference (WC) and waist-to-hip ratios (WHR)193-195. These individuals consequentially have an 
increased risk of type 2 diabetes and CVD 354,355 356 similar to more overweight or obese individuals. This 
population evidences the shortcomings of the BMI with respect to ethnic differences. 
 
Although BMI is considered by many to be a useful population-level measure of obesity, it does not 
capture variations in fat distribution and it does not correspond to the same degree of adiposity or health 
risk across different individuals or populations1. There is growing evidence that the relationship between 
BMI and adiposity (body fat percent) varies considerably between populations of different ethnicities 
197,317,415-428. This ethnicity based variation poses an additional problem since the majority of data used to 
establish BMI cut-off points (for increased risk of adverse health outcomes: overweight (BMI ≥25.0) and 
obese (BMI ≥30.0)) were collected from Caucasian populations364. This multiplication of potential 
inaccuracies could potentially explain criticisms of BMI as a poor indicator of body adiposity in 
racial/ethnic minorities429 and individuals with a large body build337. For example individuals of Polynesian 
ancestry have reduced body fat and increased muscle mass at a given BMI compared to Caucasian 
participants 422,430,431. Conversely, Asians from Asia-Pacific regions including Chinese, Koreans, South 
Asians, Japanese and Singaporean have higher body fat levels at any given BMI compared to 
Caucasians198,423-425,430-432.    
 
South Asians, in particular consistently exhibit the greatest adiposity differences compared to Caucasians, 
with up to 5% higher body fat at any BMI value425,430,433. This culminates in increased risk of type 2 
diabetes and CVD at relatively low BMI values. Since South Asians exhibit elevated adiposity at a lower 
body weight compared to Caucasians, BMI cannot be regarded as an accurate indicator of adiposity in 
South Asians428. As a consequence, the number of individuals who are classified as obese (and 
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subsequently at risk of related comorbidities) will be vastly underestimated when using unadjusted BMI 
classifications. 
 
 An increased incidence of type-2 diabetes and impaired glucose tolerance has been reported in South 
Asians compared to Caucasian populations. Given the strong correlations between insulin resistance, 
visceral adipose tissue and ectopic fat content that have been reported in Caucasian populations60,434-437, 
it is wholly possible that in South Asians, their additional proneness to visceral fat accumulation, is a 
major part of the mechanism underlying their greater propensity to develop type-2 diabetes and related 
morbidities 438-442 at comparatively lower BMI values than other ethnic groups199.  
 
Most previous studies to measure South Asian adiposity have relied on indirect measurements, such as 
waist-to-hip ratio (WHR) and body mass index (BMI), few have applied direct imaging studies to 
accurately map whole body adipose tissue content and distribution (see Table 6.0).  
 
The aim of this study was to develop a detailed phenotype of South Asian adiposity compared to 
Caucasians, and specifically to determine whether TOFI-like characteristics underlie the increased 
metabolic risk traditionally associated with this population.  
 
 
Objectives:  
1. Quantify adiposity stores (across all BMI) in a cohort of healthy South Asian male and female 
volunteers using MRI and MRS. 
2. Identify MONW South Asian individuals (BMI 18.4 – 25 kg/m2) based on the clinical index 
developed in Chapter 4 and assess the relationship between their adiposity and established 
proxy (anthropometric) measures.   
3. Compare the South Asian and Caucasian MONW groups to assess the extent of ethnic 
differences in adiposity stores and abdominal adipose tissue (IAAT/ASAT ratio).  
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Study 4 Hypotheses: 
Hypothesis 1:   South Asians have greater internal and ectopic adipose stores than age and BMI 
matched Caucasians of the same gender. 
Hypothesis 2: The established TOFI index can identify South Asian MONW individuals with 
adverse fat distribution within the normal BMI range (18.5<25 kg/m2). 
Hypothesis 3:   Established proxy (anthropometric) measures are able to successfully identify 
South Asian MONW individuals. 
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Year Authors Participants Measurement Technique Metabolic measurements 
Anthropometry U
W
W 
Body 
water 
dilution 
BIA DXA CT MRI  
1991 Cruickshank 314: 107(A), 101(C), 106(AfrC) ? - - - - - - C-peptide, insulin 
1994 Dhawan 200 M: 83(A), 87(C), 30(A_mig) BMI, WHR - - - - - - Lipids, OGTT 
1996 Bose (A) vs (C) BMI, WC             - 
1999 Banerji 20 (A) (M)  Skf, WC. - - - - 22 slices - adipokines, NEFA’s etc, OGTT 
1999 Chandalia 44: 21(A),23(C) Skf Y - - - - - eu-clamp 
1999 Forouhi 40: 20(A), 20(C) - - - - Yes L4-5 slice IMCL (MRS) OGTT, NEFA, 
2001 Forouhi 141 BMI, WC       Yes L4-5 slice   OGTT, C-reactive protein, lipids,  
2001 Raji 24: 10M (5A, 5C), 12F (7A, 7C) - - - - - L2-3+L3-4 - Lipids, PAI-1, eu-clamp 
2004 Abate 140 M: 79(A) 61(C) Skf x9 Y - - - - - adipokines, NEFA’s etc, OGTT 
2005 Bhat 141(A) (M) Skf - Y Y - - - -  
2005 Tillin 3,662: 1787(CM),1420(AM),455(AfrC_M) n/a - - - - - - OGTT, lipids, ecg (CHD test) 
2008 Goel 168 A: (94M,74F). Skf x7 - - - (n=171) - L3-4 (n=100) - 
2009 Deepa 2350 (A): 1096(M), 1254(F) BMI, WC  - - - - - - lipids and standard bloods, OGTT 
 
Table 6.0  Summary table of South Asian adiposity studies published detailing the participant numbers, measurement techniques used and proxy measures (if 
any) used.  
 
Key:  
Participants.  A – Asian, C – Caucasian, AfrC – Afro-Caribbean,  mig – migrant, M – male, F – female.  
Measurement technique. UWW - underwater weighing, BIA – bioelectrical impedance, DXA – dual-energy X-ray absorptiometry, CT – computerised 
tomography, MRI - magnetic resonance imaging, IMCL – intramyocellular lipid, MRS – magnetic resonance spectroscopy, L4 – lumbar vertebra location (4th). 
Anthropmetry. WC – waist circumference, BMI – body mass index, Skf – skinfold, WHR – waist to hip ratio.  
Metabolic measurements.  OGTT – oral glucose tolerance test,  NEFA – non-esterified fatty acids, PAI-1 – plasminogen activator inhibitor-1,  CHD – coronary 
heart disease, eu-clamp – euglycaemic clamp 
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6.2. Methods 
Participants 
 
Written, informed consent was acquired from all volunteers. Ethical approval permission for this study 
was obtained from the Research Ethics Committee of Hammersmith and Queen Charlotte’s and Chelsea 
Research Ethics Committee Hospital, London (Rec: 07Q04011/19). In total, 68 South Asian (49 male, 19 
female) and 192 Caucasian (99 male, 93 female) age and BMI matched volunteers were recruited.  
 
Self-reported exclusion criteria included participants suffering from chronic disease including diabetes, 
cardiovascular or liver disease, metabolic conditions, anyone taking prescribed medication and women on 
the contraceptive pill. Volunteers underwent anthropometric assessment, total body MRI scanning and in 
vivo proton 1H MRS of liver and calf muscle. 
Ethnicity was determined by self-report and all parents and grandparents were required to be South Asian 
decent and European Caucasian for the South Asian and Caucasian participants, respectively.  
 
Anthropometric measurements 
Body mass (kg), height (cm), midpoint328 waist circumference (WC) (cm) and hip circumference (cm) were 
measured in each participant as detailed in the General Research Methods and Procedures section 
(Chapter 2). From these values, BMI (kg/m2) and waist-to-hip ratio (WHR, waist/hip) were calculated. BMI 
grouping corresponded to the following ranges; 1: 20.5<25 kg/m2, 2: 25<30 kg/m2, 3: 30<40 kg/m2, 4: 40+ 
kg/m2. 
 
MRI scanning: Total body and regional adipose tissue content 
On a single visit, participants underwent total body MRI scanning as described in the General Research 
Methods and Procedures chapter (Chapter 2). The adiposity data obtained was expressed as previously 
described (Chapter 2 - section 2.5.1.3).  
 
MRS of liver and muscle fat 
During the same scanning session, 1H MR spectra were also acquired on a 1.5T scanner and analysed 
using methods previously described (Chapter 2).   
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Statistical Analysis 
Differences relating to gender and/or ethnicity were analysed using one-way ANOVA. Significance was 
taken as p<0.05. All data are presented as mean ± standard deviation. Data which was found not to be 
normally distributed (IHCL and IMCL) is presented as a geometric mean, while statistical analysis was 
performed on log10 transformed variables.  Associations between variables were investigated using 
Pearson partial correlation r values. The statistical analysis was performed using SPSS software (version 
17.0, SPSS Inc., Chicago, Il, USA). 
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6.3. Results 
 
Of the participants included in this part of the study 32.4% of the South Asians were classified as 
overweight (34% of men, 26.3% women, BMI: 25<30), 19.1% qualifying as obese (16% of men, 26.3% of 
women, BMI: 30<40) and none as morbidly obese (BMI: 40+).  
 
Gender Differences 
Male South Asian vs Female South Asian comparison 
Gender specific characteristics are shown in Table 6.1. South Asian males were significantly taller (P < 
0.001), heavier (P < 0.001) and younger (p=0.028) than the South Asian females. Despite this, the only 
difference between the groups that could be detected using anthropometry was the WHR, which was 
significantly lower in the female group.  
 
Significant differences in body composition could be measured using MRI. South Asian female 
participants were found to have significantly higher levels of adipose tissue, predominantly reflecting 
increases in the subcutaneous depots, with significant increases in TAT, SAT, ASAT, NASAT, (P < 
0.0001 for all). While the IAAT/ASAT ratio was significantly lower in female, compared to male 
participants (P < 0.01), there were no gender differences in any of the internal adipose tissue depots 
(including IAAT, TIAT or NAIAT). There was a small but significant difference in some of the ectopic fat 
depots, T-IMCL was higher in female compared to the male South Asian participants, though there was 
no difference in S-IMCL.  While there were no significant differences in ectopic fat content in the liver, 
there was a trend of elevated IHCL in the male group, similar to the gender differences found in 
Caucasian participants in Chapter 4.  
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Table 6.1. Gender differences in South Asian participants. 
 
 South Asian Male  (n=49) 
South Asian Female 
(n=19) SAM vs SAF 
 Mean ± SD Range Mean ± SD Range p 
Age 28.41 ± 6.65 19 - 44 33.11 ± 10.0 21 - 49 0.028 
Weight  77.3 ± 11.4 57.6 - 102 65.7 ± 14.8 44 - 93.3 <0.001 
BMI 26.0 ± 3.5 20.4 – 34.3 25.6 ± 5.1 18.1 - 34.7 0.69 
WC  89.4 ± 10.9 70.5 - 110.4 85.9 ± 9.8 68.6 - 98.0 0.29 
Hip 100.2 ± 6.0 88.5 - 112.0 100.9 ± 10.7 84.5 - 117.5 0.80 
Height 172 ± 6.75 155 – 192 160.5 ± 5.4 152.5 – 171 <0.0001 
WHR 0.89 ± 0.06 0.73 – 0.99 0.84 ± 0.06 0.77 - 0.98 0.020 
WHtR 0.52 ± 0.07 0.42 - 0.70 0.54 ± 0.06 0.44 - 0.61 0.44 
IHCL 4.05 ± 7.68 0 – 48.07 2.61 ± 5.13 0 – 17.97 0.086 
S-IMCL 12.77 ± 6.84 3.31 - 32.51 10.95 ± 7.85 3.45 – 38.38 0.272 
T-IMCL 5.01 ± 2.34 1.08 - 11.69 6.88  ± 2.97 2.40 – 10.79 0.027 
%TAT 26.9 ± 6.6 14.7 - 44.8 38.8 ± 7.0 24.0 - 51.0 <0.0001 
%SAT 21.4 ± 5.4 12.2 – 35.1 33.5 ± 6.3 21.2 - 44.7 <0.0001 
%ASAT 6.3 ± 2.2 2.8 – 12.0 9.4 ± 2.6 4.8 – 15.3 <0.0001 
%NASAT 15.1 ± 3.5 8.9 - 23.4 24.7 ± 4.0 16.4 - 30.7 <0.0001 
%TIAT 5.4 ± 1.9 2.4 – 9.7 5.3 ± 1.8 2.8 – 10.3 0.76 
%IAAT 2.9 ± 1.3 0.7 – 6.0 2.5 ± 1.1 1.0 – 5.3 0.23 
%NAIAT 2.6 ± 0.7 1.4 – 4.2 2.8 ± 0.8 1.8 – 5.1 0.20 
IAAT/ASAT 0.47 ± 0.19 0.19 - 1.55 0.26 ± 0.11 0.14 - 0.55 <0.0001 
 
 
All data are presented as mean ± SD and range. Data analysed by one-way Anova: SAM: South 
Asian Male; SAF: South Asian Female. Fat stores are presented as a percentage of total body 
weight. WC – waist circumference; WHR – waist-to-hip ratio; WHtR - waist-to-height ratio; IHCL - 
intrahepatocellular lipid; IMCL - intramyocellular lipid (S - soleus, T - tibialis); IHCL and IMCL data 
were analysed as log transformed data; TAT - total adipose tissue; SAT – subcutaneous; ASAT - 
subcutaneous abdominal; NASAT - subcutaneous non-abdominal; TIAT - Total internal; IAAT - 
Intra-abdominal adipose tissue; NAIAT - Non-abdominal internal; IAAT/ASAT (L). All data are 
presented as mean ± SD. 
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Ethnic Differences 
Male South Asian vs Male Caucasian comparison 
Since Male participants had been matched for age and BMI, unsurprisingly there were no differences in 
these variables. Interestingly there were significant differences in weight and height, with South Asian 
males being significantly lighter (<0.0001) and shorter (<0.0001) compared to the Caucasian participants 
(Table 6.2). No other differences in body composition were detected using anthropometry. However, 
phenotyping using MRI and MRS showed several striking differences. South Asian males were 
significantly ‘fatter’ with significant increases in all subcutaneous depots compared to the Caucasian male 
group. Specifically there were increases in TAT, SAT, ASAT and NASAT (p<0.0001) compared to 
Caucasian males. There were no significant differences in any of the internal adipose tissue depots 
measured. 
 
Similarly there were no ethnic differences in muscle fat content between male and female participants. 
However South Asian males had significantly higher levels of IHCL compared to the Caucasian group 
(p=0.017). 
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Table 6.2. Comparison between South Asian Male vs Caucasian Male Participants. 
 
 South Asian Male  (n=49) 
Caucasian Male 
(n=99) 
SAM vs 
CM 
 Mean ± SD Range Mean ± SD Range P 
Age 28.41 ± 6.65 19 - 44 30.19 ± 6.51 19 - 44 0.12 
Weight  77.3 ± 11.4 57.6 - 102 82.95 ± 12.3 62.4 - 117 <0.0001 
BMI 26.0 ± 3.5 20.4 – 34.3 25.7 ± 3.6 20.1 – 35.2 0.71 
WC  89.4 ± 10.9 70.5 - 110.4 90.4 ± 10.3 70.0 -113.0 0.66 
Hip 100.2 ± 6.0 88.5 - 112.0 101.3 ± 7.4 87.0 - 119.0 0.45 
Height 172 ± 6.75 155 – 192 179.4 ± 6.63 166 - 193 <0.0001 
WHR 0.89 ± 0.06 0.73 – 0.99 0.89 ± 0.06 0.75 – 1.02 0.75 
WHtR 0.52 ± 0.07 0.42 - 0.70 0.51 ± 0.06 0.38 - 0.64 0.24 
IHCL 4.05 ± 7.68 0 – 48.07 3.37 ± 7.03 0 – 43.86 0.017 
S-IMCL 12.77 ± 6.84 3.31 - 32.51 13.11 ± 6.89 3.10 – 38.97 0.72 
T-IMCL 5.01 ± 2.34 1.08 - 11.69 6.10 ± 7.42 1.48 – 72.36 0.30 
%TAT 26.9 ± 6.6 14.7 - 44.8 22.1 ± 7.4 7.8 – 43.8 0.0002 
%SAT 21.4 ± 5.4 12.2 – 35.1 17.0 ± 5.8 6.2 – 31.5 <0.0001 
%ASAT 6.3 ± 2.2 2.8 – 12.0 4.7 ± 2.2 1.1 – 11.2 <0.0001 
%NASAT 15.1 ± 3.5 8.9 - 23.4 12.3 ± 3.9 1.7 - 20.6 <0.0001 
%TIAT 5.4 ± 1.9 2.4 – 9.7 5.1 ± 2.5 1.3 – 13.2 0.38 
%IAAT 2.9 ± 1.3 0.7 – 6.0 2.7 ± 1.6 0.4 – 7.9 0.47 
%NAIAT 2.6 ± 0.7 1.4 – 4.2 2.4 ± 1.0 1.0 – 6.2 0.31 
IAAT/ASAT 0.47 ± 0.19 0.19 - 1.55 0.59 ± 0.27 0.18 - 1.54 0.0077  
 
 
All data are presented as mean ± SD and range. Data analysed by one-way Anova: SAM: South Asian Male; 
CM: Caucasian Male; AF. Fat stores are presented as a percentage of total body weight. WC – waist 
circumference; WHR – waist-to-hip ratio; WHtR - waist-to-height ratio; IHCL - intrahepatocellular lipid; IMCL - 
intramyocellular lipid (S - soleus, T - tibialis); IHCL and IMCL data were analysed as log transformed data; 
TAT - total adipose tissue; SAT – subcutaneous; ASAT - subcutaneous abdominal; NASAT - subcutaneous 
non-abdominal; TIAT - Total internal; IAAT - Intra-abdominal adipose tissue; NAIAT - Non-abdominal 
internal; IAAT/ASAT (L). All data are presented as mean ± SD. 
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Female South Asian vs Female Caucasian comparison 
Age and BMI matched groups of South Asian and Caucasian were compared. As with the previous 
comparison in male participants, female Asians were significantly shorter (p=0.016) than their Caucasian 
counterparts, although interestingly there were no differences in weight in the female group. Unlike the 
findings in the Male comparison, several significant differences could be detected between South Asian 
and Caucasian female participants using standard anthropometric measurements. Waist circumference, 
WHR and WTHR were all significantly greater in the South Asian female group. Again there were 
significant differences in adiposity measurable by MRI, and as in the male comparison, the differences 
were restricted to the subcutaneous depots. Female South Asian participants had significantly higher 
levels of TAT, SAT, ASAT and NASAT (p<0.001) compared to Caucasian females. 
 
There were no significant differences in IMCL in either the soleus or tibialis muscles. However, as in the 
male participants, South Asian females had significantly higher levels of ectopic fat deposited within their 
livers (p=0.037). 
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Table 6.3. Comparison between South Asian and Caucasian Female participants. 
 
 South Asian Female  (n=19) 
Caucasian Female 
(n=93) 
SAF vs 
CF 
 Mean ± SD Range Mean ± SD Range P 
Age 33.11 ± 10.0 21 - 49 32.18 ± 9.07 21 - 49 0.69 
Weight  65.7 ± 14.8 44 - 93.3 67.2 ± 11.9 47.7 – 105.1 0.63 
BMI 25.6 ± 5.1 18.1 - 34.7 24.5 ± 4.0 18.6 - 34.5 0.32 
WC  85.9 ± 9.8 68.6 - 98.0 78.8 ± 10.8 62.3 – 114.4 0.024 
Hip 100.9 ± 10.7 84.5 - 117.5 100.3 ± 8.6 85.0 - 119.0 0.83 
Height 160.5 ± 5.4 152.5 – 171 165.6 ± 6.97 145.5 - 182 0.0016 
WHR 0.84 ± 0.06 0.77 - 0.98 0.79 ± 0.06 0.61 - 0.99 0.0025 
WHtR 0.54 ± 0.06 0.44 - 0.61 0.48 ± 0.06 0.38 - 0.66 0.0015 
IHCL 2.61 ± 5.13 0 – 17.97 0.78 ± 1.98 0 – 16.7 0.037 
S-IMCL 10.95 ± 7.85 3.45 – 38.38 10.40 ± 5.63 2.8 – 39.2 0.88 
T-IMCL 6.88  ± 2.97 2.40 – 10.79 6.4 ± 3.6 0.96 – 19.1 0.47 
%TAT 38.8 ± 7.0 24.0 - 51.0 34.8 ± 8.0 20.3 - 54.5 0.047 
%SAT 33.5 ± 6.3 21.2 - 44.7 30.0 ± 6.9 17.0 – 47.3 0.043 
%ASAT 9.4 ± 2.6 4.8 – 15.3 8.3 ± 2.8 3.0 – 15.8 0.095 
%NASAT 24.7 ± 4.0 16.4 - 30.7 21.7 ± 4.5 13.6 - 36.6 0.037 
%TIAT 5.3 ± 1.8 2.8 – 10.3 4.8 ± 2.0 1.9 - 11.6 0.37 
%IAAT 2.5 ± 1.1 1.0 – 5.3 2.2 ± 1.3 0.7 - 6.4 0.44 
%NAIAT 2.8 ± 0.8 1.8 – 5.1 2.6 ± 0.9 1.1 – 6.7 0.36 
IAAT/ASAT 0.26 ± 0.11 0.14 - 0.55 0.28 ± 0.15 0.09 - 0.97 0.68 
 
 
All data are presented as mean ± SD and range. Data analysed by one-way Anova: South Asian Female; 
CF: Caucasian Female. Fat stores are presented as a percentage of total body weight. WC – waist 
circumference; WHR – waist-to-hip ratio; WHtR - waist-to-height ratio; IHCL - intrahepatocellular lipid; IMCL - 
intramyocellular lipid (S - soleus, T - tibialis); IHCL and IMCL data were analysed as log transformed data; 
TAT - total adipose tissue; SAT – subcutaneous; ASAT - subcutaneous abdominal; NASAT - subcutaneous 
non-abdominal; TIAT - Total internal; IAAT - Intra-abdominal adipose tissue; NAIAT - Non-abdominal 
internal; IAAT/SAAT (L). All data are presented as mean ± SD. 
 
 
 
 !
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Correlation Analysis 
 
Correlation analysis of Asian Indian male data resulted in a similar pattern of r values to that seen in 
Caucasian counterparts, with WTHR and WHR the best representatives of adiposity stores (Chapter 4, 
Table 4.3). Unlike Caucasian males, abdominal adipose stores in South Asian males were most strongly 
correlated to WTHR rather than WC. There was a large reduction in correlation between BMI and internal 
fat stores (%TIAT, %IAAT, %NAIAT) in South Asian women, with age providing the best marker for these 
adipose deposits (Table 6.4).  
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Table 6.4. Pearson correlation analysis between anthropometric measurements, lipid stores and percentage body fat stores in South Asian male participants. 
MALE 
SOUTH 
ASIAN 
ANTHROPOMETRIC VARIABLES ECTOPIC FAT STORES PERCENTAGE ADIPOSITY STORES 
n = 49 Age Weight BMI WC Hip Height WHR WHtR IHCL S-IMCL T-IMCL %TAT %SAT %ASAT %NASAT %TIAT %IAAT %NAIAT 
Weight 0.526**                  
BMI 0.456** 0.930**                 
WC 0.696** 0.895** 0.828**                
Hip 0.279 0.910** 0.927** 0.822**               
Height 0.358* 0.554** 0.213 0.476* 0.354              
WHR 0.780** 0.796** 0.701** 0.933** 0.563** 0.554**             
WHtR 0.660** 0.856** 0.855** 0.981** 0.822** 0.301 0.910**            
IHCL 0.382* 0.614** 0.557** 0.630** 0.577** 0.327 0.618** 0.624**           
S-IMCL 0.654** 0.532** 0.529** 0.690** 0.656** 0.193 0.696** 0.694** 0.450**          
T-IMCL 0.441** 0.344* 0.279 0.529** 0.482* 0.257 0.296 0.511** 0.472** 0.652**         
%TAT 0.286 0.584* 0.640** 0.696** 0.691** 0.093 0.517** 0.756** 0.363** 0.685** 0.401*        
%SAT -0.067 0.553** 0.629** 0.558** 0.726** 0.04 0.348 0.625** 0.238 0.422* 0.213 0.887**       
%ASAT 0.048 0.624** 0.729** 0.552** 0.715** 0.014 0.402 0.627** 0.282 0.430** 0.192 0.819** 0.920**      
%NASAT -0.13 0.469** 0.521** 0.540** 0.710** 0.052 0.30 0.598** 0.20 0.385* 0.209 0.860** 0.972** 0.803**     
%TIAT 0.725* 0.292 0.28 0.570** 0.149 0.131 0.592** 0.593** 0.344* 0.734** 0.490** 0.604** 0.168 0.161 0.159    
%IAAT 0.764** 0.370* 0.362* 0.606** 0.18 0.148 0.665** 0.627** 0.415* 0.724** 0.458** 0.597** 0.172 0.209 0.137 0.976**   
%NAIAT 0.587** 0.135 0.119 0.468** 0.052 0.089 0.334 0.492* 0.198 0.674** 0.490** 0.554** 0.142 0.066 0.177 0.936** 0.837**  
IA/SA 0.691** 0.052 0.001 0.322 -0.225 0.122 0.399 0.31 0.232 0.383* 0.237 0.176 -0.268 -0.269 -0.247 0.838** 0.840** 0.749** 
 
Abbreviations: WC – waist circumference; WHR - waist-hip ratio; WHtR - waist-to-height ratio; IHCL - intrahepatocellular lipid; IMCL - intramyocellular lipid (S-soleus, T-tibialis); 
Fat stores were analysed as a percentage of body-weight; TAT - total adipose tissue, SAT - subcutaneous, ASAT - subcutaneous abdominal, NASAT - subcutaneous non-
abdominal, TIAT - Total internal, IAAT - Intra-abdominal adipose tissue, NAIAT - Non-abdominal internal, IHCL - intrahepatocellular lipid; IMCL - intramyocellular lipid (S - 
soleus, T - tibialis); IHCL and IMCL data are presented as the logarithm of MRS readings; IA/SA = IAAT/ASAT; Bold typeface indicates a significant correlation; The shaded 
boxes indicate the anthropometric variable which most highly correlates with individual ectopic fat or adiposity stores; * = p<0.05, ** = p<0.01. 
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Table 6.5 Pearson correlation analysis between anthropometric measurements, lipid stores and percentage body fat stores in South Asian female participants. 
 
FEMALE 
SOUTH 
ASIAN 
ANTHROPOMETRIC VARIABLES ECTOPIC FAT STORES PERCENTAGE ADIPOSITY STORES 
n = 19 Age Weight BMI WC Hip Height WHR WHtR IHCL S-IMCL T-IMCL %TAT %SAT %ASAT %NASAT %TIAT %IAAT %NAIAT 
Weight 0.015                  
BMI 0.189 0.951**                 
WC 0.16 0.755** 0.855**                
Hip -0.196 0.947** 0.934** 0.865**               
Height 0-.551* 0.252 -0.054 -0.176 0.131              
WHR 0.367 -0.149 -0.021 0.283 -0.235 -0.395             
WHtR 0.341 0.578* 0.789** 0.952** 0.774** -0.464 0.372            
IHCL 0.617** 0.208 0.32 0.256 -0.208 -0.289 0.598 0.442           
S-IMCL 0.48 0.174 0.308 0.418 0.54 -0.388 -0.387 0.548 0.520*          
T-IMCL -0.02 0.544* 0.513* 0.457 0.557 0.155 -0.221 0.329 0.288 0.452         
%TAT 0.369 0.766** 0.843** 0.53 0.768** -0.156 -0.095 0.528 0.33 0.525* 0.311        
%SAT 0.161 0.849** 0.897** 0.605* 0.865** -0.057 -0.244 0.551 0.193 0.389 0.355 0.963**       
%ASAT 0.237 0.856** 0.920** 0.898** 0.891** -0.106 0.076 0.863** 0.351 0.337 0.411 0.900** 0.920**      
%NASAT 0.109 0.787** 0.822** 0.415 0.769** -0.025 -0.387 0.358 0.082 0.388 0.293 0.931** 0.976** 0.812**     
%TIAT 0.794** 0.131 0.257 -0.06 -0.341 -0.371 0.404 0.073 0.544* 0.651** 0.057 0.603** 0.364 0.384 0.329    
%IAAT 0.828** 0.128 0.261 0.032 -0.208 -0.38 0.352 0.168 0.517* 0.493* -0.006 0.558* 0.326 0.405 0.26 0.957**   
%NAIAT 0.523* 0.101 0.181 -0.292 -0.642* -0.256 0.367 -0.221 0.457 0.793** 0.162 0.535* 0.344 0.245 0.376 0.825** 0.625**  
IA/SA 0.778** -0.245 -0.137 -0.213 -0.453 -0.348 0.343 -0.079 0.395 0.39 -0.149 0.189 -0.07 -0.023 -0.091 0.854** 0.893** 0.557* 
 
 
Abbreviations: WC – waist circumference; WHR - waist-hip ratio; WHtR - waist-to-height ratio; IHCL - intrahepatocellular lipid; IMCL - intramyocellular lipid (S-soleus, T-tibialis); 
Fat stores were analysed as a percentage of body-weight; TAT - total adipose tissue, SAT - subcutaneous, ASAT - subcutaneous abdominal, NASAT - subcutaneous non-
abdominal, TIAT - Total internal, IAAT - Intra-abdominal adipose tissue, NAIAT - Non-abdominal internal, IHCL - intrahepatocellular lipid; IMCL - intramyocellular lipid (S - 
soleus, T - tibialis); IHCL and IMCL data are presented as the logarithm of MRS readings; IA/SA - IAAT/ASAT; Bold typeface indicates a significant correlation; The shaded 
boxes indicate the anthropometric variable which most highly correlates with individual ectopic fat or adiposity stores; * = p<0.05, ** = p<0.01. 
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TOFI Analysis 
The mean IAAT/ASAT ratio was significantly higher in Caucasian males compared to that measured in 
South Asian participants (IAAT/ASAT: Caucasian male 0.59 ± 0.27 vs. Asian male: 0.47 ± 0.19 
p=0.0077), despite the range being similar in both groups. There were no significant differences in 
IAAT/ASAT between South Asian and Caucasian female participants. Interestingly, applying the TOFI 
cut-off discussed in Chapter 4 to this South Asian population, only one female and no male 
participants would be defined as TOFI. 
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6.4. Discussion 
 
 
Ethnic effects 
South Asian Indian men and women have a higher incidence and mortality rate from CVD than 
Caucasians211,217. The pathology of this increased susceptibility is yet to be fully elucidated; however 
for any proposed value of BMI, South Asians have a higher degree of adiposity, abdominal obesity 
and a lower muscle mass than Caucasians443.  This was confirmed in this study where I showed that 
age and BMI matched male and female South Asian participants had significantly higher levels of 
subcutaneous adipose tissue compared to a Caucasian population. The mechanism behind this 
apparent increase in adiposity is unclear, although there have been studies which would suggest that 
these differences occur as early as infancy with South Asian newborn infants demonstrating increased 
fat deposition in all abdominal adipose compartments compared to Caucasian infants444.  British South 
Asian children (10-11 years old)445,446 and adolescents (13-16 years old)447,448 have also been found to 
be significantly more insulin resistant than Caucasians despite similar adiposity levels, further 
supporting early risk development prior to obesity.   
 
These findings are in agreement with previous body composition studies using computerised 
tomography (CT) which have shown that South Asian Indian men have lower muscle mass and more 
body fat than Caucasian counterparts442. Interestingly although the authors report that visceral fat is 
high in their South Asian population, they didn’t directly compare it with measurements from a 
Caucasian population. Their assertion that the increased insulin resistance in South Asians is related 
to increased visceral adipose tissue may therefore be incorrect. Indeed I found a significant increase in 
total percentage adiposity and subcutaneous depots in South Asians compared Caucasians 
counterparts, but no significant differences in internal adipose tissue depots. This suggests that the 
differences in adiposity between Caucasian and South Asians are limited to subcutaneous fat deposits 
as opposed to internal adipose stores. Therefore, the increased insulin resistance and metabolic risk 
in South Asians does not appear to be linked to an internal adiposity, suggesting ethnic differences in 
the pathogenicity of individual adipose stores.  
 
A greater understanding the changes in body composition is essential if we are to understand the 
mechanism behind the increased metabolic risk in this population. The rapid increase in the 
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prevalence of type 2 diabetes449-454 and cardiovascular disease in India and in South Asian migrant 
populations455-458 has been associated with rapid urbanization, dietary changes459 and increasing 
obesity449,460-464. Type-2 diabetes in South Asians is also accompanied with a higher risk of 
complications, particularly cardiovascular and renal, compared to Caucasians465-467.  
 
Although the research in this thesis does not address the underlying mechanism responsible for type-2 
diabetes in the South Asian population, the results suggest that research should perhaps refocus from 
visceral from the involvement of subcutaneous fat as a potential basis. Indeed, data published by 
Chandalia et al.468 revealed South Asian male participants have larger subcutaneous abdominal 
adipocytes compared to age and weight matched Caucasian controls which was negatively correlated 
with glucose disposal469. 
 
Another potential mechanism may well be related to the elevated levels of liver fat found in both male 
and female South Asians compared to the Caucasian controls. Indeed it has been suggested that in 
the development of insulin resistance and type 2 diabetes, accumulation of lipids outside the classical 
adipose tissue depots may be the critical factor470. As previously mentioned (Chapter 1) lipid 
accumulation in non-adipose cells such as the liver may impair the normal housekeeping function 
through a process known as ‘lipotoxicity’107. Ectopic storage of excess lipids in the liver, pancreas and 
muscle has been proposed as the causative link between fat distribution and the metabolic 
syndrome61.  
 
There were no ethnic differences in IMCL in male participants, and no difference in S-IMCL in female 
participants, which would suggest that perhaps IMCL is not a key mechanism.  Indeed Forouhi et al.156 
reported that while there was an association between IMCL and insulin sensitivity and obesity in 
Caucasians participants, consistent with the idea that IMCL mediates the effect of obesity on insulin 
sensitivity, this is not the case in Asian participants. They suggested that in the absence of a 
relationship between insulin sensitivity and IMCL in South Asians another mechanism must underlie 
the high insulin resistance observed in this population.  
 
An alternative mechanism is the elevated IHCL observed in my Asian population. Recent studies have 
shown that 25–50% of patients with fatty liver subsequently became diabetic, suggesting that hepatic 
steatosis may have a direct causative effect in the development of diabetes471,472. This steatosis has 
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also been linked to the development of CVD472, suggesting that non-alcoholic fatty liver disease is an 
independent risk factor for metabolic disease. There have been several studies assessing the 
incidence of fatty liver in South Asian populations473-475, which have reported an incidence of NAFLD 
from 8.7% (Kolkata, India) to as high as 32% (Chennai, India) and 32.6% (Ragama, Sri Lanka).  
 
Despite elevated IHCL being a feature of the TOFI phenotype, it appeared that TOFI classification was 
not useful in identifying ‘at risk’ participants within the Asian population, in part because 
‘disproportional’ deposition of visceral adipose tissue does not appear to be a key component of the 
Asian phenotype. Perhaps measurements of IHCL alone would be sufficient to identify individuals ‘at 
risk’ of developing metabolic disease within the Asian population, although prospective longitudinal 
studies would be essential to determine if IHCL was a driving factor, or secondary to the development 
of impaired glucose tolerance and related metabolic changes. 
The hypothesis for this current study: South Asians have greater internal and ectopic adipose stores 
than age and BMI matched Caucasians of the same gender is rejected as not all aspects were true. 
The hypothesis for this current study: the established TOFI index can identify South Asian MONW 
individuals with adverse fat distribution within the normal BMI range (18.5<25 kg/m2) is rejected. 
 
Differences in body composition in male participants in particular were not readily measurable using 
anthropometric measurements. Given the significant differences in abdominal subcutaneous adipose 
tissue content, it is somewhat surprising that these could not be detected from measures of waist 
circumference. This reinforces the need for accurate direct measurements of body composition for 
studies of this nature. The hypothesis for this current study: established proxy (anthropometric) 
measures are able to successfully identify South Asian MONW individuals is rejected. 
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Chapter(7.(((Summary!
 
 
 
The original stimulus for the present thesis was the observation that in the health, medical and 
insurance industries, body mass index (BMI) can be an ambiguous diagnostic for obesity in that it can 
potentially classify a power athlete as obese and also indicate a normal body weight individual as 
healthy when they that may actually be at significant risk of metabolic dysfunction. Unanswered 
questions surrounding the accuracy of industry standard body composition measuring devices as well 
as how being obese and fit might be acceptable captured the imagination and provided a focus for this 
work to be carried out.  
 
The work central to the thesis sought to add further insight in this area by investigating the variation of 
body fat distribution in healthy volunteers using whole body MRI techniques. A series of studies were 
undertaken to explore further the relationship between BMI and adiposity in the adult.  
 
Findings from the present thesis have demonstrated that:  
 
1. When whole cohort data were compared to MRI adiposity data there was no significant 
difference between the measures derived. However when the cohort was divided by ethnicity 
(Asian vs Caucasian) differences were more apparent. Caucasian adiposity was 
overestimated by up to 3% and Asian adiposity was underestimated by up to 11%. Bodpod 
would be best suited to measuring Asian adiposity and BIA devices would be best suited to 
measuring Caucasian adiposity.  
 
2.  An abdominal transimpedance device (ViScan) based in BIA technology developed for 
measuring abdominal adiposity was tested.  The Viscan measurement system was not able to 
conclusively measure intra-abdominal adipose tissue (IAAT) adiposity in obese males and 
females.  It appeared to be better at measuring abdominal subcutaneous adipose tissue 
(ASAT). Additionally, the ViScan measurements appeared to be influenced by organ volumes 
– in particular the liver.  
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3. The ‘Thin on the Outside – Fat on the Inside’ (TOFI) phenotype can be defined using the ratio of 
IAAT and ASAT (IAAT/ASAT). The resulting TOFI index provides a quantitative means of 
comparing intra-abdominal fat deposition and thereby identifying “at risk” individuals. In 
Caucasians, cut-off values of >1.0 in males and >0.45 in females are proposed for TOFI 
definition. Additionally, anthropometric measurements such as waist circumference (WC) and 
waist to height ratio (WHtR) are not appropriate for classifying the TOFI phenotype.  This is 
because these surrogates generally correlated more with total and subcutaneous adipose 
tissue stores than internal or ectopic depots.  
 
4.  IAAT and liver fat are lower in men who are fat, fit and active than in men who are fat, unfit and 
inactive. These ‘metabolically healthy’ individuals have the capacity to store excess fat in 
insulin-sensitive abdominal subcutaneous adipose tissue (ASAT) and this may help explain 
why the risk of chronic disease is lower in the ‘fat-fit’ than the ‘fat-unfit’.  As a consequence, 
aerobic activity and the pursuit of physical fitness may be more appropriate goals in the battle 
against chronic disease than weight loss. 
 
5. Asian Indian males were found to be significantly ‘fatter’ with significantly higher subcutaneous 
fat depots compared to similar Caucasian males. Given the increased metabolic risks seen in 
the Asian population, increased IAAT measures were not found to be significantly higher.  If 
these results could be replicated in a larger cohort, there might be merit in assuming that the 
metabolic risks this group are prone to may be linked to dysfunctional ASAT and not IAAT as 
was initially thought. An exercise study with metabolic data would be beneficial in testing this 
theory. Additionally, the TOFI classification was not useful in identifying ‘at risk’ individuals in 
the Asian group. Also, waist circumference measurements did not identify Asian males that 
had significantly elevated ASAT. However, elevated liver fat stores were seen in Asian males 
and females compared to Caucasians. Liver fat may therefore be a potential ‘at risk’ identifier 
in this ethnic group. 
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Obesity is a complex, multi-faceted issue that is not fully accounted for in the simplicity of the BMI. 
There are issues in many BMI related population studies. In particular, BMI, and other anthropometric 
proxies (WC, WHR) do not measure body fat directly, which questions the validity of these methods. 
Further error is introduced with some of these proxies – for instance Wang339 reported that he found 
14 different descriptions of the waist measurement site.  
Another major limitation in BMI related population studies is their use of different gold standards for the 
definition of excess adiposity. As shown in this thesis, it is clear that some techniques to measure 
body composition are suboptimal for measuring adiposity.  For this reason MRI and other high quality 
(and high cost) imaging methods are still the best method for health risk based research. While 
beyond the remit of this thesis, DXA for example cannot accurately differentiate internal fat stores 
(IAAT from ASAT) and has an additional radiation exposure risk. 
 
BMI may be an inexpensive, non-invasive measure of obesity for predicting the risk of related 
complications, but its accuracy is limited by its dysregulation with adiposity. While obesity means 
excess body fat, the current definition of obesity using BMI is based on body weight regardless of its 
composition. The studies in this thesis have highlighted that fact that there are several different sub-
populations of individuals for whom BMI does not tell the whole story. The Fat-Fit, the TOFI and the 
Asian Indian are specific phenotypic examples of these sub-populations. This is evidence of the fact 
that BMI should not be considered as the only measure of obesity. 
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7.1. Limitations (What went wrong)  
Recruitment. 
During the research for this thesis there were limitations.  One of the most significant of these was the 
lack of South Asian volunteers. Whilst study 1 was limited by a small sample size (N= 21) the lack of 
Asian participants is not a new issue. Other research teams have identified this as a potential 
obstacle. To put this in context, whilst was recruiting for my studies I was fortunate enough to be 
working as part of a team that had significant media exposure based on the MR adiposity work being 
performed. TV and journalist exposure to the work was very helpful for marketing purposes. Any 
articles written or TV shows screened would carry a contact detail for the team. This was a deliberate 
move to develop a database of wiling participants for the research group.  I developed a simple web 
based response questionnaire that could be automated and completed by prospective volunteers. The 
information would populate our database with relevant information, including a metal check, magnet 
suitability etc.  
When this was interrogated regularly the percentage of South Asian respondents was approximately 
4%. Of that 4%, 50 % would lose contact after first follow-up phone call to discuss testing dates 
availability, and a further 50% again would either not be available of change their mind. From 2000 
respondents we would invariably get 2-4 successful South Asian tests. 
 
Contact with BBC Asian radio to increase public interest of our recruitment and to engage with the  
South Asian community never paid dividends.  
 
Distribution of Asian specific volunteer flyers at solely South Asian events (e.g. London & Birmingham 
Mela festivals) failed to stimulate new volunteers to come forward.    
 
Contact with local places of worship to help engage the community elders etc was unsuccessful, as 
was contacting and visiting South Asian GP clinics.        
 
In Chapter 2, I highlighted the additional problems with recruiting to the multiple 2-C techniques 
comparison study, in which UWW and BodPod both presented significant obstacles to recruitment of 
volunteers. An unwillingness / discomfort with being a confined space for the measurements as well as 
being in a state of undress (swimwear etc) were the main issues.   
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Funding  
Several charities (including a South Asian charity) were approached for research funding in response 
to to their annual bid announcements. The funds were to enabling payment for volunteers in case that 
would encourage a greater project take-up. Unfortunately none of these were successful. 
 
Documentation. 
Diet diary completion was an area where participants became less compliant. It is well known that 7 
day food diaries are more accurate for assessing all 3 macronutrients (CHO, fats, proteins) than 3 day 
diaries; but the reality is that participants get bored after 3 days and tend to forget to complete the rest 
usually.    
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7.2. Future Directions  
 
The relatively small number of participants included in the comparison of 2-C measurement 
techniques made generalization of results beyond the study limited to a small BMI range. It would be 
desirable to have a much larger cohort that represented obese individuals too as well as other 
ethnicities. This would help in the development of better ethnic specific algorithms for these 2-C 
devices.  
 
 Asian adiposity and health risk appears to be significantly more complex than just BMI and adipose 
stores. Since the onset and progression of diabetes and other obesity-related diseases are also linked 
to family history and ethnicity, the larger picture of genetic influence in this group requires greater 
detail of metabolic data included to support the adiposity findings in this thesis. This should also be 
accompanied by genetic markers a well if possible. Some potential candidates might include blood 
samples for: Cholesterol, Triglycerides, Cholesterol (Total, HDL, LDL), Glucose, Insulin  HOMA-IR, C-
Peptide, PAI-1, IL-18 (plasma interleukin-18) linked to insulin resistance, Adiponectin (serum) - HMW 
(high molecular weight) 12- to 18-mer, Leptin, ALT, A1C (%) - Glycosylated Haemoglobin, TFTs, 
SHBG, Apolipoprotein A and B. 
 
The participant of body build was mentioned as a potential influencing factor in conjunction with 2-C 
measurements (Chapter 3).  The addition of additional measurements to BMI has been muted. The 
possibility of combining somatotype (accurate body geometry) data with adiposity measures may yield 
greater predictive accuracy than BMI. Also, since adiposity measures are a ‘snapshot’ of the 
individuals status at the time of their scan, there is often a lack of historical information regarding the 
individuals, dietary habits, activity levels, birthweight etc., that might give a better indication of how 
they came to be the way they are.   
 
Exercise is a validated way of reducing the risk of diabetes and coronary heart disease. While 
numerous studies have reported significant associations between fitness measures (physical activity 
and cardiorespiratory), insulin resistance and most other separate components of the metabolic 
syndrome, very few have quantified the resulting regional fat loss using MRI and none have involved 
the British South Asian population. Previous research476 measured the effect of regular aerobic 
exercise on visceral adiposity and showed (in females) that there was a preferential loss of visceral 
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adiposity. This area would benefit from a project assessing the dose response of regular moderate 
aerobic exercise / or high intensity, short duration exercise on intra-abdominal fat and total adiposity in 
a group of South Asians. With increased interest in exercise prescription for at risk groups, the Asian 
population has had little such attention or uptake.  
 
A study of free-living activity monitoring (in conjunction with diet diaries) study would be effective in 
quantifying the degree of habitual activity, or lack of it, in South Asians. This could take the form of an 
intervention study baseline period using micro activity monitors (eg. Actiheart, actigrah etc). However 
these are expensive (approx. £500 each) and would therefore require funding support.  
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Information Sheet for Research Participants  
 
Study title: 
Characterising the functional phenotype of Asian Indian adiposity. 
 
Invitation paragraph. 
You are being invited to take part in a research study. Before you decide it is important for you to 
understand why the research is being done and what it will involve. Please take time to read the 
following information carefully and discuss it with others if you wish. Ask us if there is anything that is 
not clear or if you would like more information. Take time to decide whether or not you wish to take 
part.  
• Part 1 tells you the purpose of this study and what will happen to you if you take part.   
• Part 2 gives you more detailed information about the conduct of the study.  
 
We will be happy to let you have a copy of the leaflet entitled ‘Medical Research and You’ - published 
by Consumers for Ethics in Research (CERES). This leaflet gives further information about medical 
research and looks at some questions you may want to ask. 
 
PART ONE 
 
What is the purpose of this study? 
The purpose of this study to measure the differences in regional body fat distribution in British South 
Asian and Caucasian males. We believe that British South Asian males’ abdominal fat (internal and 
subcutaneous) distribution is different from that of Caucasians and behaves differently (when an 
individual performs exercise) which has a direct effect on health. The fat content of the liver and calf 
muscle will be measured by magnetic spectroscopy (MRS), the total body fat by magnetic resonance 
imaging (MRI). This study is also part of an academic qualification (PhD). 
 
Why have I been chosen? 
You have been asked to participate because we believe you may be able to help us with this research 
as you are in good health, are not taking part in regular exercise and are a member of the ethnic groups 
being researched. You will be one of 180 patients participating in this study. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form. If you do decide to take part you are 
still free to withdraw at any time and without giving a reason. Also, your doctor may withdraw you 
from the study at any time if he/she feels it is not in your best interest. A decision to withdraw at any 
time, or a decision not to take part, will not affect the standard of care you receive. 
 
What are the possible disadvantages and risks of taking part? 
Some of the procedures in this study, such as the recording of your weight, height and blood pressure 
present no risk to you. Other procedures, such as the insertion of a needle into your arm in order to 
take blood samples, can cause mild discomfort. We will offer you local anaesthetic before inserting the 
needle in order to minimise this if necessary. It is also possible to develop a small amount of bruising 
at the site of insertion of the needle; to minimise this we will apply firm pressure to your arm for 2-3 
minutes after removing the needle. 
 
Magnetic resonance imaging (MRI) does not involve any radioactivity or radiation and is free from 
side effects, provided that you are not wearing any metal jewellery or a watch (which can come loose 
or break in the magnet). You will be asked to remove your jewellery and watch before the scans take 
place. We will give you an alarm bell to sound at any time if you are upset or worried during the 
examination; and if the procedure does not suit you for any reason it can be stopped at any time. 
 
What are the possible benefits of taking part? 
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The information we get from this study may help us to better understand ethnic differences in body fat 
distribution and hopefully identify effective exercise therapy guidelines to improve the health of those 
at risk within this ethnic group. This would have an enormous impact on the health and productivity of 
this population. 
 
Who will interpret the images? 
All the images from this study will be read by a qualified person, usually a radiologist, who holds a 
Hammersmith Hospital Trust clinical contract and is designated by the trust as competent to report that 
study. The only exception would be if you do not want such a qualified person to look at the images. If 
this is the case, please let us know on the consent form which you will be asked to sign. Images may 
also be analysed by other qualified persons for data analysis. 
 
What if new information becomes available during the study? 
Sometimes during the course of a research study, new information becomes available about the 
condition that is being studied. If this happens, we will tell you about it and discuss with you whether 
you want to continue in the study. If you decide to withdraw we will make arrangements for your care 
to continue. If you decide to continue in the study you will be asked to sign an updated consent form.  
 
What happens when the research study stops? 
At the end of the research study we will thank you for your participation, answer any questions you 
may have, and let you know when we hope to be able to inform you of the results. 
 
What if something goes wrong? 
If you suffer an adverse event or deterioration in health as a result of your participation in this study, 
appropriate compensation will be paid to you through the Imperial College School of Medicine’s “No 
Fault” Compensation Scheme. 
 
PART TWO  
What will happen to me if I take part and what will I have to do?  
All participants will be asked to attend the Robert Steiner Magnetic Resonance Imaging (MRI) Unit at 
Hammersmith Hospital on 1 occasion. Before attending you should fast for 10-12 hours overnight. 
You should not have anything to eat on the morning of the study and you should only drink water. 
Any tea, coffee or snacks will invalidate the results. We will ask you to refrain from drinking alcohol 
on the day before the study.  
 
(i) The assessments during the study visit will include:  
• A physical examination with measurements of body weight, blood pressure, body circumferences 
and a fitness assessment at each visit.  
• Blood samples. These are taken to measure the levels of fats (lipids) in your blood and to look at 
chemical indicators of your health status. During the visit, approximately 12 teaspoonfuls of 
blood will be taken for analysis (after an overnight fast). 
• During the study the total body fat content and the content of fat in the liver and in the calf 
muscle will be scanned by non-invasive, painless techniques. These MRI scans will be carried out 
at the Hammersmith Hospital. 
 
Main Visit:  At your visit to the MRI Unit (following a 10-12 hour overnight fast) you will have a 
short clinical assessment during which the study researcher will ask you a few questions about your 
general health (including the medications you normally take) and will measure your pulse, blood 
pressure, height, weight, waist and hip circumferences and skinfold thickness. A fasting blood sample 
will be taken for the measurement of cardiovascular risk factors (including cholesterol) and other 
lipoproteins (to estimate the contents of individual fatty acids in circulating fats), insulin and glucose. 
Some liver function tests will also be performed. The total amount of blood taken will be 
approximately 60 mL (about 12 teaspoons). All this will take about 20 minutes. With your permission 
(on one occasion only) we will also take a sample of DNA from blood or saliva to look for changes in 
your genes or chromosomes that may be involved in the how the body controls appetite, body 
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composition, fat and sugar levels. This will enable us to see what effect the changes may have on how 
and where your body stores fat. (These samples will be under the guardianship of Professor J. Bell 
and will be stored for a maximum period of 10 years. During this period, as with all other study data, 
all personal details will be fully anonymised in compliance with medical research data protection 
policies.)  
We will perform magnetic resonance scans of your liver, calf and whole body. These scans are safe 
and do not involve any radioactivity or radiation. These scans may NOT be suitable for you if you 
suffer from claustrophobia. You will go into the magnet and will be asked to lie still for the study. You 
will hear an intermittent knocking noise during part of the procedure, and you will experience no 
discomfort. As this noise can be loud ear defenders will be provided for your comfort and safety. We 
will be able to talk to you while you are in the scanner through an intercom. We will give you an alarm 
buzzer to sound at any time in case you are upset or worried during the examination and if the 
procedure does not suit you for any reason it can be stopped at any time. The length of examination 
varies, but is generally about 40 minutes in total, including change of positions. Scans performed will 
include: (i) a liver MRS scan (approx’ 10mins), (ii) a leg MRS scan (approx’ 10 minutes), and (iii) a 
total body MRI scan (approx’ 20 minutes).  
Procedures for liver, calf muscle and total body fat scanning. 
Before starting the scanning we will ask you to complete a short checklist to identify whether you have 
any metal parts in your body (for example, metal heart valve, artificial joint, cardiac pacemaker etc.) 
which will stop us performing the scan.  
 
• We will initially scan (MRS) your liver. For this you will be asked to lie on a scanner bed and 
then be moved into the magnet and asked to lie still for the study. The length of the examination 
varies, but is generally 10 minutes.  
• Once the liver scan is complete, we will scan (MRS) your left calf muscle. You will remain 
lying on the bed and we will get you to place your left leg in a small coil. We will ensure you’re 
comfortable by placing some foam pads against your legs. You will still have the alarm buzzer 
to sound if you need us to attend to you for any reason. The scan will take approximately 10 
minutes.  
• Lastly we will scan your whole body to measure the amount and distribution of fat in your 
body, this generally takes 15-20 minutes. All care will be as with previous scans. 
 
Following the scans we will ask you to perform a short (20 minutes maximum) exercise test on a 
stationary bicycle to measure your aerobic capacity. This procedure will involve you cycling at a set 
rate at increasing difficulties (every 2 minutes) while wearing a heart rate monitor to measure your 
heart rate and a (open ended) mouthpiece attached to a computer to measure the amount of air your 
breathe in and out. These combined measurements will tell us how well your heart and lungs are 
performing and ho w fit you are. A trained specialist (researcher) will be with you to ensure your 
safety and assist you. You will be free to stop the test at any stage if you feel discomfort or pain or 
simply do not wish to continue. Additionally the researcher may ask you to stop before you intend to if 
he feels for any reason you do not need to continue the test. This test may make you breathe hard and 
sweat slightly towards the end. After a brief rest (10 mins) you will proceed to the scanning area. In 
some cases (if you prefer) it may be possible to perform this fitness test on another day before your 
scanning day if or any reason you are not able to do all measures in the one visit.  
During the study you will be asked to record and submit a 7 day food and activity diary (using forms 
provided) via email or by return post in prepaid envelopes provided. Telephone & email support will 
also be provided for you if needed.  
 
Will my taking part in this study be kept confidential? 
If you consent to take part in the study we may need access to your medical records. All information, 
which is collected about you during the course of the research will be kept strictly confidential. Any 
information about you that leaves the hospital will have your name and address removed so that you 
cannot be recognised from it. 
 
We will inform your GP of your participation in this study. We will also inform all other doctors 
treating you (for example, hospital specialists), unless you have any objection to us doing so. 
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What will happen to the results of the research study? 
When the study has been completed, we hope to be able to publish the results of the study in a 
scientific journal. Individual patients will not be identifiable from the information in any publication. 
 
Who is organising and funding the research? 
The study is organized and funded by the Medical Research Council (MRC).  
 
Who has reviewed the study? 
This research study has been reviewed by the Charing Cross Hospital Research Ethics Committee in 
accordance with local regulations. 
 
Contact for Further Information 
 
Mr. John McCarthy,  
Robert Steiner MR Unit 
Imaging Science Dept 
MRC Clinical Sciences Centre 
Hammersmith Hospital 
Imperial College London 
Du Cane Rd 
London W12 0HS 
 
john.mccarthy@imperial.ac.uk 
 
Mob. 07910516422 
 
 
You will be given a copy of this information sheet and a signed consent form to keep. 
 
Thank you for taking the time to read this information sheet. We would appreciate it very much 
if you could help us with this important study. 
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Robert Steiner MRI Unit, Imaging Sciences Department 
MRC Clinical Sciences Centre, Imperial College 
Hammersmith Hospital Campus 
Du Cane Road, London W12 0NN 
 
 
THIS INFORMATION SHEET IS VALID FOR USE UNTIL: 31 March 2012  
 
 
STUDY PROTOCOL:  
Magnetic resonance imaging and spectroscopy for body 
composition analysis. 
 
PRINCIPAL INVESTIGATOR Dr. A.P. Goldstone 
 
BACKGROUND  
 
Increased body fat is associated with significant adverse effects on health. The 
associated risks of obesity include insulin resistance, type 2 diabetes mellitus, high 
blood pressure, cardiovascular disease and high blood fat levels. A cluster of 
metabolic changes are associated with obesity (‘syndrome X’): resistance to 
insulin-stimulated glucose uptake by muscle and liver, glucose intolerance, 
elevated insulin levels, increased blood triglyceride (fat) concentration, decreased 
high density lipoprotein (HDL)-cholesterol concentration and high blood pressure, 
that have their origin in insulin resistance. 
 
High blood glucose and insulin levels, insulin resistance in blood vessels and high 
fat and cholesterol contribute to the development of heart disease, and 
hypertension, through effects on blood clotting, formation of fat deposits in blood 
vessels and the contraction of blood vessels.  
 
Central or visceral obesity (in the abdomen around the internal organs), high 
amounts of liver or muscle fat are especially associated with increased insulin 
resistance, glucose intolerance, high lipids, heart disease and mortality. A number 
of products secreted by adipose tissue, including some known as ‘adipocytokines’, 
have been found to influence insulin action and affect blood vessels and blood 
clotting. They are therefore candidates for the link between increased adiposity, 
insulin resistance, sugar diabetes and heart disease. 
 
These products released from fat cells into the blood include adiponectin, IL-6, 
tumour necrosis factor-alpha (TNFa), IL-1a, IL-8, MCP-1, leptin, plasminogen 
activator inhibitor-1 (PAI-1), resistin, visfatin and retinol binding protein-4. 
 
However the links between particular fat depots (visceral, muscle and liver), these 
circulating products and the development of insulin resistance has not yet been 
fully characterised. We do not know which of the various fat depots have the 
greatest effect on insulin resistance and blood markers of increased cardiovascular 
and metabolic risk. We do not know which regional fat depots are particularly 
associated with the development of diabetes mellitus. 
 
Previous work by our Group has developed methods for whole body multi-slice 
human magnetic resonance (MR) imaging to quantitatively measure total and 
regional adipose volumes in adults to measure individual fat deposits, including 
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visceral, muscle and liver fat content, in different diseases, patients with genetic 
abnormalities, on different diets and with different levels of physical activity. There 
is great variation in the fat distribution between individuals that cannot be easily 
predicted by their overall size. 
 
For example we have found that non-diabetic adult females and males with Prader-
Willi syndrome (PWS), a genetic disease causing profound hunger and obesity from 
childhood due to a defect on chromosome 15, have reduced visceral fat and 
surprisingly low insulin and blood fat levels. An increasing number of genetic 
studies have shown various gene markers and variations to be associated with 
obesity and crude measurements of fat distribution in the general population. 
 
 
OBJECTIVE 
 
The purpose of this cross-sectional study is to develop novel biomarkers for 
obesity, insulin resistance, diabetes mellitus and cardiovascular risk by: 
 
(i) scannning a large cohort of control subjects, both with and without type 2 
diabetes mellitus, of both gender and of various BMI, to measure total, visceral and 
subcutaneous, liver and muscle fat to allow correlation with blood measurements of 
factors involves in insulin resistance, metabolic and cardiovascular risk such as 
adipocytokines (including insulin, homeostasis model assessment of insulin 
resistance (HOMA-IR), leptin, adiponectin, IL-6, TNFa, IL-1a, IL-8, MCP-1, PAI-1, 
resistin, visfatin, retinol binding protein-4, CRP and lipids), collected when fasted 
and after drinking a sugary drink (oral glucose tolerance test); 
 
(ii) using the genetic obesity syndrome, Prader-Willi syndrome (PWS), as a model 
of extreme obesity associated with abnormal fat distribution, to investigate whether 
their reduction in visceral fat, low insulin and blood fat are also associated with 
reduced liver and muscle fat, and altered blood levels of adipocytokines and other 
circulating markers of metabolic and heart disease risk, and examine if there are 
differences in those patients with PWS who have diabetes mellitus compared to 
those that do not; 
 
(iii) examining whether abnormal fat distribution is seen in other patients with 
childhood-onset morbid obesity and genetic causes of obesity; 
 
(iv) collecting and store DNA samples to allow analysis of the influence of genetic 
variants and mutations on total and regional adiposity. 
 
 
SUBJECTS 
 
Inclusion criteria 
 
x Age 18-80 
x Male or female 
x Healthy volunteers; patients with impaired glucose tolerance, diabetes mellitus, 
cardiovascular disease, hyperlipdaemia or fatty liver; patients with genetic 
causes of obesity including Prader-Willi syndrome, or severe childhood-onset 
obesity.  
x Normal weight, overweight and obese subjects 
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Exclusion criteria 
 
x Medical or psychological condition or social circumstances which would interfere 
with ability to participate reliably in the study. 
x Body mass index less than 16 kg/m2 (underweight) 
x Women who are pregnant. 
x Patients with claustrophobia, as they may find the confined conditions within the 
MR scanner uncomfortable.  
x Pacemaker, metal implant, clips, implanted device, shrapnel or bullet, metal in 
eyes that precludes magnetic resonance imaging. 
x Patients with Cushing’s syndrome or untreated clinical hypothyroidism. 
 
No. of subjects 
 
580 in total: 300 non-diabetic, 200 diabetic, 40 Prader-Willi syndrome, 40 other 
genetic causes of obesity 
 
 
PROTOCOL 
 
Subjects will attend the Robert Steiner MRI Unit at the Hammersmith Hospital after 
an overnight fast. They will be asked to refrain from taking strenuous exercise and 
drinking alcohol for twenty-four hours before the visit. 
 
BLOOD SAMPLING 
 
Blood (up to 100ml in total) will be taken by venepuncture before and 2 hours after 
oral administration of a drink containing 75g glucose. Plasma and serum will be 
assayed for routine clinical chemistry, lipids (total, HDL and LDL cholesterol), 
triglycerides and free fatty acids, glucose, thyroid function; hormones, regulators of 
appetite, adipocytokines and markers of insulin resistance and blood clotting, 
including insulin, leptin, adiponectin, IL-6, TNFa, IL-1a, IL-8, MCP-1, PAI-1, 
resistin, visfatin, retinol binding protein-4, CRP and tPA-Ag. Assays will be 
performed by the Dept. of Chemical Pathology at Hammersmith Hospitals and by 
commercial kits for radio-immunoassay and ELISA, including the Lincoplex 
multiplexed immunoassay system. 
 
DNA SAMPLING 
 
Blood or saliva will be taken, with specific consent, to extract DNA to enable 
confirmation or exclusion of PWS and determination of molecular class by the 
appropriate regional cytogenetics laboratory (by SNRPN methylation and FISH 
analysis); examination of genetic abnormalities causing obesity (using array 
comparative genomic hybridisation for chromosomal abnormalities, and DNA 
sequencing of candidate genes such as MC4R, POMC, leptin receptor, SIM1); and 
polymorphisms or mutations associated with obesity, diabetes mellitus, fat 
distribution and body composition (using PCR based SNP analysis), in collaboration 
with Prof. Philippe Froguel, Dept. of Genomic Medicine, Imperial College, 
Hammersmith Hospital. 
 
ANTHROPOMETRY 
 
Baseline anthropometric measurements of height, weight, waist and hip 
Appendix 1. Research Protocol 07-Q0411-19 v1 27 Feb 2007 4 
circumference, skinfold thickness, blood pressure, and bio-electrical impedance 
analysis of percentage body fat. The latter technique is a painless, safe procedure 
which involves either lying on a couch with sticky pads placed on a hand and foot, 
or standing on a metal platform for 1 minute so that the body’s electrical resistance 
can be measured. 
 
MAGNETIC RESONANCE SCANNING 
 
Subjects will be in the MR scanner for up to 1 hour. Scanning will be performed on 
either the Philips 3.0 Tesla or Philips 1.5 Tesla MR scanners in the Robert Steiner 
MR Unit, or the Philips 3.0 Tesla research MR scanner in the Neonatal Unit, at the 
Hammersmith Hospital. None of the magnetic resonance imaging techniques to be 
used employs ionising radiation or intravenous contrast agents and all techniques 
mentioned may be performed during a single imaging session.  
 
Subjects lie supine or prone in the scanner and are automatically moved through 
the scanner. While in the scanner volunteers will have access to a buzzer to sound 
an alarm, and will be able to hear and respond to instructions from the scanning 
console. Whole body anatomical MR scanning will be performed to determine total 
and regional fat volumes, and magnetic resonance spectroscopy (MRS) performed 
to measure lipid content in internal organs, such as liver (IHCL) and muscles 
(IMCL), such as soleus and tibialis. 
 
QUESTIONNAIRES 
 
Assessment of individual activity levels and dietary habits will be performed by 
completion of the International Physical Activity Questionnaire (IPAQ) and a 3 day 
food diary. Clinical information on medications, past medical history, family history 
of diabetes, obesity and cardiovascular disease, smoking and alcohol intake will 
also be recorded. This will enable assessment of the contribution from physical 
activity and diet towards body fat distribution, cardiovascular and metabolic risk. 
 
 
OUTCOME MEASURES 
 
PRIMARY OUTCOMES 
 
Total, visceral and subcutaneous obesity, liver and muscle fat content. 
 
SECONDARY OUTCOMES 
 
Circulating bio-markers of insulin resistance, obesity and cardiovascular risk, 
including insulin, HOMA-IR, lipids, CRP, leptin, adiponectin, PAI-1, IL-6, resistin, 
visfatin, MCP-1, retinol-binding protein 4, tPA-Ag. 
 
Reported average level of physical activity. 
 
Reported 3 day caloric and macronutrient intake. 
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SAFETY AND PROTECTION OF VOLUNTEERS 
 
The MRI scanner contains a very strong magnet. Therefore, individuals may not be 
able to have the MRI if they have any type of metal implanted in their body, for 
example, any pacing device (such as a heart pacer), any metal in their eyes, or 
certain types of heart valves or brain aneurysm clips.  
 
There is not much room inside the MRI scanner. Some people may be 
uncomfortable if they do not like to be in close spaces (“claustrophobia”). This is 
therefore an exclusion criterion for recruitment to the study and they will have an 
opportunity to get used to the procedure during the dummy infusion. If, however, 
subjects experience discomfort within the scanner despite the measures taken to 
ensure patient comfort, the patient may request immediate cessation of the 
procedure with withdrawal from the scanner by ringing the patient alarm bell.  
 
The MRI produces a “hammering noise” but subjects wear earplugs and 
headphones to prevent discomfort or damage to hearing. 
 
The risks of placing a needle to draw blood from a vein include minor discomfort at 
the site of the puncture; possible bruising and swelling around the puncture site; 
rarely, infection or faintness during the procedure. 
 
 
FINANCING AND INSURANCE  
 
The study will be funded using core funding from the Molecular Imaging Group, 
Imaging Sciences Department, MRC Clinical Sciences Centre, and Section of 
Genomic Medicine, Imperial College at Hammersmith Hospital. All participants will 
be covered by the Imperial College "no fault" indemnity scheme.  
REC Ref: 06/Q0411/173. 
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 Robert Steiner MR Unit 
 Imaging Sciences Dept 
 MRC Clinical Sciences Centre 
 Hammersmith Hospital 
 Imperial College London 
 Du Cane Road 
 London W12 0HS 
 Tel: +44 (0)20 8383 3298  
 
 
Participant Consent Form 
 
Title of Project:   
 
Characterising the functional phenotype of Asian Indian adiposity. 
 
Name of Researcher:  MR JOHN McCARTHY 
 
          Please initial each box 
 
I have read and understand the information sheet “for Research Participants” 
for the above study and have had the opportunity to ask questions.    
             
 
I have received enough information about the study and satisfactory answers to 
all my questions. 
 
 
I understand that sections of any of my medical notes and images may be looked 
at by responsible individuals from our research collaborators or from regulatory  
authorities where it is relevant to my taking part in research. I give my permission  
for these individuals to have access to my records and images.      
 
I agree for a DNA sample to be taken and stored to look for changes that may be  
involved in obesity, diabetes, appetite, and how much fat and muscle is in the body. 
 
 
I understand that I am free to withdraw from the study at any time, without having 
to give a reason for withdrawing and without affecting my future medical care.   
  
 
I agree to take part in the above study. 
 
 
 
________________________ ________________ ____________________ 
Name of Participant Date Signature 
 
 
_________________________ ________________ ____________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
 
_________________________ ________________ ____________________ 
Researcher Date Signature 
 
 
 1 for volunteer; 1 for researcher; 1 to be kept with hospital notes 
 
 
 Robert Steiner MR Unit 
NHS R&D Project Ref: MCCJ001  REC Ref: 06/Q0411/173. 
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 Imaging Sciences Dept 
 MRC Clinical Sciences Centre 
 Hammersmith Hospital 
 Imperial College London 
 Du Cane Road 
 London W12 0HS 
 Tel: +44 (0)20 8383 3298  
 
Participant Safety Checklist Form 
 
Please check the following list carefully, answering all appropriate questions. 
Please do not hesitate to ask staff, if you have any queries regarding these questions. 
 
 YES NO 
Cardiac pacemaker   
Any major surgery (cardiac bypass / orthopaedic,etc.)   
Mechanical heart valve   
History of foreign body in eye   
Occupation as metal worker, grinder, welder   
Metallic implant, metal prosthesis, orthopaedic plates, screws   
Shrapnel   
Aneurysm clip/haemostatic clip   
Ear Implants   
Artificial Eye   
Coloured contact lenses   
Interventional radiological devices   
Pregnancy   
IUCD   
Implantable pumps / neurostimulators   
Allergies   
Are you wearing a watch?   
Are you wearing any jewellery?   
Is there anything in your pockets such as keys, etc.?   
Are you susceptible to claustrophobia?       
 
If the answer to any of the above questions is “YES” please give details. 
 
NB:  A device not known to be safe must be assumed to be unsafe.  In the case of devices operated 
by microprocessors (e.g. implantable pumps) device malfunction caused by field effects or circuitry 
must be considered.  Other devices such as ventricular shunts, orthodontic braces may be safe, but 
may degrade image quality significantly.  Images may also be degraded by metal containing tattoos or 
cosmetics.  (see AJR 1988; 151: 811) 
 
I have understood the above questions and have marked the answers correctly. 
 
 
Signed: !!!!!!!!!!!!. (participant)   Date: !!!!!!! 
 
 
Signed: !!!!!!!!!!!!. (MR Unit Personnel)  Date: !!!!!.!... 
 
NHS R&D Project Ref: MCCJ001  REC Ref: 06/Q0411/173. 
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Patient Registration Form 
Please complete this form and e-mail it to john.mccarthy@imperial.ac.uk 
 
PATIENT DETAILS : 
 
Surname: First name: 
Address: Home telephone No: 
Work telephone No: 
Postcode: Mobile telephone No: 
Date of Birth: Place if Birth: 
Marital status: Single/Married/Widowed 
Separated/Divorced (please circle) 
Religion: 
NHS number (if known): Hospital number (if known): 
E-mail address: 
 
ETHNIC ORIGIN (Please circle letter of alphabet that applies): 
 
White Black or Black British 
A British M Caribbean 
B Irish N African 
C Any other white background P Any other black background 
Mixed Asian or Asian British 
D White and Black Caribbean H Indian 
E White and Black African J Pakistani 
F White and Asian K Bangladeshi 
    
G Any other mixed background L Any other Asian background 
Other Ethnic Groups 
R Chinese S Any other  
GP Details : 
Name of GP: Address: 
 
 
Telephone No: 
Next of Kin : 
Name: Relationship to you: 
Address: Home telephone No: 
Work telephone No: 
Postcode: Mobile telephone No: 
REC Ref: 04/Q0403/87 
PATIENT INFORMATION SHEET: FOR OBESE MEN WITH NON-
ALCOHOLIC FATTY LIVER DISEASE (NAFLD) 
 
 
Study Title: The pathogenesis of non-alcoholic fatty liver disease in obesity 
 
Introduction 
 
You are being invited to take part in a research study. Your participation in this study 
is entirely voluntary and your medical care will not be affected if you decide not to 
participate. Before you decide whether or not to participate it is important for you to 
understand why the research is being done and what it will involve. Please take time 
to read the following information carefully and discuss it with others should you wish. 
Ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part.  
 
We will be happy to let you have a copy of the leaflet entitled ‘Medical Research and 
You’ published by Consumers for Ethics in Research (CERES). This leaflet gives 
more information about medical research and looks at questions you may want to ask. 
 
What is the purpose of the study? 
 
It is known that people with obesity have a greater risk of accumulating fat in their 
liver. The mechanism of fat accumulation is not known. In a small amount of cases 
such fat accumulation can lead to swelling and scarring of the liver. 
The increased fat accumulation in the liver may be related to the rate at which the 
liver secretes fat and the way in which the body handles a hormone called insulin.  
 
We do not know if the fat accumulation in the liver is out of proportion to the fat 
accumulation elsewhere. This study will help answer the above questions. 
The study duration is 3 years but you will only be asked to attend on 4 occasions. 
These attendances will all be within a 12-week time period. 
 
Why have I been chosen? 
 
You have been asked to participate because we believe you may be able to help us 
with this research as you are in good health and of above average weight and your 
ultrasound scan / liver biopsy showed you to have fat in your liver. You will be 
one of 60 patients participating in this study. 
Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. If 
you do decide to take part you are still free to withdraw at any time and without 
giving a reason. Also, your doctor may withdraw you from the study at any time if 
he/she feels it is not in your best interest. A decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care you receive. 
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What will happen to me if I take part and what will I have to do? 
 
You will be asked to attend the Metabolic Day Ward at St Mary’s Hospital on 3 
occasions and the Robert Steiner Magnetic Resonance Imaging (MRI) Unit at 
Hammersmith Hospital on 1 occasion during a 12 week time period.  Before each 
attendance at the Metabolic Day Ward, you should fast for 10-12 hours overnight.  
You should not have anything to eat on the morning of the study and you should only 
drink water. Any tea, coffee or snacks will invalidate the results. We will ask you to 
refrain from drinking alcohol on the day before the study.  
 
Visit 1:  At your first attendance to the Metabolic Day Ward, following a 10-12 hour 
overnight fast, you will have a short clinical assessment during which the study doctor 
will ask you a few questions about your general health (including the medications you 
normally take) and will measure your pulse, blood pressure, height, weight, waist and 
hip circumferences and skinfold thickness. A fasting blood sample will be taken for 
the measurement of cardiovascular risk factors (including cholesterol) and other 
lipoproteins (to estimate the contents of individual fatty acids in circulating fats), 
insulin and glucose. Some liver function tests will also be performed. The total 
amount of blood taken will be approximately 15 mls (about 3 teaspoons). All this will 
take about 20-30 minutes. You will then be given a snack and a drink. 
 
Visit 2: Your second attendance to the Metabolic Day Ward will be for an 
intravenous glucose tolerance test (IVGTT). This study will examine the way your 
body handles the hormone insulin. You will be asked to come to the Metabolic Day 
Ward at St Mary’s Hospital in the morning for about three hours following a 10-12 
hour overnight fast.  A small plastic needle will be placed into a vein in each forearm. 
The right arm will be placed in a heated box that will warm up the right hand. Blood 
samples will be taken through the plastic needle in the warm arm and between 25-
50mls of a concentrated glucose solution will be given through the plastic needle in 
the left arm. Small amounts of blood will be taken at regular intervals throughout the 
test (the total amount will be 120mls – less than one quarter of a pint). The blood 
samples will be taken over approximately three hours. 
 
Visit 3: Your third attendance to the Metabolic Day Ward will be for the kinetic 
study. This will examine the rate at which fat is secreted by the liver. This is 
important because the increased fat accumulation in the liver in non-alcoholic fatty 
liver disease may be related to the rate at which the liver secretes fat. You will be 
asked to arrive on the Metabolic Day Ward at St Mary’s Hospital in the morning 
following a 10-12 hour overnight fast. You will be encouraged to include at least 
150g carbohydrate in your diet during the three days prior to your visit (you will be 
advised how to do this) and should abstain from very strenuous exercise and excess 
alcohol for the same period. During the study day, you will be asked to remain lying 
on a bed throughout the 6-hour procedure and will remain fasting (you may consume 
water). A meal will be given to you on completion of the procedure. You will have 
two small cannulae (plastic needles), one in the forearm and one in the back of the 
hand, using some local anaesthetic and these will be the only needles involved 
(subsequent blood tests will be taken through one of the cannulae and will not 
therefore hurt). One of these cannulae will be used to infuse a solution containing the 
non-radioactive isotopes [1-13C]-leucine and [1-13C]-palmitate into your arm for 6 
hours. [1-13C]-leucine is a specially tagged version of one of the building blocks of 
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protein normally present in your blood and is used to measure the lipid turnover. [1-
13C]-palmitate is a fatty acid present in the blood and is used to measure the fatty acid 
turnover. Both have been many times and are very safe. The other intravenous 
cannula will be used to take regular blood samples every hour throughout the 6-hour 
infusion. This hand will be in a hot box which blows out hot air to maintain a 
temperature of 40oC. The amount of blood that will be taken if you participate in the 
study is 90 mls (less than one quarter of a pint). One of the blood tests, performed at 
the end of the study, involves an injection of a small amount of the anticoagulant 
heparin. At single small doses administered in this way, it is not known to have side 
effects.  
Visit 4 (MRI): On one occasion you will be asked to attend the Robert Steiner MRI 
Unit at the Hammersmith Hospital after a 6 hour fast (you should not eat anything 
during this time but can drink water and take any medication you would normally 
take). We will perform magnetic resonance scans of your liver, calf and whole body. 
These scans are safe and do not involve any radioactivity or radiation. Before starting 
the scanning we will ask you to complete a short checklist. This will ensure that you 
do not have any magnetic implant (such as a cardiac pacemaker) which will stop us 
performing the scan. You will go into the magnet and will be asked to lie still for the 
study. You may hear a knocking noise during part of the procedure, and you will 
experience no discomfort. We will give you an alarm bell to sound at any time if you 
are upset or worried during the examination and if the procedure does not suit you for 
any reason it can be stopped at any time. The length of examination varies, but is 
generally about 40 minutes. Once the liver scan is complete, we will scan your left 
calf muscle. You will remain lying on the bed and we will get to place your left leg in 
a small coil. We will ensure you are comfortable by placing some foam pads against 
your legs. You will still have the alarm bell to sound if you need us for any reason. 
The scan will take approximately 20 minutes. You will then have a MR scan of your 
whole body to measure the amount and distribution of fat in your body. This scan will 
take approximately 30 minutes. 
 
 
 
What are the possible disadvantages and risks of taking part? 
 
Some of the procedures in this study, such as the recording of your weight, height and 
blood pressure present no risk to you. Other procedures, such as the insertion of 
cannulae (plastic needles) into your arm in order to take blood samples, can cause 
mild discomfort. We will offer you local anaesthetic before inserting the cannulae in 
order to minimise this. It is also possible to develop a small amount of bruising at the 
site of insertion of the cannulae ;  to minimise this we will apply firm pressure to your 
arm for 2-3 minutes after removing the cannulae. 
 
Magnetic resonance imaging does not involve any radioactivity or radiation and is 
free from side effects, provided that you are not wearing any metal jewellery or a 
watch (which can come loose or break in the magnet). You will be asked to remove 
your jewellery and watch before the scans take place. We will give you an alarm bell 
to sound at any time if you are upset or worried during the examination and if the 
procedure does not suit you for any reason it can be stopped at any time. 
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What are the possible benefits of taking part? 
 
The information we obtain from this study will further our understanding of non-
alcoholic fatty liver disease, tell us more about the risks associated with accumulating 
fat in the liver, and help develop treatments for the condition. Yourself and other 
patients with non-alcoholic fatty liver disease may benefit from this in the future. If 
your liver tests are abnormal, or there is any evidence of any other liver disease, we 
will refer you to a specialist in liver disease for further investigation. 
 
 
What if new information becomes available during the study? 
 
Sometimes during the course of a research study, new information becomes available 
about the condition that is being studied. If this happens, we will tell you about it and 
discuss with you whether you want to continue in the study. If you decide to withdraw 
we will make arrangements for your care to continue. If you decide to continue in the 
study you will be asked to sign an updated consent form.  
 
What happens when the research study stops? 
 
At the end of the research study we will thank you for your participation, answer any 
questions you may have, and let you know when we hope to be able to inform you of 
the results. 
 
What if something goes wrong? 
 
If you suffer an adverse event or deterioration in health as a result of your 
participation in this study, appropriate compensation will be paid to you through the 
Imperial College School of Medicine’s “No Fault” Compensation Scheme. 
Will my taking part in this study be kept confidential? 
 
If you consent to take part in the study we may need access to your medical records. 
All information which is collected about you during the course of the research will be 
kept strictly confidential. Any information about you that leaves the hospital will have 
your name and address removed so that you cannot be recognised from it. 
 
We will inform your GP of your participation in this study. We will also inform all 
other doctors treating you (for example, hospital specialists), unless you have any 
objection to us doing so. 
What will happen to the results of the research study? 
 
When the study has been completed, we will talk to and also write to you informing 
you of the results of the study. We hope to be able to publish the results of the study 
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in scientific journals. You will not be identifiable from the information in any 
publications. 
 
Who is funding the research? 
 
The research is being funded by the Novo Nordisk UK Research Foundation. 
The doctor conducting the research will not receive any payment for including you in 
this study. 
Who has reviewed the study? 
 
St Mary’s Local Research Ethics Committee has reviewed the study. 
 
Who can I contact to find out more about the study? 
 
If you have any further questions please contact: 
 
Dr Sanjeev Mehta 
Department of Endocrinology & Metabolic Medicine, 2nd Floor, Mint Wing, St 
Mary’s Hospital, London. 
Tel: 020 7886 6120 (Work); 07961 839052 (Mobile) 
 
You will be given a copy of this information sheet and a signed consent form to keep. 
 
Thank you for taking the time to read this information sheet. We would 
appreciate it very much if you could help us with this important study. 
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Section of Endocrinology & Metabolic 
Medicine 
Imperial College London 
2nd Floor, Mint Wing 
St Mary’s Hospital 
Praed Street 
London W2 1NY 
Tel: +44 (0)20 7886 6120  
Fax: +44 (0) 20 7886 1790 
 
Centre Number: : 
Study Number: 
Patient Identification Number for this trial: 
 
 
CONSENT FORM 
 
 
Title of Project:  THE PATHOGENESIS OF NON-ALCOHOLIC FATTY LIVER DISEASE IN OBESITY 
 
Name of Researcher:  DR SANJEEV R MEHTA 
 
 
          Please initial box 
 
1. I confirm that I have read and understand the information sheet “For Obese Men With   
 Non-Alcoholic Fatty Liver Disease (NAFLD)” for the above study and have had the  
 opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time,  
 without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked at by responsible  
 individuals from [company name] or from regulatory authorities where it is relevant to my 
 taking part in research.  I give permission for these individuals to have access to my records. 
 
4. I agree to take part in the above study.                                                        
 
 
________________________ ________________ ____________________ 
Name of Patient Date Signature 
 
 
_________________________ ________________ ____________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
 
_________________________ ________________ ____________________ 
Researcher   Date 
 Signature 
 
 1 for patient; 1 for researcher; 1 to be kept with hospital notes 
    201 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 2 
Asian Males 
needed
Free health scans
Volunteers (unpaid) needed:
This cutting edge research into body fat and health is 
being done to measure ethnic differences in internal 
fat storage. This  work may help identify and possibly 
limit future health problems in Asians - related to 
obesity, diabetes, high blood pressure and heart dis-
ease. 
• Aged 20 - 40 yrs
• Average Fitness level 
• Healthy & Inactive
When: 	Now (2009)
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Asian Males 
Needed
Free health scans
Volunteers needed:
This cutting edge research into body fat and 
health is being done to measure ethnic differ-
ences in internal fat storage. This work may 
help identify and possibly limit future Asian 
health problems related to obesity, diabetes, 
high blood pressure and heart disease.
To date very little work has been done with the 
Asian community - your help is greatly appre-
ciated and needed.
You should be :
• Aged 20 - 40 yrs
• Average fitness level 
• Healthy & Inactive
When: 	Now (2009)
Where: 	Hammersmith Hospital (White City Tube).
Time: 	 2 hour / visit
Other: 	 Two hour visit for health screen =  total body MRI scan, fitness test & diet analysis.       
Potential for follow-up study (exercise program option).
Contact:
07910516422 / john.mccarthy@imperial.ac.uk
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Date   Range 
FBC    
U+E    
LFT    
ALT         (IU/L)   0 - 37 
AST         (IU/L)   30 - 130 
! GT        (IU/L)   2 – 50 
Calcium  (mmol/L)    
Glucose  (mmol/L)   3.0 – 7.8 
Insulin    (mU/L)   3.0 - 
17.0 
HbA1c (mmol/mol)   20 – 42 
HbA1C    (%)   4.0 – 6.0 
SHBG    (nmol/L)   15 - 55 
TFTs    
Chol      (mmol/L)   < 5 
TG         (mmol/L)   0 – 2.0 
HDL      (mmol/L)   0.9 – 1.9 
LDL       (mmol/L)   2.0 – 5.0 
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 SHORT LAST 7 DAYS SELF-ADMINISTERED version of the IPAQ.  Revised August 2002. 
INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
(August 2002) 
 
SHORT LAST 7 DAYS SELF-ADMINISTERED FORMAT 
 
 
FOR USE WITH YOUNG AND MIDDLE-AGED ADULTS (15-69 years) 
 
The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 questionnaires. 
Long (5 activity domains asked independently) and short (4 generic items) versions for use by 
either telephone or self-administered methods are available. The purpose of the questionnaires 
is to provide common instruments that can be used to obtain internationally comparable data on 
health–related physical activity. 
 
Background on IPAQ 
The development of an international measure for physical activity commenced in Geneva in 
1998 and was followed by extensive reliability and validity testing undertaken across 12 
countries (14 sites) during 2000.  The final results suggest that these measures have 
acceptable measurement properties for use in many settings and in different languages, and are 
suitable for national population-based prevalence studies of participation in physical activity. 
 
Using IPAQ  
Use of the IPAQ instruments for monitoring and research purposes is encouraged. It is 
recommended that no changes be made to the order or wording of the questions as this will 
affect the psychometric properties of the instruments.  
 
Translation from English and Cultural Adaptation 
Translation from English is supported to facilitate worldwide use of IPAQ. Information on the 
availability of IPAQ in different languages can be obtained at  www.ipaq.ki.se. If a new 
translation is undertaken we highly recommend using the prescribed back translation methods 
available on the IPAQ website. If possible please consider making your translated version of 
IPAQ available to others by contributing it to the IPAQ website. Further details on translation 
and cultural adaptation can be downloaded from the website. 
 
Further Developments of IPAQ  
International collaboration on IPAQ is on-going and an International Physical Activity 
Prevalence Study is in progress. For further information see the IPAQ website.  
 
More Information 
More detailed information on the IPAQ process and the research methods used in the 
development of IPAQ instruments is available at www.ipaq.ki.se and Booth, M.L. (2000).  
Assessment of Physical Activity: An International Perspective.  Research Quarterly for Exercise 
and Sport, 71 (2): s114-20.  Other scientific publications and presentations on the use of IPAQ 
are summarized on the website. 
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INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
 
We are interested in finding out about the kinds of physical activities that people do as 
part of their everyday lives.  The questions will ask you about the time you spent being 
physically active in the last 7 days.  Please answer each question even if you do not 
consider yourself to be an active person.  Please think about the activities you do at 
work, as part of your house and yard work, to get from place to place, and in your spare 
time for recreation, exercise or sport. 
 
Think about all the vigorous activities that you did in the last 7 days.  Vigorous 
physical activities refer to activities that take hard physical effort and make you breathe 
much harder than normal.  Think only about those physical activities that you did for at 
least 10 minutes at a time. 
 
1. During the last 7 days, on how many days did you do vigorous physical 
activities like heavy lifting, digging, aerobics, or fast bicycling?  
 
_____ days per week  
 
   No vigorous physical activities  Skip to question 3 
 
 
2. How much time did you usually spend doing vigorous physical activities on one 
of those days? 
 
_____ hours per day  
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
Think about all the moderate activities that you did in the last 7 days.  Moderate 
activities refer to activities that take moderate physical effort and make you breathe 
somewhat harder than normal.  Think only about those physical activities that you did 
for at least 10 minutes at a time. 
 
 
3. During the last 7 days, on how many days did you do moderate physical 
activities like carrying light loads, bicycling at a regular pace, or doubles tennis?  
Do not include walking. 
 
_____ days per week 
 
   No moderate physical activities  Skip to question 5 
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4. How much time did you usually spend doing moderate physical activities on one 
of those days? 
 
_____ hours per day 
_____ minutes per day 
 
  Don’t know/Not sure  
 
 
Think about the time you spent walking in the last 7 days.  This includes at work and at 
home, walking to travel from place to place, and any other walking that you might do 
solely for recreation, sport, exercise, or leisure. 
 
5. During the last 7 days, on how many days did you walk for at least 10 minutes 
at a time?   
 
_____ days per week 
  
   No walking     Skip to question 7 
 
 
6. How much time did you usually spend walking on one of those days? 
 
_____ hours per day 
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
The last question is about the time you spent sitting on weekdays during the last 7 
days.  Include time spent at work, at home, while doing course work and during leisure 
time.  This may include time spent sitting at a desk, visiting friends, reading, or sitting or 
lying down to watch television. 
 
7. During the last 7 days, how much time did you spend sitting on a week day? 
 
_____ hours per day  
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
This is the end of the questionnaire, thank you for participating. 
No changes permitted. You are encouraged to photocopy the PAR-Q but only if you use the entire form.
1.    Has your doctor ever said that you have a heart condition and that you should only do physical activity 
recommended by a doctor?
2.    Do you feel pain in your chest when you do physical activity?
3.    In the past month, have you had chest pain when you were not doing physical activity?
4.    Do you lose your balance because of dizziness or do you ever lose consciousness?
5.    Do you have a bone or joint problem (for example, back, knee or hip) that could be made worse by a 
change in your physical activity?
6.    Is your doctor currently prescribing drugs (for example, water pills) for your blood pressure or heart con-
dition? 
7.    Do you know of any other reason why you should not do physical activity?
PLEASE NOTE:  If  your health changes so that you then answer YES to 
any of  the above questions, tell your fitness or health professional.  
Ask whether you should change your physical activity plan.
Regular physical activity is fun and healthy, and increasingly more people are starting to become more active every day.  Being more active is very safe for most 
people. However, some people should check with their doctor before they start becoming much more physically active.
If  you are planning to become much more physically active than you are now, start by answering the seven questions in the box below.  If  you are between the 
ages of  15 and 69, the PAR-Q will tell you if  you should check with your doctor before you start.  If  you are over 69 years of  age, and you are not used to being 
very active, check with your doctor.
Common sense is your best guide when you answer these questions.  Please read the questions carefully and answer each one honestly:  check YES or NO.
Talk with your doctor by phone or in person BEFORE you start becoming much more physically active or BEFORE you have a fitness appraisal.  Tell 
your doctor about the PAR-Q and which questions you answered YES.
•  You may be able to do any activity you want — as long as you start slowly and build up gradually.  Or, you may need to restrict your activities to 
those which are safe for you. Talk with your doctor about the kinds of  activities you wish to participate in and follow his/her advice.
•  Find out which community programs are safe and helpful for you.
PAR-Q & YOU
 !
Physical Activity Readiness
Questionnaire - PAR-Q 
(revised 2002)
DELAY BECOMING MUCH MORE ACTIVE:
•  if  you are not feeling well because of  a temporary illness such as 
a cold or a fever – wait until you feel better; or
•  if  you are or may be pregnant – talk to your doctor before you 
start becoming more active.
If 
you 
answered 
If  you answered NO honestly to all PAR-Q questions, you can be reasonably sure that you can:
•  start becoming much more physically active – begin slowly and build up gradually.  This is the 
safest and easiest way to go.
•  take part in a fitness appraisal – this is an excellent way to determine your basic fitness so 
that you can plan the best way for you to live actively. It is also highly recommended that you 
have your blood pressure evaluated.  If  your reading is over 144/94, talk with your doctor 
before you start becoming much more physically active.
NOTE:  If  the PAR-Q is being given to a person before he or she participates in a physical activity program or a fitness appraisal, this section may be used for legal or administrative purposes.
"I have read, understood and completed this questionnaire.  Any questions I had were answered to my full satisfaction."
NAME ________________________________________________________________________         
SIGNATURE _______________________________________________________________________________            DATE______________________________________________________
SIGNATURE OF PARENT _______________________________________________________________________            WITNESS ___________________________________________________
or GUARDIAN (for participants under the age of  majority)
Informed Use of  the PAR-Q:  The Canadian Society for Exercise Physiology, Health Canada, and their agents assume no liability for persons who undertake physical activity, and if  in doubt after completing 
this questionnaire, consult your doctor prior to physical activity.
continued on other side...
(A Questionnaire for People Aged 15 to 69)
   YES         NO
YES to one or more questions
NO to all questions
Note:  This physical activity clearance is valid for a maximum of 12 months from the date it is completed and 
becomes invalid if your condition changes so that you would answer YES to any of the seven questions.
© Canadian Society for Exercise Physiology Supported by:
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Baecke Activity Questionnaire 
 
1. what is your main occupation? ………………never / seldom / sometimes/ often / always 
 
2. At work I sit………………………………….. never / seldom / sometimes/ often / always 
 
3. At work I stand………………………………. never / seldom / sometimes/ often / always 
 
4. At work I walk ………………………………. never / seldom / sometimes/ often / always 
 
5. At work I life heavy loads……………………. never / seldom / sometimes/ often / always 
 
6. After working I am tired……………………… never / seldom / sometimes/ often / very often 
 
7. At work I sweat………………………………. never / seldom / sometimes/ often / very often 
 
8. In comparison with others of my age I think my 
 work is physically……………..……...much lighter / lighter /as heavy / heavier / much heavier 
 
9.  Do you play sport…….yes / no 
a. if yes:  
i.  which sport do you play most frequently? 
- how many hours a week?................< 1 / 1 - 2 / 2 - 3 / 3 - 4 / > 4 
- how many months a year? ..............< 1 / 1 - 3 / 4 - 6 / 7 - 9 / > 9 
ii. If you play a 2nd sport :  
- Which sport is it? 
- how many hours a week? ...............< 1 / 1 - 2  / 2 - 3 / 3 - 4 / > 4 
- how many months a year? ..............< 1 / 1 - 3  / 4 - 6 / 7 - 9 / > 9 
 
10. In comparison with others of my age I think my  
physically activity during leisure time is……….much less / less/ the same/ more / much more 
 
11. During leisure time I sweat……………………. never / seldom / sometimes/ often / very often 
 
12. During leisure time I play sport………………. never / seldom / sometimes/ often / very often 
 
13. During leisure time I watch television…...……. never / seldom / sometimes/ often / very often 
 
14. During leisure time I walk………………..……. never / seldom / sometimes/ often / very often 
 
15. During leisure time I cycle……………….……. never / seldom / sometimes/ often / very often 
 
16. How many minutes do you walk and / or cycle per day to and from work, school and shopping?    
 
…………………………………………………………< 5  /  5 – 15  / 15 - 30  / 30 - 45  /  > 45 
 
ViScan validation data sheet 
Scan number______________ 
 
Date __________________  Subject name_________________________________ 
 
D.O.B ________________ Age ____________ Ethnicity _________________ 
 
 
Anthopometry 
 
Weight  (M1)___________ Height (H1) _______________                Hip (G17)_________ 
 
 
Waist(s):  (mid point)(G16) _______ (umbil)________ (min)_________ (iliac) _________   
 
Flexed bicep girth(G15) ____________ Calf girth (G12) ______________ 
 
Humorus epicondyle (B6)___________ Femoral epicondyle (B8)_____________ 
 
 1 2 (3) mean 
Bicep (S13)     
Tricep (S4)     
Subscapular (S5)     
Supraspinalae (S7)     
Iliac crest      
Abdominal     
Medial calf (S16)     
 
VISCAN 
 
Waist _________________   over 130cm used  [] Manual supine waist__________ 
 
Trunk % body far _______________     Visceral fat area _________________ 
 
Trunk fat rating _________________ Visceral fat rating ________________ 
 
 
Somatotype 
 
Endomorphy rating ________ Mesomorphy rating ________ Ectomorphy rating_________ 
 
 
BVI (Body Volume Index):  
 
Total vol._________Litres    Neck vol: _________   Abdom vol: _________ 
 
Waist : _________ cms  Hips: _________ cms 
Observer initials 
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